UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☒

~~QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

For the quarterly period ended ~~September~~June 30, ~~2021~~2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐

~~TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

Commission File Number: 001-37369

HTG Molecular Diagnostics, ~~Inc.~~Inc.

(Exact Name of Registrant as Specified in its Charter)


Delaware	86-0912294
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

3430 E. Global Loop Tucson, AZ	85706
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (877)289-2615

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	HTGM	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐		Accelerated filer	☐
Non-accelerated filer	☒	☒		Smaller reporting company	☒
			Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November~~August 5, ~~2021,~~2022, the registrant had ~~7,567,759~~11,048,111 shares of common stock, $0.001 par value per share, outstanding.

Table of Contents


		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (Unaudited)	1
	Condensed Consolidated Balance Sheets as of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020~~2021	1
	Condensed Consolidated Statements of Operations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021	2
	Condensed Consolidated Statements of Comprehensive Loss for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021	3
	Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021	4
	Condensed Consolidated Statements of Cash Flows for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021	76
	Notes to Unaudited Condensed Consolidated Financial Statements	87
Item 2.	Management’s Discussion and Analysis of Financial Condition and Consolidated Results of Operations	2522
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3230
Item 4.	Controls and Procedures	3230
PART II.	OTHER INFORMATION	3432
Item 1.	Legal Proceedings	3432
Item 1A.	Risk Factors	3432
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	7069
Item 5.	Other Information	7069
Item 6.	Exhibits	7170
Signatures		7372

PART I—FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited).

HTG Molecular Diagnostics, Inc.

Condensed Consolidated Balance Sheets


	September 30,		December 31,		June 30,		December 31,
	2021		2020		2022		2021
Assets	(Unaudited)				(Unaudited)
Current assets:
Cash and cash equivalents	$	10,229,646	$	22,397,812	$	5,756,578	$	9,599,950
Short-term investments available-for-sale, at fair value		15,187,672		6,298,075		8,342,184		12,343,456
Accounts receivable		1,904,534		1,588,767
Inventory, net of allowance of $16,393 at September 30, 2021 and $26,052 at December 31, 2020		2,340,766		1,492,126
Accounts receivable, net of allowance of $20,315 at June 30, 2022 and December 31, 2021						1,259,093		2,092,466
Inventory, net						1,955,922		1,987,753
Prepaid expenses and other		2,082,410		1,094,273		2,011,072		1,163,339
Total current assets		31,745,028		32,871,053		19,324,849		27,186,964
Operating lease right-of-use assets		1,444,348		1,009,097		1,143,270		1,345,361
Property and equipment, net		1,219,190		1,227,402		780,695		1,118,886
Other non-current assets		98,828		90,356		956,655		809,476
Total assets	$	34,507,394	$	35,197,908	$	22,205,469	$	30,460,687


Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,145,868		$	1,348,762		$	1,119,452		$	1,649,440
Accrued liabilities		1,609,001			1,459,878			1,334,287			2,022,569
Contract liabilities – current		213,462			185,083
NuvoGen obligation – current		530,657			512,729
Current portion of long-term debt		4,167,107			3,022,139			6,614,817			5,167,586
Operating lease liabilities – current		398,313			685,220
NuvoGen obligation - current								523,849			548,301
Operating lease liabilities - current								429,200			413,865
Other current liabilities		17,558			22,563			137,644			141,749
Total current liabilities		8,081,966			7,236,374			10,159,249			9,943,510
NuvoGen obligation - non-current, net of discount		4,072,831			4,479,396			3,646,858			3,900,880
Long-term debt, net of current portion, discount and debt issuance costs		6,309,416			8,568,308			2,023,579			5,178,629
Operating lease liabilities - non-current		1,055,984			368,682
Other non-current liabilities		99,825			60,488			806,094			1,037,844
Total liabilities		19,620,022			20,713,248			16,635,780			20,060,863
Commitments and Contingencies (Note 15)
Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; 23,770 shares authorized, issued and outstanding at September 30, 2021 and December 31, 2020		24			24
Common stock, $0.001 par value; 26,666,667 shares authorized at September 30, 2021 and December 31, 2020, 7,513,733 shares issued and outstanding at September 30, 2021 and 5,199,997 shares issued and outstanding at December 31, 2020		7,514			5,200
Series A convertible preferred stock, $0.001 par value; 0 shares authorized, issued and outstanding at June 30, 2022; 23,770 shares authorized, issued and outstanding at December 31, 2021								—			24
Common stock, $0.001 par value; 26,666,667 shares authorized at June 30, 2022 and December 31, 2021, 11,045,986 shares issued and outstanding at June 30, 2022 and 7,588,085 shares issued and outstanding at December 31, 2021								11,046			7,588
Additional paid-in-capital		218,018,993			205,661,999			226,293,112			218,723,349
Accumulated other comprehensive income		2,583			5,298
Accumulated other comprehensive income (loss)								(15,710	)		1,894
Accumulated deficit		(203,141,742	)		(191,187,861	)		(220,718,759	)		(208,333,031	)
Total stockholders’ equity		14,887,372			14,484,660			5,569,689			10,399,824
Total liabilities and stockholders' equity	$	34,507,394		$	35,197,908		$	22,205,469		$	30,460,687

~~See notes to the unaudited condensed consolidated financial statements~~

~~HTG Molecular Diagnostics, Inc.~~

~~Condensed Consolidated Statements of Operations~~

~~(Unaudited)~~

Three Months Ended September 30,

Nine Months Ended September 30,

2021

2020

2021

2020

Revenue:

Product and product-related services

$
2,520,410

$
1,701,068

$
6,029,760

$
5,417,731

Collaborative development services

—

76,030

—

548,135

Total revenue

2,520,410

1,777,098

6,029,760

5,965,866

Operating expenses:

Cost of product and product-related services revenue

983,761

940,892

2,740,004

2,931,026

Selling, general and administrative

4,232,313

4,752,321

11,995,747

13,683,069

Research and development

1,534,818

1,255,416

4,188,219

4,914,467

Total operating expenses

6,750,892

6,948,629

18,923,970

21,528,562

Operating loss

(4,230,482
)

(5,171,531
)

(12,894,210
)

(15,562,696
)

Other income (expense):

Interest expense

(266,593
)

(273,312
)

(797,239
)

(749,401
)
Interest income

8,387

34,636

22,419

244,534

Other income

—

—

—

22,268

Gain on forgiveness of PPP Loan

—

—

1,735,792

—

Loss on extinguishment of MidCap Credit Facility and
QNAH Convertible Note

—

—

—

(522,394
)
Total other income (expense)

(258,206
)

(238,676
)

960,972

(1,004,993
)
Net loss before income taxes

(4,488,688
)

(5,410,207
)

(11,933,238
)

(16,567,689
)
Provision for income taxes

(1,934
)

(1,581
)

(20,643
)

(12,548
)
Net loss

$
(4,490,622
)

$
(5,411,788
)

$
(11,953,881
)

$
(16,580,237
)
Net loss per share, basic and diluted

$
(0.60
)

$
(1.12
)

$
(1.78
)

$
(3.68
)
Shares used in computing net loss per share, basic and diluted

7,440,287

4,821,562

6,727,916

4,504,469

See notes to the unaudited condensed consolidated financial statements.

HTG Molecular Diagnostics, Inc.

Condensed Consolidated Statements of ~~Comprehensive Loss~~Operations

(Unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2021

2020

2021

2020

Net loss

$
(4,490,622
)

$
(5,411,788
)

$
(11,953,881
)

$
(16,580,237
)
Other comprehensive income (loss), net of tax effect:

Unrealized gain (loss) on short-term investments

—

(17,501
)

—

4,060

Foreign currency translation adjustment

(1,013
)

1,225

(2,715
)

7,631

Total other comprehensive income (loss)

(1,013
)

(16,276
)

(2,715
)

11,691

Comprehensive loss

$
(4,491,635
)

$
(5,428,064
)

$
(11,956,596
)

$
(16,568,546
)


	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Product and product-related services revenue	$	1,491,582		$	2,074,204		$	2,676,036		$	3,509,350

Operating expenses:
Cost of product and product-related services revenue		1,014,469			971,043			1,869,517			1,756,243
Selling, general and administrative		4,306,916			3,903,815			8,969,927			7,763,434
Research and development		1,847,101			1,281,361			3,767,531			2,653,401
Total operating expenses		7,168,486			6,156,219			14,606,975			12,173,078
Operating loss		(5,676,904	)		(4,082,015	)		(11,930,939	)		(8,663,728	)

Other income (expense):
Interest expense		(238,515	)		(260,289	)		(487,827	)		(530,646	)
Interest income		32,090			7,820			38,304			14,032
Gain on forgiveness of PPP Loan		0			1,735,792			0			1,735,792
Total other income (expense)		(206,425	)		1,483,323			(449,523	)		1,219,178
Net loss before income taxes		(5,883,329	)		(2,598,692	)		(12,380,462	)		(7,444,550	)
Provision for income taxes		(4,880	)		(16,260	)		(5,266	)		(18,709	)
Net loss	$	(5,888,209	)	$	(2,614,952	)	$	(12,385,728	)	$	(7,463,259	)
Net loss per share, basic and diluted	$	(0.54	)	$	(0.39	)	$	(1.30	)	$	(1.17	)
Shares used in computing net loss per share, basic and diluted		11,002,456			6,687,330			9,515,376			6,365,827

See notes to the unaudited condensed consolidated financial statements.

HTG Molecular Diagnostics, Inc.

Condensed Consolidated Statements of ~~Changes in Stockholders’ Equity~~Comprehensive Loss

(Unaudited)

Three and Nine Months Ended September 30, 2021

Series A Convertible Preferred Stock

Common Stock

Additional
Paid-In

Accumulated
Other
Comprehensive

Accumulated

Total
Stockholders'

Shares

Amount

Shares

Amount

Capital

Income (Loss)

Deficit

Equity

Balance at January 1, 2021

23,770

$
24

5,199,997

$
5,200

$
205,661,999

$
5,298

$
(191,187,861
)

$
14,484,660

Stock-based compensation expense

—

—

—

—

337,823

—

—

337,823

Release of restricted stock awards

—

—

1,390

1

—

—

—

1

Net share settlement of restricted stock awards

—

—

(250
)

—

(1,197
)

—

—

(1,197
)
Employee stock purchase plan expense

—

—

—

—

13,115

—

—

13,115

Issuance of common stock from ATM offering, net of commissions of approximately $0.2 million

—

—

1,058,045

1,058

6,854,140

—

—

6,855,198

Exercise of stock options

—

—

75

—

326

—

—

326

Net loss

—

—

—

—

—

—

(4,848,307
)

(4,848,307
)
Foreign currency translation adjustment

—

—

—

—

—

(1,557
)

—

(1,557
)
Balance at March 31, 2021

23,770

$
24

6,259,257

$
6,259

$
212,866,206

$
3,741

$
(196,036,168
)

$
16,840,062

Stock-based compensation expense

—

—

—

—

339,369

—

—

339,369

Release of restricted stock awards

—

—

992

1

—

—

—

1

Net share settlement of restricted stock awards

—

—

(127
)

—

(695
)

—

—

(695
)
Employee stock purchase plan expense

—

—

—

—

13,116

—

—

13,116

Stock issued under stock purchase plans

—

—

13,637

13

53,424

—

—

53,437

Issuance of common stock from ATM offering, net of commissions of approximately $0.1 million

—

—

992,834

993

3,809,628

—

—

3,810,621

Exercise of pre-funded warrants

—

144,881

145

(145
)

—

—

—

Net loss

—

—

—

—

—

—

(2,614,952
)

(2,614,952
)
Foreign currency translation adjustment

—

—

—

—

—

(145
)

—

(145
)
Balance at June 30, 2021

23,770

$
24

7,411,474

$
7,411

$
217,080,903

$
3,596

$
(198,651,120
)

$
18,440,814

Stock-based compensation expense

—

—

—

—

323,172

—

—

323,172

Release of restricted stock awards

—

—

1,158

2

—

—

—

2

Net share settlement of restricted stock awards

—

—

(117
)

—

(679
)

—

—

(679
)
Employee stock purchase plan expense

—

—

—

—

15,719

—

—

15,719

Issuance of common stock in connection with LP Purchase Agreement

—

—

101,218

101

599,878

—

—

599,979

Net loss

—

—

—

—

—

—

(4,490,622
)

(4,490,622
)
Foreign currency translation adjustment

—

—

—

—

—

(1,013
)

—

(1,013
)
Balance at September 30, 2021

23,770

$
24

7,513,733

$
7,514

$
218,018,993

$
2,583

$
(203,141,742
)

$
14,887,372


	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Net loss	$	(5,888,209	)	$	(2,614,952	)	$	(12,385,728	)	$	(7,463,259	)
Other comprehensive loss, net of tax effect:
Unrealized loss on short-term investments		(12,214	)		0			(12,214	)		0
Foreign currency translation adjustment		(3,097	)		(145	)		(5,390	)		(1,702	)
Total other comprehensive loss		(15,311	)		(145	)		(17,604	)		(1,702	)
Comprehensive loss	$	(5,903,520	)	$	(2,615,097	)	$	(12,403,332	)	$	(7,464,961	)

Three and Nine Months Ended September 30, 2020

Series A Convertible Preferred Stock

Common Stock

Additional
Paid-In

Accumulated
Other
Comprehensive

Accumulated

Total
Stockholders'

Shares

Amount

Shares

Amount

Capital

Income (Loss)

Deficit

Equity

Balance at January 1, 2020

-

$
-

3,872,682

$
3,873

$
194,288,368

$
(4,964
)

$
(170,317,643
)

$
23,969,634

Stock-based compensation expense

—

—

—

—

415,256

—

—

415,256

Release of restricted stock awards

—

—

2,396

2

34

—

—

36

Net share settlement of restricted stock awards

—

—

(751
)

(1
)

(7,051
)

—

—

(7,052
)
Employee stock purchase plan expense

—

—

—

—

5,379

—

—

5,379

Issuance of common stock from ATM offering, net of commissions and issuance costs of approximately $0.2 million

—

—

293,271

293

2,435,619

—

—

2,435,912

Issuance of Series A convertible preferred stock in private placement, net of issuance costs of $37,000

10,170

10

—

—

562,945

—

—

562,955

Issuance of Series A convertible preferred stock in exchange for outstanding common stock

41,100

41

—

—

2,424,859

—

—

2,424,900

Cancellation of common stock received in exchange for Series A convertible preferred stock

—

—

(274,000
)

(274
)

(2,424,626
)

—

—

(2,424,900
)
Exercise of pre-funded warrants

—

—

211,784

212

31,556

—

—

31,768

Issuance of common stock in connection with LP Purchase Agreement

—

—

41,026

41

(41
)

—

—

—

Transaction costs incurred in connection with LP Purchase Agreement

—

—

—

—

(96,000
)

—

—

(96,000
)
Net loss

—

—

—

—

—

—

(5,457,898
)

(5,457,898
)
Unrealized gain on short-term investments

—

—

—

—

—

47,697

—

47,697

Foreign currency translation adjustment

—

—

—

—

—

5,497

—

5,497

Balance at March 31, 2020

51,270

$
51

4,146,408

$
4,146

$
197,636,298

$
48,230

$
(175,775,541
)

$
21,913,184

Stock-based compensation expense

—

—

—

—

361,477

—

—

361,477

Release of restricted stock awards

—

—

1,583

2

22

—

—

24

Net share settlement of restricted stock awards

—

—

(426
)

—

(2,108
)

—

—

(2,108
)
Stock issued under stock purchase plan

—

—

3,033

3

30,509

—

—

30,512

Issuance of common stock from ATM offering, net of commissions of $43,000

—

—

138,981

139

1,394,919

—

—

1,395,058

Conversion of Series A convertible preferred stock for common stock

(27,500
)

(27
)

183,333

183

(156
)

—

—

—

Adjustment in connection with LP Purchase Agreement commitment fee and transaction costs

—

—

—

—

301,538

—

—

301,538

Issuance of common stock warrants in connection with SVB Term Loan

—

—

—

—

420,000

—

—

420,000

Net loss

—

—

—

—

—

—

(5,710,551
)

(5,710,551
)
Unrealized loss on short-term investments

—

—

—

—

—

(26,136
)

—

(26,136
)
Foreign currency translation adjustment

—

—

—

—

—

909

—

909

Balance at June 30, 2020

23,770

$
24

4,472,912

$
4,473

$
200,142,499

$
23,003

$
(181,486,092
)

$
18,683,907

Stock-based compensation expense

—

—

—

—

386,911

—

—

386,911

Release of restricted stock awards

—

—

2,542

3

35

—

—

38

Net share settlement of restricted stock awards

—

—

(339
)

—

(3,664
)

—

—

(3,664
)
Employee stock purchase plan expense

—

—

—

—

5,214

—

—

5,214

Issuance of common stock from ATM offering, net of commissions costs of $79,000

—

—

263,482

263

2,556,749

—

—

2,557,012

Net loss

—

—

—

—

—

—

(5,411,788
)

(5,411,788
)
Unrealized loss on short-term investments

—

—

—

—

—

(17,501
)

—

(17,501
)
Foreign currency translation adjustment

—

—

—

—

—

1,225

—

1,225

Balance at September 30, 2020

23,770

$
24

4,738,597

$
4,739

$
203,087,744

$
6,727

$
(186,897,880
)

$
16,201,354

See notes to the unaudited condensed consolidated financial statements.

HTG Molecular Diagnostics, Inc.

Condensed Consolidated Statements of ~~Cash Flows~~Changes in Stockholders’ Equity

(Unaudited)

Nine Months Ended September 30,

2021

2020

Operating activities

Net loss

$
(11,953,881
)

$
(16,580,237
)
Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

568,380

1,039,989

Accretion of discount on NuvoGen obligation

(9,206
)

(9,771
)
Provision for excess inventory

60,143

5,649

Amortization of QNAH Convertible Note issuance costs

—

6,505

Amortization of MidCap Credit Facility discount and issuance costs

—

101,482

Amortization of SVB Term Loan discount and issuance costs

351,068

121,168

Stock-based compensation expense

1,000,368

1,163,742

Employee stock purchase plan expense

41,950

15,972

Non-cash operating lease expense

359,014

465,504

Accrued interest on available-for-sale securities investments

(18,394
)

(101,996
)
Stock compensation expense in connection with LP Purchase Agreement

—

205,538

Gain on forgiveness of PPP Loan

(1,735,792
)

—

Loss on extinguishment of Midcap Credit Facility and QNAH Convertible Note

—

522,394

Loss on abandonment and disposal of assets, net

178,925

77,498

Changes in operating assets and liabilities:

Accounts receivable

(597,489
)

1,793,975

Inventory

(892,655
)

(255,718
)
Prepaid expenses and other

(300,469
)

457,504

Deferred offering costs

—

140,320

Accounts payable

(50,230
)

(778,706
)
Accrued liabilities

205,015

(474,521
)
Contract liabilities

53,062

(74,700
)
Operating lease liabilities

(378,355
)

(583,828
)
Net cash used in operating activities

(13,118,546
)

(12,742,237
)
Investing activities

Purchase of property and equipment

(590,736
)

(418,712
)
Maturities of available-for-sale securities

9,000,000

25,450,000

Purchase of available-for-sale securities

(17,871,203
)

(11,565,882
)
Net cash (used in) provided by investing activities

(9,461,939
)

13,465,406

Financing activities

Proceeds from issuance of SVB Term Loan

—

10,000,000

Payment of SVB Term Loan issuance costs

—

(115,193
)
Payments for extinguishment of MidCap Credit Facility

—

(7,438,623
)
Payments for extinguishment of QNAH Convertible Note

—

(3,000,000
)
Proceeds from ATM Offering, net of commissions of $0.3 million

10,665,819

6,387,982

Proceeds from LP Purchase Agreement

599,979

—

Proceeds from PPP Loan

—

1,717,000

Proceeds from Series A convertible preferred stock in private placement

—

562,955

Payments on NuvoGen obligation

(379,431
)

(539,323
)
Proceeds from exercise of pre-funded warrants

—

31,768

Proceeds from shares purchased under stock purchase plans

53,437

25,133

Payments on financing leases

(18,040
)

(32,553
)
Proceeds from exercise of stock options

326

—

Taxes paid for net share settlement of restricted stock awards

(2,571
)

(12,824
)
Payments on 2021 and 2020 Insurance Notes

(494,352
)

(324,301
)
Net cash provided by financing activities

10,425,167

7,262,021

Effect of exchange rates on cash

(12,848
)

9,283

Increase (decrease) in cash, cash equivalents and restricted cash

(12,168,166
)

7,994,473

Cash, cash equivalents and restricted cash at beginning of period

22,397,812

10,889,995

Cash, cash equivalents and restricted cash at end of period

$
10,229,646

$
18,884,468

Supplemental disclosure of noncash investing and financing activities

Issuance of Series A convertible preferred stock in exchange for outstanding common stock

$
-

$
2,424,900

Issuance of common stock upon conversion of Series A convertible preferred stock

—

1,622,500

Issuance of common stock from cashless exercise of pre-funded warrants

145

—

Operating lease right-of-use assets obtained in exchange for operating lease liabilities

1,302,457

21,078

Carrying value of demonstration units transferred from property and equipment to inventory

16,128

18,817

2021 and 2020 Insurance Notes issued for insurance premiums

746,360

735,195

Gain on forgiveness of PPP Loan

1,735,792

—

Supplemental cash flow information

Cash paid for interest

$
450,344

$
719,676

Cash paid for taxes

12,665

9,961


	Three and Six Months Ended June 30, 2022
	Series A Convertible Preferred Stock						Common Stock						Additional Paid-In			Accumulated Other Comprehensive			Accumulated			Total Stockholders'
	Shares			Amount			Shares			Amount			Capital			Income (Loss)			Deficit			Equity

Balance at January 1, 2022		23,770		$	24			7,588,085		$	7,588		$	218,723,349		$	1,894		$	(208,333,031	)	$	10,399,824
Stock-based compensation expense		—			—			—			—			251,214			—			—			251,214
Release of restricted stock awards		—			—			4,148			4			(4	)		—			—			—
Net share settlement of restricted stock awards		—			—			(1,500	)		(1	)		(8,128	)		—			—			(8,129	)
Employee stock purchase plan expense		—			—			—			—			16,591			—			—			16,591
Issuance of common stock from March 2022 Purchase Agreement, net of approximately $0.4 million of issuance costs		—			—			834,054			834			7,107,952			—			—			7,108,786
Conversion of Series A convertible preferred stock for common stock		(23,770	)		(24	)		158,466			158			(134	)		—			—			—
Net loss		—			—			—			—			—			—			(6,497,519	)		(6,497,519	)
Foreign currency translation adjustment		—			—			—			—			—			(2,293	)		—			(2,293	)
Balance at March 31, 2022		—		$	—			8,583,253		$	8,583		$	226,090,840		$	(399	)	$	(214,830,550	)	$	11,268,474
Stock-based compensation expense		—			—			—			—			214,742			—			—			214,742
Release of restricted stock awards		—			—			4,148			4			(4	)		—			—			—
Net share settlement of restricted stock awards		—			—			(1,355	)		(1	)		(1,884	)		—			—			(1,885	)
Employee stock purchase plan expense		—			—			—			—			16,592			—			—			16,592
Stock issued under stock purchase plans		—			—			49,007			49			23,278									23,327
Exercise of pre-funded warrants		—			—			2,410,933			2,411			—			—			—			2,411
Issuance costs related to March 2022 Purchase Agreement		—			—			—			—			(50,452	)		—			—			(50,452	)
Net loss		—			—			—			—			—			—			(5,888,209	)		(5,888,209	)
Unrealized loss on short-term investments		—			—			—			—			—			(12,214	)		—			(12,214	)
Foreign currency translation adjustment		—			—			—			—			—			(3,097	)		—			(3,097	)
Balance at June 30, 2022		—		$	—			11,045,986		$	11,046		$	226,293,112		$	(15,710	)	$	(220,718,759	)	$	5,569,689


	Three and Six Months Ended June 30, 2021
	Series A Convertible Preferred Stock				Common Stock					Additional Paid-In			Accumulated Other Comprehensive			Accumulated			Total Stockholders'
	Shares		Amount		Shares			Amount		Capital			Income (Loss)			Deficit			Equity

Balance at January 1, 2021		23,770	$	24		5,199,997		$	5,200	$	205,661,999		$	5,298		$	(191,187,861	)	$	14,484,660
Stock-based compensation expense		—		—		—			—		337,823			—			—			337,823
Release of restricted stock awards		—		—		1,390			1		—			—			—			1
Net share settlement of restricted stock awards		—		—		(250	)		—		(1,197	)		—			—			(1,197	)
Employee stock purchase plan expense		—		—		—			—		13,115			—			—			13,115
Issuance of common stock from ATM offering, net of commissions of approximately $0.2 million		—		—		1,058,045			1,058		6,854,140			—			—			6,855,198
Exercise of stock options		—		—		75			—		326			—			—			326
Net loss		—		—		—			—		—			—			(4,848,307	)		(4,848,307	)
Foreign currency translation adjustment		—		—		—			—		—			(1,557	)		—			(1,557	)
Balance at March 31, 2021		23,770	$	24		6,259,257		$	6,259	$	212,866,206		$	3,741		$	(196,036,168	)	$	16,840,062
Stock-based compensation expense		—		—		—			—		339,369			—			—			339,369
Release of restricted stock awards		—		—		992			1		—			—			—			1
Net share settlement of restricted stock awards		—		—		(127	)		—		(695	)		—			—			(695	)
Employee stock purchase plan expense		—		—		—			—		13,116			—			—			13,116
Stock issued under stock purchase plans		—		—		13,637			13		53,424			—			—			53,437
Issuance of common stock from ATM offering, net of commissions of approximately $0.1 million		—		—		992,834			993		3,809,628			—			—			3,810,621
Exercise of pre-funded warrants				—		144,881			145		(145	)		—			—			—
Net loss		—		—		—			—		—			—			(2,614,952	)		(2,614,952	)
Foreign currency translation adjustment		—		—		—			—		—			(145	)		—			(145	)
Balance at June 30, 2021		23,770	$	24		7,411,474		$	7,411	$	217,080,903		$	3,596		$	(198,651,120	)	$	18,440,814

See notes to the unaudited condensed consolidated financial statements.

HTG Molecular Diagnostics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Six Months Ended June 30,
	2022			2021
Operating activities
Net loss	$	(12,385,728	)	$	(7,463,259	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		353,269			375,334
Accretion of discount on NuvoGen obligation		(5,850	)		(6,149	)
Provision for excess inventory		157,409			5,507
Amortization of SVB Term Loan discount and issuance costs		227,303			234,927
Stock-based compensation expense		465,956			677,194
Employee stock purchase plan expense		33,183			26,231
Non-cash operating lease expense		202,091			254,584
Accrued interest on available-for-sale securities investments		(218	)		(10,530	)
Gain on forgiveness of PPP Loan		—			(1,735,792	)
(Gain) loss on abandonment and disposal of assets, net		(4,000	)		178,925
Changes in operating assets and liabilities:
Accounts receivable		833,373			(114,735	)
Inventory		(232,328	)		(831,511	)
Prepaid expenses and other		1,104			(573,569	)
Accounts payable		(544,368	)		443,816
Accrued liabilities		(676,855	)		(117,926	)
Contract liabilities		(11,114	)		21,241
Operating lease liabilities		(202,331	)		(266,464	)
Net cash used in operating activities		(11,789,104	)		(8,902,176	)
Investing activities
Purchase of property and equipment		(15,078	)		(241,474	)
Gain on sales of property and equipment		4,000			—
Maturities of available-for-sale securities		11,600,000			6,300,000
Purchase of available-for-sale securities		(7,610,724	)		(16,173,223	)
Net cash (used in) provided by investing activities		3,978,198			(10,114,697	)
Financing activities
Proceeds from ATM Offering, net of commissions of $0.3 million		—			10,665,819
Proceeds from March 2022 Purchase Agreement, net of $0.4 million of issuance costs		7,073,950			—
Payments on NuvoGen obligation		(272,624	)		(254,979	)
Payments on SVB Term Loan		(2,500,000	)		—
Payments on deferred offering costs		(67,845	)		—
Payments on financing leases		(9,082	)		(12,694	)
Proceeds from exercise of stock options		—			326
Taxes paid for net share settlement of restricted stock awards		(10,014	)		(1,892	)
Proceeds from shares purchased under stock purchase plans		23,327			53,437
Proceeds from exercise of pre-funded warrants		2,411			—
Payments on insurance notes		(258,011	)		(247,047	)
Net cash provided by financing activities		3,982,112			10,202,970
Effect of exchange rates on cash		(14,578	)		(7,464	)
Decrease in cash and cash equivalents		(3,843,372	)		(8,821,367	)
Cash and cash equivalents at beginning of period		9,599,950			22,397,812
Cash and cash equivalents at end of period	$	5,756,578		$	13,576,445
Supplemental disclosure of noncash investing and financing activities
Fixed asset purchases payable and accrued at period end	$	—		$	41,864
Issuance of common stock upon conversion of Series A convertible preferred stock		1,402,430			—
Issuance of common stock from cashless exercise of pre-funded warrants		—			145
Deferred financing costs payable and accrued at period end		15,616			—
2022 and 2021 Insurance Notes issued for insurance premiums		822,889			746,360
Gain on forgiveness of PPP Loan		—			1,735,792
Reclassification of refund liability to accounts receivable		—			281,722
Supplemental cash flow information
Cash paid for interest	$	272,920		$	296,835
Cash paid for taxes		5,399			12,665

See notes to the unaudited condensed consolidated financial statements.

HTG Molecular Diagnostics, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

Note 1. Description of Business, Basis of Presentation and Principles of Consolidation

HTG Molecular Diagnostics, Inc. (the “Company”) is a life science company whose mission is to advance precision medicine through its innovative transcriptome-wide profiling technology. The Company derives revenue primarily from sales of its HTG EdgeSeq ~~instrument~~ system and integrated next-generation sequencing-based (“NGS-based”) HTG EdgeSeq ~~assays, from sample processing and custom~~ research use only (“RUO”) ~~assay design services~~assays and from ~~collaborative development services.~~sample processing services performed in its VERI/O laboratory.

The Company operates in 1 segment and its customers and distributors are located primarily in the United States and Europe. For sales to distributors, their locations may be different from the locations of the end customers. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022, approximately ~~24%~~42% and ~~30%~~32%, respectively, of the Company’s revenue was generated from sales originated by customers located outside of the United States, compared with ~~19%~~30% and ~~31%~~34% for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively.

COVID-19 Pandemic

The full impact of the COVID-19 pandemic ~~(“COVID-19”~~("COVID-19") continues to evolve as of the date of this report and management continues to actively monitor the potential impact of the global situation on its financial condition, liquidity, ~~and future results of~~ operations, suppliers, industry and workforce. Given the ongoing evolution of COVID-19, including ~~the emergence of variants and~~ resurgences in many areas of the world and the global responses to curb its spread, the Company is not able to fully estimate the effects of COVID-19 on its results of operations, financial condition or liquidity.

The Company experienced a significant slowing of product and product-related services revenue generation beginning in March 2020 and ~~continuing~~believes that while it has seen some recovery, this impact will continue to be seen at some level at least throughout ~~2020 and the three quarters of 2021.~~2022. The extent of this impact has varied from customer to customer depending upon how they have been directly or indirectly impacted by local stay-at-home orders and other social distancing measures, ~~prioritization by those customers~~how they have prioritized studies and previously planned trials as the immediate impacts of the pandemic have passed, and ~~the workforce~~how significantly their workforces and supplier ~~impacts that COVID-19 has had on each customer.~~

~~In March 2020,~~networks have been impacted by the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to COVID-19. On April 21, 2020, the Company received proceeds from a loan pursuant to the Paycheck Protection Program (“PPP”) of the CARES Act (the “PPP Loan”) in the amount of $1.7 million from Silicon Valley Bank (“SVB”), as lender (see Note 8).pandemic. The Company ~~applied for full forgiveness~~has not experienced delays in development even with its efforts to prioritize the safety of its employees during this pandemic. In addition, the ~~PPP Loan~~impact of COVID-19 on the Company’s ability to source raw materials and other supplies has not been significant to date. However, a change in October 2020. In May 2021, the Company received notification that the PPP Loan and related accrued interest, totaling $1,735,792, were forgiven by the U.S. Small Business Administration (“SBA”), and that the PPP Loan note had been canceled.

~~In December 2020, the Consolidated Appropriations Act (the “Appropriations Act”) was signed into law~~or loss of suppliers or other supply chain or distribution network partners due to ~~further address~~ the ongoing impacts of ~~COVID-19. The Appropriations Act introduced several additional potential credits and benefits for employers to consider applying for, including, but not limited to,~~ the ~~ability for employers who have previously obtained a PPP Loan to potentially also qualify for Employee Retention Credits (“ERC”), initially created as part of~~pandemic on the ~~CARES Act. In March 2021,~~global economy could adversely affect the American Rescue Plan of 2021 was enacted to, amongst other things, extend and expand ERC benefits through December 31, 2021. The Company has qualified for certain ERC benefits during the year ended December 31, 2020Company’s business and the ~~first three quarters~~business of ~~2021~~its vendors, partners and ~~expects to continue to seek out these benefits~~customers, and could result in future ~~periods as appropriate. ERC benefits of approximately $0.6 million~~reductions in sales and ~~$1.7 million were included in~~ operating ~~expenses as an offset to the related compensation costs in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2021, respectively.~~results.

While there remains uncertainty as to the ~~ultimate~~future impact of COVID-19, the Company has considered the known impacts on its business as of the date these condensed consolidated financial statements were issued and has reflected any known or expected impacts in its condensed consolidated financial statements, including consideration of potential impairment risks to its long-lived assets, potential accounts receivable collection risks and potential impacts to its overall liquidity position.

As a result of various government programs enacted to address the ongoing impacts of COVID-19, the Company was able to qualify for and receive Employee Retention Credits (“ERC”) during the year ended December 31, 2021. ERC benefits of approximately $0.2 million, $0.3 million, and $0.1 million were included in cost of product and product-related services revenue, selling, general and administrative and research and development, respectively, as an offset to the related compensation costs in the accompanying condensed consolidated statements of operations for the three months ended June 30, 2021. ERC benefits of approximately $0.3 million, $0.5 million, and $0.3 million were included in cost of product and product-related services revenue, selling, general and administrative and research and development, respectively, as an offset to the related compensation costs in the accompanying condensed consolidated statements of operations for the six months ended June 30, 2021. In November 2021, the Infrastructure Investment and Jobs Act was signed into law, making wages paid after September 30, 2021 ineligible for these credits. As such, 0 further ERC benefits were received for the three and six months ended June 30, 2022. ERC benefits receivable of $0.4 million were included in prepaid expenses and other in the accompanying condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021.

In April 2020, the Company received proceeds from a loan pursuant to the Paycheck Protection Program (“PPP”) of the CARES Act (the “PPP Loan”) in the amount of $1.7 million from SVB, as lender. The Company applied for full forgiveness of the PPP Loan in October 2020. In May 2021, the Company received notification that the PPP Loan and related interest, totaling $1,735,792, were forgiven by the U.S. Small Business Administration (“SBA”), and that the PPP Loan had been canceled. Accordingly, the Company recorded a gain on forgiveness of the PPP Loan of $1.7 million for both the three and six months ended June 30, 2021, included in other income (expense) in the accompanying condensed consolidated statements of operations.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of ~~September~~June 30, ~~2021~~2022 and for ~~the~~ three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020.~~2021. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. The accompanying condensed consolidated financial statements reflect all normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The accompanying condensed consolidated balance sheet at December 31, ~~2020~~2021 has been derived from the audited consolidated financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, ~~2020,~~2021, included in the Company’s Annual Report on Form 10-K filed with the SEC on March ~~25, 2021.~~29, 2022.

All share and per share amounts within the condensed consolidated financial statements and notes thereto have been adjusted to reflect the reverse stock split completed by the Company in November 2020 for all periods and dates presented. See Note 14 for more information about the Company’s reverse stock split.

Going Concern and Liquidity

Management has assessed the Company’s ability to continue as a going concern within one year of issuance of these financial statements. The accompanying interim unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of ~~the~~ assets and satisfaction of liabilities in the normal course of business. However, the Company has had recurring operating losses and negative operating cash flows since its inception and has an accumulated deficit of ~~$203.1~~$220.7 million as of ~~September~~June 30, ~~2021.~~2022. As of ~~September~~June 30, ~~2021,~~2022, the Company had working capital of ~~$23.7~~$9.2 million and long-term liabilities of ~~$11.5~~$6.5 million. The Company’s liability balances consist primarily of its debt obligations, including an asset-secured loan (the "SVB Term Loan") with Silicon Valley Bank ~~(the “SVB Term Loan”~~("SVB"), as well as an obligation to NuvoGen Research, LLC (the “NuvoGen obligation”) (see Note 10). ~~Potentially~~The Company does not currently expect that its existing resources will be sufficient to fund its planned operations and expenditures through at least the next 12 months from issuance of these consolidated financial statements. The Company currently expects that its existing resources will be sufficient to fund its planned operations and expenditures until January 2023. In addition, potentially changing circumstances, including those related to COVID-19 ~~uncertainties,~~and inflation, may result in the depletion of the Company’s capital resources more rapidly than it currently anticipates, resulting in the Company not having adequate resources to fund its planned operations and expenditures for at least the next 12 months and to comply with the financial covenant in the Loan and Security Agreement for the SVB Term Loan (the “Loan Agreement”).anticipates. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.

The Company will need to raise additional capital to fund its operations and service its long-term debt obligations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. ~~In addition,~~If the Company must comply with a financial covenant in the SVB Term Loan requiring the Company to maintain unrestricted cash of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months. ~~If sufficient additional capital~~ is not ~~available as and when needed,~~able to generate additional capital, the Company may have to delay, scale back or discontinue one or more product development programs, curtail its ~~commercialization~~commercial activities, significantly reduce expenses, sell assets (potentially at a discount to their fair value or carrying value), enter into relationships with third parties to develop or commercialize products or technologies that the Company otherwise would have sought to develop or commercialize independently, cease operations altogether, pursue a sale of the Company at a price that may result in a significant loss on investment for its stockholders, file for bankruptcy or seek other protection from creditors, or liquidate all assets. In addition, if the Company defaults under any of the provisions of the Loan and Security Agreement for the SVB Term Loan (the "Loan Agreement"), SVB could charge an interest rate of 5% above the otherwise applicable floating rate, accelerate ~~the~~ payment of the SVB Term Loan and ultimately foreclose on the Company’s assets.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, HTG Molecular Diagnostics France, SARL, after elimination of all intercompany transactions and ~~balances as of September 30, 2021 and December 31, 2020.~~balances.

Concentration Risks

Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market

accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant.

The Company sells its instrument, related consumables, sample processing services and custom RUO assay design ~~and collaborative development~~ services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date.

~~The Company’s top 2~~NaN customers accounted for ~~27%~~19% and ~~13%~~15% of the Company’s ~~total~~revenue for three months ended June 30, 2022, compared with a single customer accounting for 31% of the Company’s revenue for the three months ended ~~September~~June 30, ~~2021,~~2021. NaN customers accounted for 19%, 12% and 10% of the Company’s revenue for the six months ended June 30, 2022, compared with ~~the Company’s top 2~~3 customers accounting for ~~24%~~15%, 11% and ~~10%~~10% of the Company’s ~~total~~ revenue for the ~~three~~six months ended ~~September~~June 30, ~~2020. The Company’s top 2~~2021.

NaN customers accounted for ~~23%~~23%, 22% and 12% of the Company’s total revenue for the nine months ended September 30, 2021, compared with the Company’s top two customer accounting for 16% and 10% of the Company’s total revenue for the nine months ended September 30, 2020.

~~The largest 2 customers accounted for 52% and 11%~~15% of the Company’s accounts receivable, net as of ~~September~~June 30, ~~2021. The largest 2~~2022. NaN customers accounted for approximately 9%18% and 17% of the Company’s accounts receivable, net as of December 31, 2021. NaN additional customers accounted for approximately 10% each of the Company’s accounts receivable, net as of December 31, ~~2020.~~2021.

NaN vendors accounted for ~~26%, 14%~~11% and ~~10%~~10% of the Company’s accounts payable as of ~~September~~June 30, ~~2021,~~2022, compared with 2 vendors who accounted for ~~21%~~28% and ~~20%~~16% of the Company’s accounts payable as of December 31, ~~2020.~~2021.

The Company ~~currently relies~~is also subject to supply chain risks related to the reliance on a single supplier to ~~produce~~manufacture a subcomponent used in its HTG EdgeSeq ~~processors. A~~instruments. Although there are a limited number of manufacturers for components of this type, the Company believes that other suppliers could provide similar products on comparable terms. However, a change in or loss of this supplier could significantly delay the delivery of ~~processors,~~products, which in turn ~~could~~would materially affect the Company’s ability to generate revenue.

Note 2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s estimates include revenue recognition, stock-based compensation expense, bonus and warranty accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, lease liability, inventory ~~obsolescence and~~ valuation, ~~of inventory,~~ accounts receivable, allowance for doubtful accounts and available-for-sale securities. Actual results could materially differ from those estimates, especially in light of the significant uncertainty that remains as to the full impact of COVID-19 on the Company’s operations, as well as those of its workforce, supply chains, distribution networks and those of its customers.

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the consolidated financial statements included in the Company’s Annual Report on Form 10-K, filed with the SEC on March ~~25, 2021.~~29, 2022.

Fair Value of Financial Instruments

The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which is determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the SVB Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt with similar terms and risk characteristics.

The ~~NuvoGen~~Company’s obligation ~~relates~~related to an asset purchase transaction with a then-common stockholder of the Company, ~~(see Note 10). As of September 30, 2021, the~~(the “NuvoGen obligation”) had an estimated ~~aggregate~~ fair value of ~~the NuvoGen obligation is~~ approximately ~~$4.7~~$3.9 million as of June 30, 2022. This estimated fair value represents a Level 3 measurement that has been determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates.

Inventory

Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.

We charge cost of sales for inventory provisions to write-down our inventory to the lower of cost or net realizable value or for obsolete or excess inventory. Most of our inventory provisions relate to excess quantities of products, based on our inventory levels and future product purchase commitments compared to assumptions about future demand and market conditions. Once inventory has been written-off or written-down, it creates a new cost basis for the inventory that is not subsequently written-up.

~~Recently Adopted~~New Accounting Pronouncements

~~In October 2020, the~~The following are new Financial Accounting Standards Board ~~(“FASB”~~("FASB") ~~issued~~ Accounting ~~Standards Codification (“ASC” or~~Standard Updates ("ASU") that had not been adopted by the ~~“FASB Codification”) Update (“ASU”) No. 2020-10, Codification Improvements (“Update No. 2020-10”), which amended a variety~~Company as of topics in the FASB Codification in order to improve the consistency of the Codification and the application thereof, while leaving GAAP unchanged. Update No. 2020-10 was effective for fiscal years beginning after December 15, 2020 for public business entities. The Company’s adoption of this standard on January 1, 2021 did not have a material impact on its condensed consolidated financial statements or related footnote disclosures.June 30, 2022:

In ~~December 2019,~~June 2022, the FASB issued ASU ~~No. 2019-12,~~2022-03, ~~Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes~~Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“("ASU ~~2019-12”~~2022-03"), which amends Accounting Standards Codification ("ASC") 820 to clarify that a contractual sales restriction is ~~intended~~not considered in measuring an equity security at fair value and to ~~simplify various aspects~~introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU 2022-03 applies to both holders and issuers of ~~the accounting for income taxes.~~equity and equity-linked securities measured at fair value. The amendments in this ASU ~~2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This standard was~~are effective for the Company in fiscal years and interim periods within those fiscal years, beginning after December 15, ~~2020.~~2023. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The ~~Company’s adoption~~Company is still evaluating the impact of this ~~standard~~pronouncement on ~~January 1, 2021 did not have a material impact on its condensed consolidated~~the financial ~~statements or related footnote disclosures.~~

~~New Accounting Pronouncements~~

~~The following are new FASB ASUs that had not been adopted by the Company as of September 30, 2021:~~statements.

In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and also simplifies the diluted earnings per share calculation in certain areas. The standard isbecame effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, and adoption must be as of the beginning of the Company’s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses, which was subsequently amended by ASU 2018-19, ASU 2019-10 and ASU 2020-02, and requires the measurement of expected credit losses for financial instruments carried at amortized cost held at the reporting date based on historical experience, current conditions and reasonable forecasts. The updated guidance also amends the current other-than-temporary impairment model for available-for-sale debt securities by requiring the recognition of impairments relating to credit losses through an allowance account and limits the amount of credit loss to the difference between a security’s amortized cost basis and its fair value. In addition, the length of time a security has been in an unrealized loss position will no longer impact the determination of whether a credit loss exists. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. With the issuance of ASU 2019-10 in November 2019, the standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2022. The Company will continue to assess the possible impact of this standard, but currently does not expect the adoption of this standard will have a significant impact on its consolidated financial statements, given the high credit quality of the obligors to its available-for-sale debt securities and its history of minimal bad debt expense relating to trade accounts receivable.

Note 3. Inventory

Inventory - current, net of allowance, consisted of the following as of the dates indicated:


	September 30,			December 31,			June 30,			December 31,
	2021			2020			2022			2021
Raw materials	$	1,662,205		$	1,079,528		$	1,095,588		$	1,253,111
Work in process		235,637			147,455			263,524			312,803
Finished goods		459,317			291,195			676,278			447,145
Total gross inventory		2,357,159			1,518,178
Total gross inventory - current								2,035,390			2,013,059
Less inventory allowance		(16,393	)		(26,052	)		(79,468	)		(25,306	)
	$	2,340,766		$	1,492,126		$	1,955,922		$	1,987,753

Inventory - non-current, net of excess inventory allowance, consisted of the following and was included in other non-current assets in the condensed consolidated balance sheets as of the dates indicated:


	June 30,			December 31,
	2022			2021
Raw materials - non-current		912,094			711,296
Less excess inventory allowance		(94,048	)		—
	$	818,046		$	711,296

For the three and six months ended June 30, 2022, the Company recorded a specific inventory reserve of ($1,970) and $52,063, respectively, to adjust estimated inventory value for the projected expiration of a specific inventory item, in addition to adjustments to the provision for excess inventory of $5,978 and $11,298 respectively for the three and six months ended June 30, 2022.

For the three and ~~nine~~six months ended ~~September~~June 30, 2021, the Company recorded adjustments to provision for excess inventory of ~~$54,636~~$671 and ~~$60,143, respectively. For the three and nine months ended September 30, 2020, the Company recorded adjustments to provision for excess inventory of $10,530 and $12,202,~~$5,507, respectively. Adjustments in these periods to the allowance for estimated shrinkage, obsolescence and excess inventory have been included in cost of product and product-related services revenue in the accompanying condensed consolidated statements of operations.

In addition, for the three and six months ended June 30, 2022, the Company recorded a provision for excess inventory of $94,048 primarily related to the write-down of excess quantities of raw materials, whose inventory levels were higher than our updated forecasts of future demand for those products.

HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Finished goods inventory under evaluation was $0.2 million as of ~~September~~both June 30, ~~2021 was $169,042 compared with $50,855 as of~~2022 and December 31, ~~2020.~~2021.

Note 4. Fair Value Instruments

Financial assets and liabilities measured at fair value are classified in their entirety in the fair value hierarchy based on the lowest level input significant to the fair value measurement. The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis as of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020~~2021 in the fair value hierarchy:


	June 30, 2022
	Level 1		Level 2		Level 3		Total
Asset included in:
Cash and cash equivalents
Money market securities	$	3,537,763	$	—	$	—	$	3,537,763
Corporate debt securities		—		899,501		—		899,501
Investments available-for-sale at fair value
U.S. Treasury securities		6,994,938		—		—		6,994,938
Corporate debt securities		—		1,347,246		—		1,347,246
Total	$	10,532,701	$	2,246,747	$	—	$	12,779,448

	December 31, 2021
	Level 1		Level 2		Level 3		Total
Asset included in:
Cash and cash equivalents
Money market securities	$	9,083,302	$	—	$	—	$	9,083,302
Investments available-for-sale at fair value
Corporate debt securities		—		12,343,456		—		12,343,456
Total	$	9,083,302	$	12,343,456	$	—	$	21,426,758

September 30, 2021

Level 1

Level 2

Level 3

Total

Asset included in:

Cash and cash equivalents

Money market securities

$
10,055,376

$
—

$
—

$
10,055,376

Investments available-for-sale at fair value

Corporate debt securities

—

15,187,672

—

15,187,672

Total

$
10,055,376

$
15,187,672

$
—

$
25,243,048

December 31, 2020

Level 1

Level 2

Level 3

Total

Asset included in:

Cash and cash equivalents

Money market securities

$
17,497,282

$
—

$
—

$
17,497,282

Corporate debt securities

—

4,499,270

��

4,499,270

Investments available-for-sale at fair value

Corporate debt securities

—

6,298,075

—

6,298,075

Total

$
17,497,282

$
10,797,345

$
—

$
28,294,627

There are no other financial instruments subject to fair value measurement on a recurring basis. Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were 0 transfers between levels for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 or the year ended December 31, ~~2020.~~2021.

Level 1 instruments include investments in money market ~~funds.~~funds and U.S. Treasuries. These instruments are valued using quoted market prices for identical unrestricted instruments in active markets. The Company defines active markets for debt instruments based on both the average daily trading volume and the number of days with trading activity. Level 2 instruments include corporate debt securities, including commercial paper and corporate bonds. Valuations of Level 2 instruments can be verified to quoted prices, recent trading activity for identical or similar instruments, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Consideration is given to the nature of the quotations (e.g., indicative or firm) and the relationship of recent market activity to the prices provided from alternative pricing sources.

Fair values of these assets are based on prices provided by independent market participants that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its Level 1 or 2 securities for the ~~nine-month period~~six months ended ~~September~~June 30, ~~2021~~2022 or the year ended December 31, ~~2020 and did not have any Level 3 financial assets or liabilities during either of these periods.~~2021.

Note 5. Available-for-Sale Securities

The Company’s portfolio of available-for-sale securities consists of U.S. Treasuries and high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities as of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020:~~2021:


	June 30, 2022
			Gross		Gross			Fair Value
	Amortized		Unrealized		Unrealized			(Net Carrying
	Cost		Gains		Losses			Amount)
U.S. Treasury securities	$	7,007,152	$	—	$	(12,214	)	$	6,994,938
Corporate debt securities		1,347,246		—		—			1,347,246
Total available-for-sale securities	$	8,354,398	$	—	$	(12,214	)	$	8,342,184


	December 31, 2021
			Gross		Gross		Fair Value
	Amortized		Unrealized		Unrealized		(Net Carrying
	Cost		Gains		Losses		Amount)
Corporate debt securities	$	12,343,456	$	—	$	—	$	12,343,456
Total available-for-sale securities	$	12,343,456	$	—	$	—	$	12,343,456

September 30, 2021

Gross

Gross

Fair Value

Amortized

Unrealized

Unrealized

(Net Carrying

Cost

Gains

Losses

Amount)

Corporate debt securities

15,187,672

—

—

15,187,672

Total available-for-sale securities
$
15,187,672

$
—

$
—

$
15,187,672

December 31, 2020

Gross

Gross

Fair Value

Amortized

Unrealized

Unrealized

(Net Carrying

Cost

Gains

Losses

Amount)

Corporate debt securities

6,298,075

—

—

6,298,075

Total available-for-sale securities
$
6,298,075

$
—

$
—

$
6,298,075

There were 0 gross unrealized losses relating to the Company’s available-for-sale securities investments as of September 30, 2021. There were 0 net adjustments to unrealized gains (losses) on short-term investments, net of tax in other comprehensive income for the three and nine months ended September 30, 2021. The net adjustment to unrealized ~~gains (losses)~~holding losses on short-term investments, net of tax in other comprehensive income totaled ~~$(17,501) and $4,060~~$(12,214) for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020, respectively.~~2022. All investments that are in a gross unrealized loss position have been in a continuous unrealized loss position for less than one year as of June 30, 2022.

Contractual maturities of ~~debt investment~~all of the Company’s available-for-sale securities investments were less than one year as of ~~September~~June 30, ~~2021 are shown below.~~2022. Expected maturities may differ from contractual maturities where issuers of the securities have the right to prepay obligations without prepayment penalties.

Under

1 Year

1 to 2 Years

Total

Corporate debt securities

15,187,672

—

15,187,672

Total available-for-sale securities
$
15,187,672

$
—

$
15,187,672

Note 6. Property and Equipment

Property and equipment, net, consists of the following as of the dates indicated:


	June 30,			December 31,
	2022			2021
Furniture & fixtures	$	856,331		$	872,877
Leasehold improvements		1,940,177			1,931,762
Equipment used in manufacturing		2,400,242			2,432,242
Equipment used in research & development		2,350,592			2,343,930
Equipment used in the field		216,218			216,218
Software		480,740			480,740
Property and equipment		8,244,300			8,277,769
Less: accumulated depreciation and amortization		(7,463,605	)		(7,158,883	)
	$	780,695		$	1,118,886

September 30,

December 31,

2021

2020

Furniture & fixtures

$
1,086,341

$
1,082,717

Leasehold improvements

1,931,762

1,943,534

Equipment used in manufacturing

2,673,452

2,166,743

Equipment used in research & development

2,506,644

2,506,644

Equipment used in the field

182,762

208,005

Software

488,098

420,301

Property and equipment

8,869,059

8,327,944

Less: accumulated depreciation and amortization

(7,649,869
)

(7,100,542
)

$
1,219,190

$
1,227,402

Depreciation and leasehold improvement amortization expense was approximately ~~$0.2~~$0.2 million and ~~$0.6~~$0.4 million, respectively, for both the three and ~~nine~~six months ended ~~September~~June 30, ~~2021, respectively,~~2022 and ~~$0.3 million and $1.0 million for the three and nine months ended September 30, 2020, respectively.~~2021.

Note 7. Accrued Liabilities

Accrued liabilities consisted of the following as of the dates indicated:


	June 30,		December 31,
	2022		2021
Accrued employee bonuses	$	515,140	$	1,254,355
Payroll and employee benefit accruals		559,011		389,385
Other accrued liabilities		260,136		378,829
	$	1,334,287	$	2,022,569

September 30,

December 31,

2021

2020

Accrued employee bonuses

$
775,219

$
436,799

Payroll and employee benefit accruals

414,177

694,058

Accrued product warranty

92,696

92,696

Other accrued liabilities

326,909

236,325

$
1,609,001

$
1,459,878

Note 8. Debt Obligations

Current portion of long-term debt consisted of the following as of the dates indicated:


	June 30,		December 31,
	2022		2021
SVB Term Loan	$	5,882,353	$	5,000,000
2022 Insurance Note		732,464		0
2021 Insurance Note		0		167,586
	$	6,614,817	$	5,167,586

September 30,

December 31,

2021

2020

SVB Term Loan

$
3,750,000

$
2,000,000

PPP Loan

—

857,040

2021 Insurance Note

417,107

—

2020 Insurance Note

—

165,099

$
4,167,107

$
3,022,139

Long-term debt, net of current portion, discount and debt issuance costs, consisted of the following as of the dates indicated:

September 30,

December 31,

2021

2020

SVB Term Loan, net of discount and debt issuance costs

$
6,309,416

$
7,708,348

PPP Loan

—

859,960

$
6,309,416

$
8,568,308


	June 30,		December 31,
	2022		2021
SVB Term Loan, net of discount and debt issuance costs	$	2,023,579	$	5,178,629

SVB Term Loan

On June 24, 2020 (the “Closing Date”), the Company entered into the SVB Term Loan, by and among the Company and SVB, as lender, which provides a secured term loan in the principal amount of ~~$10.0~~$10.0 million.

The proceeds from the SVB Term Loan were fully funded on June 25, 2020. Together with cash on hand, the proceeds were used to repay in full all outstanding amounts and fees due under the Company’s credit facility with MidCap Financial Trust (the “MidCap Credit Facility”) in an aggregate amount equal to $7.5 million, including collateral agent legal fees and prepayment fees, in addition to the Company’s subordinated convertible promissory note to QNAH (the “QNAH Convertible Note”) and related accrued interest in the aggregate amount of $3.2 million. As a result of the repayment, the Company recorded a loss on extinguishment of the MidCap Credit Facility and the QNAH Convertible Note of $0.5 million in other income (expense) in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2020. All obligations under the MidCap Credit Facility and the QNAH Convertible Note were fulfilled as a result of this extinguishment.

The SVB Term Loan bears interest at a floating rate equal to the greater of ~~2.50%~~2.50% above the Prime Rate (as defined in the Loan Agreement) and ~~5.75%~~5.75%. Interest on the SVB Term Loan is due and payable monthly in arrears. The SVB Term Loan originally required interest-only payments through June 30, 2021. As a result of the Company’s achievement of an equity milestone defined in the Loan Agreement during the quarter ended June 30, 2021, the interest-only period ~~has been~~was extended for six ~~months. The~~months through December 31, 2021. Following the extended interest-only period, ~~will be followed by~~the Loan Agreement required equal monthly payments of principal and interest through the maturity date of December 1, ~~2023.~~2023

The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge), and the Company’s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the Loan Agreement. ~~In addition, the Company~~ .~~must comply with a financial covenant in the SVB Term Loan requiring the Company to maintain unrestricted cash of not less than the greater of (i)~~

~~$12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months.~~

In connection with the Loan Agreement, the Company granted to SVB a warrant to purchase up to 42,894 shares of the Company’s common stock at a purchase price of ~~$11.6565~~$11.6565 per share. The warrant will expire on June 24, 2030 and may be exercised for cash or at the election of the holder on a cashless, net exercise basis. The fair value of the warrant on the date of issuance was approximately ~~$0.4~~$0.4 million, determined using the Black-Scholes option-pricing model, and was recorded as a discount to the SVB Term Loan, with a corresponding credit to additional paid in capital since the warrant met the requirements to be classified as equity.

The Company included ~~$0.7~~$0.4 million and ~~$1.1~~$0.6 million of debt discount associated with the SVB Term Loan, resulting from fees and debt issuance costs, inclusive of the fair value of warrants issued, in long-term debt, net of current portion, discount and debt issuance costs in the accompanying condensed consolidated balance sheets as of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively. Amortization of the debt discount associated with the SVB Term Loan was ~~$0.1~~approximately $0.1 million and ~~$0.4~~$0.2 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, respectively, compared to ~~$0.1~~$0.1 million and $0.2 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, and was included in interest expense in the accompanying condensed consolidated statements of ~~operations~~operations..

~~The remaining principal repayments due under~~On July 14, 2022, the Company and SVB entered into an amendment to the SVB Term Loan ~~as of September 30, 2021 are as follows for each fiscal year:~~

2021

$
-

2022

5,000,000

2023

5,000,000

Total SVB Term Loan payments

10,000,000

Less discount and deferred financing costs

(740,584
)
Plus final fee premium

800,000

Total SVB Term Loan, net

$
10,059,416

~~Paycheck Protection Program~~(the "Term Loan

~~On April 21, 2020,~~ Amendment"). Under the Term Loan Amendment, the Company ~~received proceeds from a loan in~~and SVB agreed to remove the financial covenant under the Loan Agreement that had required the Company to maintain unrestricted cash, including short term investments available-for-sale, of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of ~~$1.7~~the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months. In exchange for this accommodation, the Company prepaid $2.5 million ~~from~~of outstanding principal under the Term Loan (the “Prepayment”). SVB ~~as lender, pursuant~~waived the prepayment fee that otherwise would have applied to the ~~PPP.~~Prepayment. The ~~PPP~~remaining outstanding principal amount due under the Term Loan was evidenced by a promissory note, which bore interest at an annual rate of 1%, and contained customary events of default relating to, among other things, payment defaults and breaches of representations, warranties or terms of the PPP Loan documents. Under the CARES Act and PPP Flexibility Act, loan forgiveness was available for the sum of documented payroll costs (including benefits), rent and utility obligations, and interest on certain of the Company’s other debt obligations incurred during the 24-week period beginning on the date of loan approval, as defined by the applicable guidelines and the SBA. The Company applied for full PPP Loan forgiveness in October 2020.

On May 26, 2021 the Company received notification from SVB that the PPP Loan and related accrued interest was forgiven in full by the SBA, and the PPP Loan note had been canceled. Accordingly, the Company recorded a gain on forgiveness of the PPP Loan of $0 and $1.7 million ~~for the three and nine months ended September 30, 2021, included in other income (expense) in the~~ ~~accompanying condensed consolidated statements of operations. The Company has~~ ~~not accrued any liability associated with the risk of an adverse SBA review~~.

~~Insurance Note~~

On April 27, 2020, the Company entered into a commercial financing agreement to extend the payment period related to its director and officer insurance policy (the “2020 Insurance Note”). The 2020 Insurance Note required a down paymentwill continue to be ~~made upon signing the agreement equal to approximately $0.2 million. The unpaid premium balance of approximately $0.7 million was financed at an annual rate of 3.61% and was repaid~~paid in ~~nine~~ equal monthly payments of principal and interest through the maturity date of ~~February 2021~~December 1, 2023.

On13

Following the Term Loan Amendment the principal repayment schedule under the SVB Term Loan as of June 30, 2022 was as follows for each fiscal year:


2022	$	4,264,706
2023		3,235,294
Total SVB Term Loan payments		7,500,000
Less discount and deferred financing costs		(394,068	)
Plus final fee premium		800,000
Total SVB Term Loan, net	$	7,905,932

Insurance Note

In May 5, 2021, the Company entered into a ~~new~~ commercial financing agreement to extend the payment period related to its director and officer insurance policy (the “2021 Insurance Note”). The 2021 Insurance Note required a down payment to be made upon signing the agreement equal to approximately ~~$0.4~~$0.4 million. The remaining unpaid premium balance of approximately ~~$0.7~~$0.7 million ~~has been~~was financed at an annual rate of ~~3.57%~~3.57% and ~~is to be~~was repaid in nine equal monthly payments of principal and interest ~~beginning in~~ through ~~June 2021~~February 2022. The 2021 Insurance Note contains customary events of default relating to, among other things, payment defaults and breaches of representations, warranties or terms of the 2021 Insurance Note documents, and may be prepaid by the Company at any time prior to maturity with no prepayment penalties.

In May 2022, the Company entered into a new commercial financing agreement to extend the payment period related to its director and officer insurance policy (the “2022 Insurance Note”). The 2022 Insurance Note required a down payment to be made upon signing the agreement equal to approximately $0.3 million. The remaining unpaid premium balance of approximately $0.8 million has been financed at an annual rate of 3.32% and is to be repaid in nine equal monthly payments of principal and interest beginning in June 2022. The 2022 Insurance Note contains customary events of default relating to, among other things, payment defaults and breaches of representations, warranties or terms of the 2022 Insurance Note documents, and may be prepaid by the Company at any time prior to maturity with no prepayment penalties.

Note 9. Revenue from Contracts with Customers

Product and ~~Product-related~~Product-Related Services Revenue

The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021 as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Product revenue:
Instrument	$	177,812	$	397,205	$	370,998	$	621,218
Consumables		830,255		867,970		1,301,469		1,472,352
Total product revenue		1,008,067		1,265,175		1,672,467		2,093,570
Product-related services revenue:
Custom RUO assay design		0		0		0		48,350
RUO sample processing		483,515		809,029		1,003,569		1,367,430
Total product-related services revenue		483,515		809,029		1,003,569		1,415,780
Total product and product-related services revenue	$	1,491,582	$	2,074,204	$	2,676,036	$	3,509,350

Three Months Ended September 30,

Nine Months Ended September 30,

2021

2020

2021

2020

Product revenue:

     Instruments

$
407,130

$
71,742

$
1,028,348

$
563,396

     Consumables

793,542

764,605

2,265,894

2,091,848

Total product revenue

1,200,672

836,347

3,294,242

2,655,244

Product-related services revenue:

     Custom RUO assay design

—

238,502

48,350

1,210,968

     RUO sample processing

1,319,738

626,219

2,687,168

1,551,519

Total product-related services revenue

1,319,738

864,721

2,735,518

2,762,487

Total product and product-related services revenue

$
2,520,410

$
1,701,068

$
6,029,760

$
5,417,731

As the Company’s agreements for product and product-related services revenue have an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations.

Sale of Instruments and Consumables

The delivery of each instrument and the related installation and calibration are considered to be a single performance obligation, as the HTG EdgeSeq instrument must be professionally installed and calibrated prior to use. Instrument product revenue is generally recognized upon installation and calibration of the instrument by field service engineers, which represents the point at which the customer has the ability to use the instrument and has accepted the asset. Installation generally occurs within one month of instrument shipment.

The delivery of each consumable is a separate performance obligation. Consumables revenue is recognized upon transfer of control, which represents the point when the customer has legal title and the significant risks of ownership of the asset. The Company’s standard terms and conditions provide that no right of return exists for instruments and consumables, unless replacement is necessary due to delivery of defective or damaged product. Customer payment terms vary but are typically between 30 and 90 days of revenue being earned from shipment or delivery, as applicable.

The Company provides instruments to certain customers under reagent rental agreements. Under these agreements, the Company installs an instrument in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances, the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. The Company measures progress toward complete satisfaction of this performance obligation to provide the instrument and deliver the consumables using an output method based on the number of consumables delivered in relation to the total consumables to be provided under the reagent rental agreement. This is considered to be representative of the delivery of outputs under the arrangement and the best measure of progress because the customer benefits from the instrument only in conjunction with the consumables. The Company expects to recover the cost of the instrument under the agreement through the fees charged for consumables, to the extent sold, over the term of the agreement.

RUO Sample Processing

The Company also provides sample preparation and processing services and molecular profiling of retrospective cohorts for its customers through its VERI/O laboratory, whereby the customer provides samples to be processed using HTG EdgeSeq technology specified in the order. Customers are charged a per sample fee for sample processing services which is recognized as revenue upon delivery of a data file to the customer showing the results of testing and completing delivery of the agreed upon service. This is when the customer can use and benefit from the results of testing and the Company has the present right to payment.

~~Custom RUO Assay Design and Related Agreements~~

The Company enters into custom RUO assay design agreements that may generate up-front fees and subsequent payments that might be earned upon completion of design process phases. The Company measures progress toward complete satisfaction of its performance obligation to perform custom RUO assay design using an output method based on the costs incurred to date compared with total expected costs, as this is representative of the delivery of outputs under the arrangements and the best measure of progress. However, because in most instances the assay design fees are contingent upon completion of each phase of the design project and the decision of the customer to proceed to the next phase, the amount to be included in the transaction price and recognized as revenue is limited to that which the customer is contractually obligated to pay upon completion of that phase, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Changes in estimates of total expected costs are accounted for prospectively as a change in estimate. From period to period, custom RUO assay design service revenue can fluctuate substantially based on the completion of design-related phases.

~~Collaborative Development Services Revenue~~

The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606 and ASC 808 to determine the appropriate recognition of revenue under its collaborative research, development and commercialization agreements. Because each SOW had an expected duration of one year or less, the Company elected the practical expedient in ASC 606-10-50-14(a) not to disclose information about its remaining performance obligations for each SOW.

Three Months Ended September 30,

Nine Months Ended September 30,

2021

2020

2021

2020

Collaborative development services

$
—

$
76,030

$
—

$
548,135

~~For the three and nine months ended September 30, 2020, collaborative development services revenue was generated through statements of work entered into a~~ Master Assay Development, Commercialization and Manufacturing Agreement (the “Governing Agreement”) with QIAGEN Manchester Limited (“QML”). Under these agreements, the Companies combined technological and commercial strengths to offer biopharmaceutical companies a complete NGS-based solution for the development, manufacture and commercialization of companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. Remaining agreed upon procedures associated with these statements of work were completed in the prior year and no additional collaborative development services programs have been entered into as of September 30, 2021.

Contract Liabilities

The Company may receive up-front payments from customers for custom RUO assay design and sample processing services. In addition, payments for instrument extended warranty contracts are required to be made in advance. The Company recognizes such up-front payments as contract liabilities. The contract liabilities are subsequently reduced as revenue is recognized. Contract liabilities of approximately ~~$0.2~~$0.1 million were included in ~~contract~~other current liabilities ~~– current~~ and an additional immaterial amount of contract liabilities were included in other non-current liabilities in the accompanying condensed consolidated balance sheets as of ~~September~~June 30, ~~2021,~~2022, reflecting the period in which the Company expects to realize the deferred revenue.

Changes in the Company’s contract liability were as follows as of the dates indicated:


	Product Revenue			Sample Processing			Total Contract Liability
Balance at January 1, 2022	$	128,529		$	30,621		$	159,150
Deferral of revenue		176,009			12,697			188,706
Recognition of deferred revenue		(161,948	)		(37,872	)		(199,820	)
Balance as of June 30, 2022	$	142,590		$	5,446		$	148,036


	Product Revenue			Sample Processing			Total Contract Liability
Balance at January 1, 2021	$	103,580		$	93,884		$	197,464
Deferral of revenue		153,400			350,224			503,624
Recognition of deferred revenue		(130,759	)		(351,626	)		(482,385	)
Balance as of June 30, 2021	$	126,221		$	92,482		$	218,703

Product
Revenue

Custom RUO
Assay Design

Sample
Processing

Total Contract
Liability

Balance at January 1, 2021

$
103,580

$
-

$
93,884

$
197,464

Deferral of revenue

261,100

—

525,899

786,999

Recognition of deferred revenue

(198,438
)

—

(535,501
)

(733,939
)
Balance at September 30, 2021

$
166,242

$
—

$
84,282

$
250,524

Product
Revenue

Custom RUO
Assay Design

Sample
Processing

Total Contract
Liability

Balance at January 1, 2020

$
95,148

$
66,216

$
438,090

$
599,454

Deferral of revenue

335,265

459,385

77,104

871,754

Recognition of deferred revenue

(325,181
)

(525,601
)

(95,670
)

(946,452
)
Balance at September 30, 2020

$
105,232

$
—

$
419,524

$
524,756

Note 10. Other Agreements

NuvoGen Obligation

Pursuant to the Company’s asset purchase agreement with NuvoGen Research, LLC (“NuvoGen”), as amended, the Company is obligated to pay NuvoGen annually the greater of ~~$400,000~~$400,000 or 6%6% of annual revenue until the NuvoGen obligation is paid in full.

In addition to the fixed quarterly ~~payments~~payment of ~~$100,000,~~$100,000, there ~~were $51,225~~was 0 revenue-based amount payable as of June 30, 2022, compared with $72,624 of revenue-based payments ~~payable as of September 30, 2021, compared with approximately $54,777 of revenue-based payments payable~~due as of December 31, ~~2020.~~2021. There have been no ~~significant~~ modifications to the terms and conditions of the ~~Company’s~~ NuvoGen obligation since the disclosures made in Part II, Item 8, Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K, filed with the SEC on March ~~25, 2021.~~29, 2022.

Remaining minimum payments to be made in ~~2021 include $51,225~~2022 and in the first and second quarters of ~~revenue-based payments payable~~2023 as ~~of September 30, 2021 and~~reflected in the ~~fourth quarter 2021 minimum payment. Minimum payments for 2022~~table below include an estimate of additional revenue-based payments to be made in ~~the first, second and third~~these quarters, ~~of 2022 relating to revenue generated in the fourth quarter of 2021 and the first and second quarters of 2022,~~ estimated using actual revenue generated in the same ~~quarters~~quarter in ~~2020 and 2021.~~the prior year. Remaining minimum payments include only the minimum quarterly payments to be made in each period. Actual payments could vary from what is shown in the table, to the extent that 6%6% of the Company’s ~~annual~~revenue for the remainder of 2022 and the first and second quarters of 2023 varies from the same periods in prior years and revenue in ~~2022~~the third quarter of 2023 and ~~beyond~~later periods exceeds ~~$400,000.~~$400,000.

The remaining minimum payments to be made to NuvoGen as of ~~September~~June 30, ~~2021~~2022 are as follows for each fiscal year:


2022	$	251,225
2023		472,624
2024		400,000
2025		400,000
2026		400,000
2027 and beyond		2,185,621
Total NuvoGen obligation payments		4,109,470
Plus interest accretion		61,237
Total NuvoGen obligation, net	$	4,170,707

2021

$
151,225

2022

479,432

2023

400,000

2024

400,000

2025

400,000

2026 and beyond

2,702,661

Total NuvoGen obligation payments

4,533,318

Plus interest accretion

70,170

Total NuvoGen obligation, net

$
4,603,488

The Company has recorded the obligation at the estimated present value of the future payments using a discount rate of ~~2.5%~~2.5%, which represents the Company’s estimate of its effective borrowing rate for similar obligations. The unamortized interest accretion was ~~$(70,170)~~$(61,237) and ~~$(79,376)~~$(67,088) as of ~~September~~June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively. Discount accreted during the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 was ~~$(3,057)~~$(2,867) and ~~$(9,206)~~$(5,850), respectively, compared with ~~$(3,115)~~ $(3,043)and ~~$(9,771)~~$(6,149) for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020, respectively.~~2021, respectively, and was included in interest expense in the accompanying condensed consolidated statements of operations.

Note 11. Leases

Operating Leases

TheThe Company leases office space under agreements classified as operating leases. The Company’s active leases as of ~~September~~June 30, ~~2021~~2022 are for office and manufacturing space in Tucson, Arizona, which expire in ~~2025.~~ 2025. The Company’s leases do not include any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees.

The Company amended its Tucson facility leases in December 2020 to extend the terms of the leases for one year, through January 31, 2022 and again in September 2021 to extend the terms of the leases for three years, through January 31, 2025. The lease extensions were treated as lease modifications for accounting purposes, and allow for an additional extension of two years on the same terms and conditions of the existing amended lease agreement, except that the lease rates would be adjusted to reflect lease rates applicable to like-kind buildings within the market at the time that the Company elects to exercise the extension options, but in no event less than the last applicable rental rate. The Company has not accounted for these renewal options in the calculation of the lease liabilities and right-of-use assets as the Company is not reasonably certain to exercise the options.

In the first quarter of 2021, the Company closed its development laboratory in San Carlos, California and, as a result, $0.2 million of operating right-of-use assets related to the abandonment of the laboratory were written off to research and development expense during the nine months ended September 30, 2021.

The components of lease cost for operating leases were as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Operating leases
Operating lease cost	$	119,458	$	108,024	$	238,916	$	275,703
Variable lease cost		24,086		20,333		51,612		46,484
Total rent expense	$	143,544	$	128,357	$	290,528	$	322,187

Three Months Ended September 30,

Nine Months Ended September 30,

2021

2020

2021

2020

Operating leases

Operating lease cost
$
107,969

$
182,287

$
383,672

$
570,163

Variable lease cost

26,636

36,554

73,120

89,716

Operating lease expense

134,605

218,841

456,792

659,879

The table below summarizes other information related to the Company’s operating leases:


	Six Months Ended June 30,
	2022			2021
Cash paid for amounts included in measurement of operating lease liabilities	$	239,156		$	287,581
Weighted-average remaining lease term – operating leases		2.6			0.6
Weighted-average discount rate – operating leases		5.8	%		6.3	%

Nine Months Ended September 30,

2021

2020

Cash paid for amounts included in measurement of operating lease liabilities
$
403,012

$
665,095

Establishment of operating lease liabilities arising from obtaining right-of-use assets
$
1,302,457

$
21,078

Weighted-average remaining lease term – operating leases

3.3

1.9

Weighted-average discount rate – operating leases

5.8
%

9.6
%

Remaining maturities of the Company’s operating leases, ~~excluding short-term leases,~~ included in operating lease liabilities – ~~non -~~ current and other non-current liabilities, in the condensed consolidated balance sheets as of ~~September~~June 30, ~~2021~~2022 are as follows:


2022	$	242,392
2023		484,719
2024		484,631
2025		40,382
Total		1,252,124
Less present value discount		(91,129	)
Total operating lease liabilities		1,160,995
Less operating lease liabilities - current		(429,200	)
Operating lease liabilities - non-current	$	731,795

2021

$
111,441

2022

481,549

2023

484,719

2024

484,631

2025

40,382

Total

1,602,722

Less present value discount

(148,425
)
Total operating lease liabilities

$
1,454,297

Less operating lease liabilities - current

(398,313
)
Operating lease liabilities - non-current

$
1,055,984

Financing Leases

The Company has ~~a number of~~ computer and copier equipment leases that are classified as financing leases. Incremental borrowing rates used to discount future lease payments in calculating lease liabilities were estimated by reference to information received by the Company from bankers regarding estimated current borrowing rates for collateralized loans with similar amount and duration as the leases. The Company does not have any material financing leases where it acts as a lessor.

The components of lease cost for financing leases were as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Financing leases
Amortization of right-of-use assets	$	4,363	$	5,958	$	8,981	$	13,057
Interest on lease liability		1,023		1,510		2,161		3,175
Total financing lease cost	$	5,386	$	7,468	$	11,142	$	16,232

Three Months Ended September 30,

Nine Months Ended September 30,

2021

2020

2021

2020

Financing leases

Amortization of right-of-use assets
$
5,444

$
10,035

$
18,501

$
34,033

Interest on lease liability

1,369

2,092

4,544

7,074

Total financing lease cost
$
6,813

$
12,127

$
23,045

$
41,107

The table below summarizes other information related to the Company’s financing leases:


	Six Months Ended June 30,
	2022			2021
Weighted-average remaining lease term – financing leases		2.4			3.2
Weighted-average discount rate – financing leases		9.77	%		9.77	%

Nine Months Ended September 30,

2021

2020

Weighted-average remaining lease term – financing leases

3.0

3.5

Weighted-average discount rate – financing leases

9.77
%

9.77
%

As of ~~September~~June 30, ~~2021,~~2022, remaining maturities of the Company’s financing leases are as follows:


2022	$	9,471
2023		18,396
2024		16,080
Total		43,947
Less present value discount		(4,920	)
Financing lease liabilities, net	$	39,027

2021

$
5,772

2022

20,715

2023

18,396

2024

16,080

Total

60,963

Less present value discount

(8,328
)
Financing lease liabilities, net

$
52,635

Financing lease liabilities net of discount of ~~$52,635, of which $17,558~~$15,550 and ~~$35,077~~$23,477 were included in other current liabilities and other non-current liabilities, respectively, and financing right-of-use assets of ~~$48,269,~~$34,671 were included in property and equipment, net, in the condensed consolidated balance ~~sheet~~sheets as of ~~September~~June 30, ~~2021.~~2022.

Note 12. Net Loss Per Share

Basic loss per common share is computed by dividing net loss allocable to common stockholders by the weighted average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive:


	Six Months Ended June 30,
	2022		2021
Options to purchase common stock		567,252		445,590
Series A Preferred		—		158,545
Common stock warrants		6,539,011		58,688
Restricted stock units		17,500		7,459

Nine Months Ended September 30,

2021

2020

Options to purchase common stock

494,250

499,033

Series A Preferred

158,545

—

Common stock warrants

58,688

58,688

Unvested restricted stock units

6,301

13,603

Note 13. Warrants

In connection with certain of its redeemable convertible preferred stock issuances, convertible debt financings and other financing arrangements, the Company has issued warrants for shares of its common stock and various issues of its redeemable convertible preferred stock, which have since been converted to common stock warrants.

In connection with the Securities Purchase Agreement (see Note 14), the Company issued and sold pre-funded warrants exercisable for an aggregate of 360,779 shares of common stock. The total exercise price of the pre-funded warrants is $9.75 per share, $9.60 of which was pre-funded and paid to the Company upon issuance of the pre-funded warrants. The remaining exercise price of the pre-funded warrants is $0.15 per share. In March 2020, 211,784 of the pre-funded warrants were exercised for proceeds of $31,768. In June 2021, the remaining 148,995 pre-funded warrants were exercised on a cashless, net exercise basis, resulting in the issuance of 144,881 shares of common stock.

~~In connection with the SVB Term Loan (see Note 8), the~~The Company granted to SVB a warrant to purchase up to 42,894 shares of the Company’s common stock at a purchase price of ~~$11.6565~~$11.6565 per ~~share.~~share in connection with the SVB Term Loan (see Note 8). The warrant will expire on June 24, 2030 and may be exercised for cash or at the election of the holder on a cashless, net exercise basis.

In connection with the March 2022 Purchase Agreement (see Note 14), the Company issued and sold pre-funded warrants exercisable for an aggregate of 2,410,933 shares of common stock. The pre-funded warrants had an exercise price of $0.001 per share and were exercised in full in May 2022 for proceeds of $2,411. The Company also issued and sold to the investor common warrants to purchase 3,244,987 shares of common stock that will expire on March 17, 2024 and common warrants to purchase an additional 3,244,987 shares of common stock that will expire on September 17, 2027. Each of these common warrants is exercisable commencing September 21, 2022 and has an exercise price of $2.062 per share.

The following table shows the common stock warrants outstanding as of ~~September~~June 30, ~~2021:~~2022:


Warrant Issuance Date	Shares of Common Stock Underlying Warrants		Exercise Price/Share		Expiration Date
August 2014		1,914	$	352.65	2024
March 2016		3,021		41.40	2026
March 2018		1,208		115.95	2028
June 2020		42,894	11.6565		2030
March 2022		3,244,987		2.062	2024
March 2022		3,244,987		2.062	2027

Warrant Issuance Date

Shares of
Common Stock
Underlying
Warrants

Exercise
Price/Share

Expiration Date
August 2014

1,914

$
352.65

2024
December 2014

9,651

210.00

2022
March 2016

3,021

41.40

2026
March 2018

1,208

115.95

2028
June 2020

42,894

11.6565

2030

Note 14. Stockholders’ Deficit

~~Reverse Stock Split~~

~~On November 20, 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every~~ ~~fifteen (15)~~ shares of issued and outstanding common stock were exchanged for one share of its common stock. NaN fractional shares were issued in the reverse stock split. Instead, fractional shares that would have otherwise resulted from the stock split were purchased by us at the applicable percentage of $4.27 per share. All share and per share amounts included within these financial statements have been retrospectively adjusted to reflect the reverse stock split.

Equity Offerings

~~Securities~~March 2022 Purchase Agreement

In ~~September 2019, concurrently with the closing of an underwritten public offering,~~March 2022, the Company entered into a Securities Purchase Agreement (the ~~“Securities~~“March 2022 Purchase Agreement”) with ~~certain institutional accredited investors (the “Purchasers”),~~a single investor pursuant to which ~~the Company sold~~it agreed to issue to the ~~Purchasers, in a private placement transaction, warrants to purchase up to an aggregate of 360,779 shares of its common stock (“Warrant Shares”),~~investor 3,244,987 units at a price of ~~$9.60~~$2.312 per unit (less $0.001 for each pre-funded warrant ~~(which $9.60 price relates~~purchased in lieu of a share of common stock) for gross proceeds, before deducting the placement agent fees and other estimated fees and expenses, of approximately $7.5 million. Each unit consists of one share of common stock (or one pre-funded warrant in lieu thereof), a common warrant to purchase one share of common stock with a term of 24 months from the ~~pre-funded portion~~issuance date, and a common warrant to purchase one share of common stock with a term of 66 months from the issuance date. Each of the ~~total $9.75~~common warrants is exercisable commencing on September 21, 2022 and has an exercise price of $2.062per ~~share).~~share. Each pre-funded warrant has ~~a remaining~~an exercise price of ~~$0.15~~$0.001 per share and ~~became~~does not expire until exercised in full. The pre-funded warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 9.99% immediately ~~exercisable upon issuance, subject to certain beneficial ownership limitations.~~

after exercise thereof. In ~~March 2020, 211,784 of~~May 2022, the2,410,933 pre-funded warrants were exercised for ~~additional~~ proceeds of ~~$31,768. In June 2021,~~$2,411.

The common warrants issued in this transaction may not be exercised if the ~~remaining 148,995 pre-funded warrants were exercised on a cashless, net exercise basis, resulting in the issuance~~aggregate number of ~~144,881~~ shares of common stock beneficially owned by the ~~Company’s common stock.~~

~~ATM Offering~~holder thereof would exceed 4.99% immediately after exercise thereof, which ownership cap may be increased by the holder up to 9.99% upon 61 days’ prior notice.

~~In November 2019, the Company entered into a Controlled Equity Offering Sales Agreement (the “Cantor Sales Agreement”~~Cantor Fitzgerald & Co. (“Cantor”) ~~with Cantor~~served as the ~~sales~~placement agent ~~pursuant~~in connection with the March 2022 Purchase Agreement. The Company has paid Cantor a fee of approximately $0.3 million plus reimbursement for certain out-of-pocket expenses for its role as placement agent and has incurred approximately $0.1 million of additional transaction costs.

The securities issued to ~~which~~ the investor under the March 2022 Purchase Agreement were offered in reliance on an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506 of Regulation D promulgated thereunder. The Company ~~may offer and sell,~~relied on this exemption from ~~time to time, through Cantor, shares of its common stock, par value $0.001 per share,~~registration based in part on representations made by ~~any method deemed to be~~the investor, including that the investor is an ~~“at the market offering”~~“accredited investor”, as defined in Rule ~~415(a)(4)~~501(a) promulgated under the Securities ~~Act (the “ATM Offering”).~~Act. The ~~shares are offered and~~securities sold pursuant to the ~~Company’s shelf~~March 2022 Purchase Agreement were subsequently registered for resale on a Form S-3 registration statement, filed with the SEC on ~~Form S-3 (File No. 333-229045).~~April 8, 2022, which was declared effective by the SEC on April 19, 2022.

Series A Preferred

~~During~~In March 2022, the ~~nine months ended September 30, 2021,~~remaining 23,770 shares of Series A convertible preferred stock (“Series A Preferred”) were converted by the ~~Company sold 2,050,879~~holders into an aggregate of 158,466 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of approximately $11.0 million. After paying sales commissions owed in connection with the ATM Offering of approximately $0.3 million, the Company’s aggregate net proceeds for the nine months ended September 30, 2021 were approximately $10.7 million.stock. Accordingly,

~~Exchange and Private Placement~~

On February 25, 2020, the Company entered into an Exchange and Purchase Agreement (the “Exchange Agreement”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to (i) issue to the Investors an aggregate of 41,100 shares of its newly designated Series A Convertible Preferred Stock, par value $0.001 per share (“Series A Preferred”), in exchange for the Investors surrendering to the Company for cancellation an aggregate of 274,000 shares of its common stock (the “Exchange”) and (ii) sell and issue to the Investors an aggregate of 10,1700 shares of Series A Preferred ~~for an aggregate purchase price~~are outstanding as of ~~$0.6 million, or $59.00 per share (the “Private Placement”).~~

~~The common stock acquired in~~June 30, 2022. All of the ~~Exchange was immediately retired.~~

~~Each share of~~previously designated Series A Preferred ~~is convertible into 6.67 shares~~have resumed the status of ~~the Company’s common~~authorized, unissued and undesignated preferred stock, subject to proportional adjustment and beneficial ownership limitations. In June 2020, certain of the Investors elected to convert 27,500 shares of Series A Preferred to common stock in the aggregate, resulting in the issuance of 183,333 shares of the Company’s common stock. The remaining 23,770 Series A Preferred shares remain outstanding as of September 30, 2021. In the event of the Company’s liquidation, dissolution or winding up, holders of Series A Preferred will participate pari passu with any distribution of proceeds to holders of the Company’s common stock. Holders of Series A Preferred are entitled to receive dividends on shares of Series A Preferred equal (on an as converted to common stock basis) to and in the same form as dividends actually paid on the Company’s common stock. Shares of Series A Preferred generally have no voting rights, except as required by law.

~~LP Purchase Agreement~~

~~On March 24, 2020, the Company entered into a purchase agreement (“LP Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to~~ which upon the terms and subject to the conditions and limitations set forth therein, the Company has the right to sell to Lincoln Park up to $20.0 million of shares of its common stock (“Purchase Shares”)may be designated from time to time ~~over the 36-month term of the LP Purchase Agreement. The purchase price of the Purchase Shares is established~~ by ~~a formula based on the recent closing prices of~~ the Company’s ~~common stock leading up to the date~~Board of sale. The Company issued Lincoln Park an aggregate of 41,026 shares of its common stock as consideration for their purchase commitment pursuant to the LP Purchase Agreement. The Company did not receive cash proceeds from the issuance of such shares. The value of this commitment consideration, as well as related transaction costs of approximately $0.1 million was included in s~~elling, general and administrative expense in the accompanying condensed consolidated statements of operations during the year ended December 31, 2020~~Directors.. ~~During the nine months ended September 30, 2021, the Company sold~~ 101,218 shares of common stock under the LP Purchase Agreement at a weighted average price of $5.93 per share for total gross proceeds of $0.6 million. Additional sales of shares of common stock to Lincoln Park under the LP Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, trading price of the Company’s common stock and determinations by the Company as to the appropriate sources of funding for the Company.

Stock-based Compensation

The Company incurs stock-based compensation expense relating to the grants of RSUs and stock options to employees, non-employee directors and consultants under its equity incentive plans and through stock purchase rights granted under the employee stock purchase plan. Stock-based compensation expense (including employee stock purchase plan expense) recorded in the accompanying condensed consolidated statements of operations for ~~the~~ three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021 was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020		2022		2021		2022		2021
Selling, general and administrative	$	293,916	$	383,679	$	934,446	$	1,079,754	$	179,579	$	320,681	$	372,482	$	640,530
Research and development		35,566		2,044		83,108		85,462		40,514		24,308		107,418		47,542
Cost of product and product-related services revenue		9,411		6,440		24,764		14,498		11,241		7,497		19,239		15,353
	$	338,893	$	392,163	$	1,042,318	$	1,179,714	$	231,334	$	352,486	$	499,139	$	703,425

Equity Compensation Plans

In August 2020, the Company’s stockholders, upon the recommendation of the Company’s Board of Directors, approved the 2020 Equity Incentive Plan (the “2020 Plan”) as a successor to and continuation of the 2014 Plan. Upon approval of the 2020 Plan, 744,685 shares of ~~the Company’s~~ common stock, including 68,552 remaining shares reserved for issuance under the 2014 Plan (excluding shares available for the granting of inducement awards under the 2014 Plan’s inducement share pool), were reserved for issuance under the 2020 Plan. NaN new awards, including inducement awards, may be granted under the 2014 Plan. The 2020 Plan does not contain an evergreen provision.

There were ~~538,959~~545,949 shares of ~~the Company’s~~ common stock available for issuance under the 2020 Plan (excluding shares available for granting of inducement awards under the 2021 Inducement Plan) as of ~~September~~June 30, ~~2021,~~2022, in addition to shares that may become available from time to time as shares of the Company’s common stock subject to outstanding awards granted under the 2014 Plan (excluding inducement awards issued from the 2014 Plan’s inducement share pool), the 2011 Equity Incentive ~~Plan or the 2001 Stock Option~~ Plan (i) are not issued because such award or any portion thereof expires or otherwise terminates without all of the shares covered by such award having been issued; (ii) are not issued because such award or any portion thereof is settled in cash; or (iii) are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares.

In August 2021, the Company’s stockholders, upon the recommendation of the Company’s Board of Directors, approved the Amended and Restated 2014 Employee Stock Purchase Plan (the “Amended 2014 ESPP”). Upon approval of the Amended 2014 ESPP, 500,000 shares of the Company’s common stock were reserved for issuance under the Amended 2014 ESPP in addition to 24,285 shares of the Company’s common stock reserved for issuance under the original 2014 Employee Stock Purchase Plan. The Amended 2014 ESPP does not contain an evergreen provision.

In July 2021, the Company’s Board of Directors adopted the Company’s 2021 Inducement Plan (the “2021 Inducement Plan”), pursuant to which 300,000 shares were initially authorized and reserved for issuance exclusively for the grant of awards to individuals who were not previously employees or non-employee directors of the Company, as inducement material to the individuals’ entering into employment with the Company (“Inducement Awards”). There were ~~270,000~~167,500 shares of ~~the Company’s~~common stock available for issuance under the 2021 Inducement Plan as of ~~September~~June 30, ~~2021,~~2022, in addition to shares that may become available from time to time as shares of ~~the Company’s~~ common stock subject to outstanding awards granted under the 2021 Inducement Plan are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares.

A summary of the Company’s stock option activity (including inducement award activity) for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 is as follows:


	Number of Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Balance at December 31, 2021		559,336		$	13.93		8.2	$	30,267
Granted		93,000			1.66
Exercised		-			-
Forfeited		(49,220	)		5.41
Expired/Cancelled		(35,864	)		33.37
Balance at June 30, 2022		567,252		$	11.43		8.1	$	21,590
Exercisable at June 30, 2022		313,518		$	16.69		7.4	$	4,562

Number of
Shares

Weighted-
Average
Exercise Price
Per Share

Weighted-
Average
Remaining
Contractual
Life (Years)

Aggregate
Intrinsic Value

Balance at December 31, 2020

487,227

$
16.78

8.6

$
1,536

Granted

70,333

5.74

Exercised

(75
)

4.35

$
107

Forfeited

(45,006
)

12.76

Expired/Cancelled

(18,229
)

25.64

Balance at September 30, 2021

494,250

$
15.25

8.2

$
19,222

Exercisable at September 30, 2021

283,107

$
20.65

7.6

$
5,882

~~Stock option activity includes 30,000 Inducement Awards granted during the three and nine months ended September 30, 2021.~~ As of ~~September~~June 30, ~~2021,~~2022, total unrecognized compensation cost related to stock option awards was approximately ~~$1.3~~$0.8 million, which is expected to be recognized over approximately ~~2.18~~2.37 years.

The following table summarizes restricted stock unit (“RSU”) award activity for the ~~nine~~six months ended ~~September~~June 30, ~~2021:~~2022:


	Number of Shares			Weighted- Average Grant Date Fair Value Per Share
Balance at December 31, 2021		31,177		$	6.93
Granted		5,000			0.69
Released		(8,296	)		9.60
Forfeited		(7,500	)		5.20
Balance at June 30, 2022		20,381		$	4.95
Vested and unissued at June 30, 2022		2,881		$	11.26

Number of
Shares

Weighted-
Average
Grant Date
Fair Value
Per Share

Balance at December 31, 2020

12,214

$
28.61

Released

(3,540
)

29.96

Forfeited

(2,373
)

51.00

Balance at September 30, 2021

6,301

$
19.40

Vested and unissued at September 30, 2021

989

$
26.14

Vested and unissued awards at ~~September~~June 30, ~~2021~~2022 represents RSU awards for which the vesting date was ~~September~~June 30, ~~2021,~~2022, but for which issuance of the awards occurred in ~~October 2021~~July 2022. As of ~~September~~June 30, ~~2021,~~2022, the total unrecognized compensation cost related to RSU awards was approximately ~~$0.1~~$0.1 million, which is expected to be recognized over approximately ~~1.29~~1.36 years.

Note 15. Commitments and Contingencies

Legal Matters

The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote.

Product Warranty

The following is a summary of the Company’s general product warranty liability. Product warranty ~~liabilities~~liability of approximately ~~$93,000 and $27,000 were~~$0.1 million was included in accrued liabilities and an additional immaterial amount of product warranty liability was included in other non-current liabilities ~~respectively,~~ in the accompanying condensed consolidated balance sheets as of ~~September~~June 30, ~~2021.~~2022. Expense relating to the recording of this reserve is recorded in cost of product and product-related services revenue within the accompanying condensed consolidated statements of operations.


	Six Months Ended June 30,
	2022			2021
Beginning balance	$	120,385		$	92,696
Cost of warranty claims		(43,170	)		(94,488	)
Increase in warranty reserve		30,329			126,591
Ending balance	$	107,544		$	124,799

Nine Months Ended September 30,

2021

2020

Beginning balance

$
92,696

$
94,482

Cost of warranty claims

(141,648
)

(19,310
)
Increase in warranty reserve

169,337

12,423

Ending balance

$
120,385

$
87,595

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with our consolidated financial statements and notes thereto for the year ended December 31, ~~2020,~~2021, and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March ~~25, 2021.~~29, 2022. This discussion and analysis contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward looking statements include, but are not limited to, statements about:

•

our ability to successfully commercialize our products, services and technology, including our HTG EdgeSeq assays and corresponding automation systems, our transcriptome product which has been designed to measure approximately 20,000 mRNA targets using our HTG EdgeSeq technology (“HTG Transcriptome Panel” or “HTP”) and our epitranscriptome profiling technology;

•

our ability to generate sufficient revenue or raise additional capital to meet our working capital needs;

•

our ability to generate revenue from our products and services and drive revenue streams;

•

the impact of the COVID-19 pandemic (“COVID-19”) on our business;

•

the activities anticipated to be performed by us and third parties under design and development projects and programs, and the expected benefits and outcomes of such projects and programs;

•

the implementation of our business model and strategic plans for our business, including, without limitation, our drug discovery business unit, HTG Therapeutics;

•

the expected capabilities and performance of our HTP, our epitranscriptome profiling technology and HTG Therapeutics business unit;

•

the regulatory landscape for our products, domestically and internationally;

•

our strategic relationships, including with holders of intellectual property relevant to our technologies, manufacturers of next-generation sequencing (“NGS”) instruments and consumables, critical component suppliers, distributors of our products, and third parties who conduct our clinical studies;

•

our intellectual property position;

•

our ability to comply with the restrictions of our debt facility and meet our debt obligations;

•

our expectations regarding the market size and growth potential for our profiling and drug discovery businesses;

•

our expectations regarding trends in the demand for sample processing by our biopharmaceutical company customers;

•

our ability to secure regulatory clearance or approval, domestically and internationally, for the clinical use of our products;

•

any estimates regarding expenses, future revenue and capital requirements; and

•

our ability to sustain and manage growth, including our ability to develop new products and enter new markets.

•

~~our ability to generate sufficient revenue or raise additional capital to meet our working capital needs;~~

•

~~our ability to generate revenue from our products and services and drive revenue streams;~~

•

~~the impact of the COVID-19 pandemic (“COVID-19”) on our business;~~

•

our ability to develop new technologies to expand our product offerings, including direct-target sequencing for detection of mutations from expressed RNA (such as single-point mutations and gene rearrangements, including gene fusions and insertions) and our recently launched transcriptome panel;

•

~~the activities anticipated to be performed by us and third parties under design and development projects and programs, and the expected benefits and outcomes of such projects and programs;~~

•

~~the implementation of our business model and strategic plans for our business, including, without limitation, our new drug discovery business unit, HTG Therapeutics;~~

•

~~the expected capabilities and performance of our HTG Transcriptome Panel, our epitranscriptome profiling technology and HTG Therapeutics business unit;~~

•

~~the regulatory landscape for our products, domestically and internationally;~~

•

~~our intellectual property position;~~

•

~~our ability to comply with the restrictions of our debt facility and meet our debt obligations;~~

•

~~our expectations regarding the market size and growth potential for our life sciences, diagnostic and drug discovery businesses;~~

•

~~our expectations regarding trends in the demand for sample processing by our biopharmaceutical company customers;~~

•

~~our ability to secure regulatory clearance or approval, domestically and internationally, for the clinical use of our products;~~

•

~~any estimates regarding expenses, future revenue and capital requirements; and~~

•

~~our ability to sustain and manage growth, including our ability to develop new products and enter new markets.~~

In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “continue,” “seek,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect our management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this filing and are subject to risks and uncertainties. We discuss many of these risks in greater detail in Part II, Item 1A - “Risk Factors” and elsewhere in this filing. You should carefully read the “Risk Factors” section of this filing to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. These statements, like all statements in this report, speak only as of their date, and except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results

could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. In addition, statements

that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.

Overview

~~Overview~~

We are a life ~~science~~sciences company advancing precision medicine through our innovative transcriptome-wide profiling technology. Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, our proprietary ~~next-generation~~ HTG EdgeSeq RNA platform technology is designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to ~~transformative~~ drug discovery.

Our product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Our menu of HTG EdgeSeq assays is automated on our HTG EdgeSeq system, which applies ~~genomic sequencing~~NGS tools that generate gene expression data in a timely manner utilizing a simplified workflow for customers. We seek to leverage key business drivers in molecular profiling for biomarker analysis and diagnostics, including the acceleration of precision medicine, the migration of molecular testing to NGS-based applications, the movement to smaller and less invasive biopsies, the need for greater diagnostic sensitivity, the need to conform to challenging healthcare economics and the need for automation and an easily deployable workflow, including simplified bioinformatics. These capabilities enable customers to extend the use of limited biological samples for retrospective or prospective analysis, gaining further understanding of the molecular drivers of disease with the goal of developing biomarker-driven targeted therapies. We also believe our HTG EdgeSeq technology can be used as a platform technology in clinical applications that will simplify, consolidate and reduce the cost of NGS-based diagnostic workflows and in commercialized companion diagnostic (“CDx”) tests.

Our existing products include instruments, consumables ~~including assay kits,~~ and software that, as an integrated platform, automate sample processing and can quickly, robustly and simultaneously profile hundreds, thousands or tens ~~hundreds or~~of thousands of molecular targets from samples a fraction of the size required by many prevailing technologies. Our objective is to establish our solutions as the standard in molecular profiling, CDx development and molecular diagnostics, and to make their benefits accessible to all molecular labs from research to the clinic. We believe that our target customers and collaborators desire high quality molecular profiling data in a multiplexed panel format from increasingly smaller and less invasive samples, providing our customers and collaborators with the option to analyze such data locally to minimize turnaround time and cost.

Biopharmaceutical companies are continually working to improve their drug development processes and the efficacy and safety of their drugs. We believe that our technology can support these initiatives by providing a seamless solution from biomarker discovery to a commercialized companion diagnostic test that can be used to assist clinicians in confidently prescribing these drugs to their patients. Our ~~development efforts over~~products and service solutions allow us to partner with our biopharmaceutical company customers to identify molecular biomarkers that can help determine which patients are most likely to benefit from a particular drug, validate these biomarkers in clinical trials and partner to commercialize the ~~past 18 months have been primarily focused on completing feasibility~~validated CDx assay. Customers can access our technology by purchasing our platform and assays for their internal use or by engaging us to perform certain services, including molecular profiling of respective cohorts in our VERI/O laboratory and development of custom RUO panels to support early-stage clinical programs, investigational-use-only assays for clinical trials or companion diagnostic assays for approved drugs. Our product and service solutions have enabled us to access a number of early-stage biomarker discovery programs and we believe will provide us access to new opportunities collaborating with biopharmaceutical companies in their future drug development programs.

In addition, HTG Therapeutics, our drug discovery business unit, leverages our HTP and epitranscriptome profiling technologies, applying them early in the drug discovery process and in conjunction with our machine learning-based chemical library design platform, with the goal of ultimately yielding de-risked drug candidate molecules with greater potential for development success.

Revenue and Commercialization of our Profiling Products

We believe the future financial performance of our profiling business will continue to be driven by adoption and utilization of our HTG EdgeSeq instruments and consumables, and an overall increase in the number and type of customers using our technology. As such, today we believe the primary measures of adoption for our technology are the number of total active customers, the number of active programs in our biopharmaceutical company customer pipeline, the number of instruments actively producing revenue in our installed base and revenue growth relating to new and existing customers. Total active customers and active installed base reflect customers and instruments that have generated revenue for the Company within the last 12 months. To be included in our active programs metric, a program needs to be associated with a pharma sponsored clinical trial, be traceable to a program on clinicaltrials.gov and have generated revenue for the Company within the last 12 months. As of June 30, 2022, we had 81 active customers, 50 active programs and 51 instruments actively producing revenue in our installed base.

Our ability to increase instrument and consumable revenue depends on several factors, including (i) our ability to increase adoption of our HTG EdgeSeq platform throughout the scientific research community; (ii) the efforts of our sales and marketing teams to demonstrate the utility of our products and technology; (iii) our ability to develop and market novel molecular profiling panels to address unmet customer needs; (iv) our ability to demonstrate the benefits of our products compared to our competitors to key opinion leaders and customers; and (v) our ability to expand the addressable market for our HTG EdgeSeq platform through enhancement of our existing products and services, the development of new applications and expansion into new markets.

In August 2021, we completed the commercial release of our HTG Transcriptome Panel, ~~including supporting~~designed to provide extensive coverage of most human mRNA transcripts, simultaneously interrogating nearly 20,000 genes, while maintaining the sample efficiency, ease of use and robust results provided by our ~~Early Adopter Program (EAP), where approximately 30 scientific collaborators throughout the U.S. and EU have partnered with us to explore potential applications of the~~existing HTG Transcriptome Panel in their research and clinical programs. In the near future we expect our EAP collaborators to assist us with customer testimonials, white papers, technical notes and peer-reviewed publications highlighting their use of the HTG Transcriptome Panel and overall experience relative to alternative technologies.EdgeSeq technology. The release of ~~the HTG Transcriptome Panel,~~our HTP, coupled with our existing ~~whole transcriptome~~ miRNA ~~panel,~~Whole Transcriptome Assay (“miRNA Assay”) is expected to further differentiate us from our competitors, to allow us to ~~not only continue to~~ expand our position ~~within~~in oncology ~~but~~and to diversify the use of our panels in other critical ~~markets~~areas such as immunology, infectious disease, diabetes, cardiology and neurology. In the first quarter of 2022, we completed a development program to harmonize the sample preparation protocols for these mRNA and miRNA panels. As a result of this harmonization, a single FFPE tissue section and just one lysis method are typically expected to be required to release all of the RNA needed for downstream testing without any confounding factors that could interfere with expression data. We ~~also~~ expect to focus our future profiling-related development efforts on the expansion of the sample types available for use with both of these assays, ~~with an initial focus on liquid biopsies.~~

~~In addition, we are working~~as deemed appropriate based upon customer needs and the ability to ~~leverage~~use these efforts to grow our ~~existing capabilities~~active installed base and ~~expand~~drive larger consumable annuities for our menu of proprietary panels. However, given the ~~utility~~length of our ~~HTG EdgeSeq platform~~sales cycle and various phases of customer programs requiring more or less sample testing, we expect to continue to see fluctuations in our instrument and consumables sales on a period-to-period basis.

We believe the increasing number of publications referencing our technology ~~through~~and the growing number of customers adopting our ~~new drug discovery business unit, HTG Therapeutics. This business unit is expected~~technology continues to ~~use~~reflect customer demand for and interest in our HTG Transcriptome Panel and an epitranscriptome profiling technology evolved from our original HTG EdgeSeq technology (“HTG EpiEdgeSeq”) to profile RNA modifications. By leveraging these profiling technologies earlier in the drug discovery process, HTG Therapeutics is expected to generate lead compounds faster, and with potentially more favorable efficacy and toxicity profiles.technology. In addition to the platform technology for molecular profiling, we are building a full machine learning-based chemical library design platform, which is expected to better predict the binding properties of a drug candidate to its target. Since June 2021, we have expanded HTG Therapeutics with the addition of several highly experienced professionals in leadership positions. Working with our Tucson-based research and development teams, these individuals have engaged several external collaborators who are expected to contribute meaningful cohorts for our initial planned studies to identify development candidates targeting RNA or RNA modifying proteins, which could be relevant in areas such as oncology, immunology, transplant, diabetes and rare disease. These efforts are

aimed at the generation of high-quality primary data from our proprietary profiling platform from known and well annotated cohorts that we believe could lead to new pharma partnerships in early-stage drug discovery by the second ~~half~~quarter of 2022, ~~and beyond. Costs~~we saw the first peer-reviewed journal article related to our HTP released by one of our customers less than a year after the product’s initial commercial release. In this ~~program were approximately 29% and 18%~~same period, three of our ~~overall research and development expense~~large pharma customers presented at bioscience conferences about their use of our technology as part of their biomarker strategies for clinical trials.

Despite this momentum, we expect that the ~~three and nine months ended September 30, 2021, respectively, but are not expected to have a material impact~~impacts of COVID-19 on our ~~projected operating expense~~business and those of our customers will continue to cause variability in our revenue period over period until operations are able to return to pre-COVID levels for ~~the remainder of the year.~~

longer periods without supply chain disruptions or additional regional shutdowns. COVID-19 and international efforts to control its spread have significantly curtailed the movement of people, goods and services worldwide, including in regions where we sell our products and services and conduct our business over the past ~~year.~~two years. We experienced a significant slowing in our product and product-related services revenue beginning in March 2020 and throughout the ~~first half~~year ended December 31, 2021 and have continued to see lower revenue in the three and six months ended June 30, 2022. While COVID-19 related closures have been limited in most regions during the past several months, the ability of ~~2021 due~~our sales and support teams to ~~continued disruptions~~access customer and potential customer sites has not returned to pre-COVID levels, with a number of facilities continuing to limit or completely restrict on site visitors. In addition, our ~~customers’ businesses from the pandemic and,~~sales cycle has been extended in many instances ~~their prioritization~~due to labor and supply shortages at many of ~~projects~~our customer locations, causing sample preparation and/or processing to take longer than it has in ~~areas related~~the past. These limitations have caused delays in our ability to ~~COVID-19. In addition, we~~get customer samples for planned sample processing programs and have resulted in study delays as other programs have been given priority for use of the limited resources. We have also experienced extended shipment times and increases in cost of product as ongoing supply chain disruptions have impacted the ability of certain of our suppliers to produce the materials necessary to build our ~~product~~products and perform our testing services. Despite ~~the~~these impacts, ~~of COVID-19 on our revenue and operations,~~ we ~~met all key development milestones throughout 2020 and 2021 to date and~~ have not experienced any substantive manufacturing delays ~~from raw material shortages. While most~~during the period due to careful management of inventory levels.

Our Drug Discovery Approach

In June 2021, we announced the formation of our ~~customers have now reopened their facilities, it remains unknown whether COVID-19 will continue~~drug discovery business unit, HTG Therapeutics, with the addition of several highly experienced drug development professionals to ~~materially impact~~ our ~~financial condition, liquidity~~leadership team. HTG Therapeutics is leveraging our existing HTP and ~~future~~epitranscriptome profiling technologies and applying these technologies early in the drug discovery process in conjunction with our machine learning-based chemical library design platform, with the goal of ultimately yielding de-risked drug candidate molecules with a greater potential for development success. Through use of this transcriptome-informed approach, we expect to accelerate the drug discovery and development process by further uncovering and understanding biological mechanisms and making more thorough assessments of on- and off-target effects of drug candidates earlier in the discovery process. During the first quarter of 2022, we released our first proof-of-approach white paper (“WP1”), demonstrating the utility of our proprietary profiling technologies as a key component of our novel drug discovery and design platform. We followed WP1 with a second white paper (“WP2”) in the second quarter of 2022. WP2 further established the utility of our transcriptome-informed approach to drug discovery and design and provided some examples of that approach being applied to our initial therapeutic target. As presented, the results of ~~operations~~the studies summarized in ~~future periods due~~WP2 revealed that analysis of the transcriptomic profiles from compound-treated human cell line test systems were highly informative and showed that differences in cellular treatment can be distinguished amongst compounds that not only shared the same pharmacologic target but were structurally closely related, illustrating the ability of our approach and technological platform to ~~further shutdowns, social distancing measures or illness.~~ design and select small molecules accordingly.

HTG Therapeutics has engaged several external collaborators who are expected to contribute meaningful sample cohorts across multiple disease and therapy areas to support the discovery, design and selection of our early candidate molecules with therapeutic promise. In addition, the team has partnered with our Tucson-based research and development team to develop assays such as an RNA modification assay to strengthen our existing capabilities, intending to leverage our existing transcriptomic profiling technology platform for use in drug discovery. This approach is expected to enable the selection and characterization of candidate molecules across selected therapeutic targets of interest, potentially leading to business development, new pharma partnerships and licensing opportunities in various therapeutic areas in the second half of 2022 and beyond.

Results of Operations

Comparison of the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021


	Three Months Ended June 30,						Change						Six Months Ended June 30,						Change
	2022			2021			$			%			2022			2021			$			%
Product and product-related services revenue	$	1,491,582		$	2,074,204		$	(582,622	)		(28	%)	$	2,676,036		$	3,509,350		$	(833,314	)		(24	%)
Operating expenses:
Cost of product and product-related services revenue		1,014,469			971,043			43,426			4	%		1,869,517			1,756,243			113,274			6	%
Selling, general and administrative		4,306,916			3,903,815			403,101			10	%		8,969,927			7,763,434			1,206,493			16	%
Research and development		1,847,101			1,281,361			565,740			44	%		3,767,531			2,653,401			1,114,130			42	%
Total operating expenses		7,168,486			6,156,219			1,012,267			16	%		14,606,975			12,173,078			2,433,897			20	%
Operating loss		(5,676,904	)		(4,082,015	)		(1,594,889	)		39	%		(11,930,939	)		(8,663,728	)		(3,267,211	)		38	%
Gain on forgiveness of PPP Loan		—			1,735,792			(1,735,792	)		(100	%)		—			1,735,792			(1,735,792	)		(100	%)
Other income (expense), net		(206,425	)		(252,469	)		46,044			(18	%)		(449,523	)		(516,614	)		67,091			(13	%)
Net loss before income taxes	$	(5,883,329	)	$	(2,598,692	)	$	(3,284,637	)		126	%	$	(12,380,462	)	$	(7,444,550	)	$	(4,935,912	)		66	%

Three Months Ended
September 30,

Change

Nine Months Ended
September 30,

Change

2021

2020

$

%

2021

2020

$

%

Revenue:

Product and product-related services

$
2,520,410

$
1,701,068

$
819,342

48
%

$
6,029,760

$
5,417,731

$
612,029

11
%
Collaborative development services

—

76,030

(76,030
)

(100
%)

—

548,135

(548,135
)

(100
%)
Total revenue

2,520,410

1,777,098

743,312

42
%

6,029,760

5,965,866

63,894

1
%
Operating expenses:

Cost of product and product-related services revenue

983,761

940,892

42,869

5
%

2,740,004

2,931,026

(191,022
)

(7
%)
Selling, general and administrative

4,232,313

4,752,321

(520,008
)

(11
%)

11,995,747

13,683,069

(1,687,322
)

(12
%)
Research and development

1,534,818

1,255,416

279,402

22
%

4,188,219

4,914,467

(726,248
)

(15
%)
Total operating expenses

6,750,892

6,948,629

(197,737
)

(3
%)

18,923,970

21,528,562

(2,604,592
)

(12
%)
Operating loss

(4,230,482
)

(5,171,531
)

941,049

(18
%)

(12,894,210
)

(15,562,696
)

2,668,486

(17
%)
Gain on forgiveness of PPP Loan

—

—

—

0
%

1,735,792

—

1,735,792

100
%
Loss on extinguishment of MidCap Credit Facility

—

—

—

0
%

—

(522,394
)

522,394

(100
%)
Other income (expense)

(258,206
)

(238,676
)

(19,530
)

8
%

(774,820
)

(482,599
)

(292,221
)

61
%
Net loss before income taxes

$
(4,488,688
)

$
(5,410,207
)

$
921,519

(17
%)

$
(11,933,238
)

$
(16,567,689
)

$
4,634,451

(28
%)

Product and Product-Related Services Revenue

~~Revenue~~

Our product and product-related services revenue is generated through the sale of our profiling instruments and consumables, sample processing services and custom assay design services to biopharmaceutical companies, academic research centers and molecular testing laboratories.

RUO profiling is currently made available to our customers through product sales and service offerings. Customers can purchase our HTG EdgeSeq instrument and related consumables, which consist primarily of our proprietary molecular profiling panels and other assay components. Customers can also access our technology through contracted services. We perform these services using our HTG EdgeSeq instruments and RUO consumables to process samples in our VERI/O laboratory. Our proprietary technology is also used to develop custom RUO panels which are expected to generate future sample processing or RUO consumables revenue.


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Product revenue:
Instrument	$	177,812	$	397,205	$	370,998	$	621,218
Consumables		830,255		867,970		1,301,469		1,472,352
Total product revenue		1,008,067		1,265,175		1,672,467		2,093,570
Product-related services revenue:
Custom RUO assay design		—		—		—		48,350
RUO sample processing		483,515		809,029		1,003,569		1,367,430
Total product-related services revenue		483,515		809,029		1,003,569		1,415,780
Total product and product-related services revenue	$	1,491,582	$	2,074,204	$	2,676,036	$	3,509,350

~~We have also previously generated collaborative development~~Product and product-related services revenue ~~through three statements of work entered into under ourMaster Assay Development, Commercialization and Manufacturing Agreement (the “Governing Agreement”) with~~

~~QIAGEN Manchester Limited (“QML”). Under these agreements, we and QML combined our technological and commercial strengths~~decreased by 28% to offer biopharmaceutical companies a complete NGS-based solution for the development, manufacture and commercialization of companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. Remaining agreed upon procedures associated with these statements of work were completed in the prior year and no additional collaborative development services programs have been entered into as of September 30, 2021. Although we continue to seek potential, new customer collaborations, we currently do not anticipate additional revenue from existing or new collaborative development services programs in 2021.

~~Total revenue increased by 42% to $2.5~~$1.5 million for the three months ended ~~September~~June 30, ~~2021,~~2022, compared with ~~$1.8~~$2.1 million for the three months ended ~~September~~June 30, 2020, reflecting increases in both product and product-related services revenue when compared with the third quarter of 2020. Total revenue increased by approximately 1% to $6.0 million for the nine months ended September 30, 2021, compared with $6.0 million for the nine months ended September 30, 2020. The increase in total revenue for the nine-month period primarily reflects an increase in product and product-related services revenue.

~~Product and product-related services revenue~~

2021. Product and product-related services revenue ~~increased~~decreased by ~~48%~~24% to ~~$2.5~~$2.7 million for the ~~three~~six months ended ~~September~~June 30, ~~2021,~~2022, compared with ~~$1.7~~$3.5 million for the ~~three~~six months ended ~~September~~June 30, ~~2020. Product and product-related services revenue increased by 11% to~~ 2021.~~$6.0 million for the nine months ended September 30, 2021, compared with $5.4 million for the nine months ended September 30, 2020.~~

Product revenue, which includes gene expression profiling revenue generated through the sale of our HTG EdgeSeq instruments and consumables, ~~increased~~decreased by ~~44%~~20% to ~~$1.2~~$1.0 million for three months ended June 30, 2022, compared with $1.3 million for three months ended June 30, 2021. Product revenue decreased by 20% to $1.7 million for the ~~three~~six months ended ~~September~~June 30, ~~2021,~~2022 compared with ~~$0.8~~$2.1 million for the ~~three~~six months ended ~~September~~June 30, ~~2020. Product revenue increased by 24% to $3.3 million for the nine months ended September 30, 2021, compared with $2.7 million for the nine months ended September 30, 2020.~~2021. This ~~increase~~decrease primarily reflects ~~additional instrument placements made during~~a reduction in the ~~period with biopharmaceutical companies and academic medical centers~~number of instruments sold when compared to the same period in prior year. Revenue from the ~~prior year, when most~~sale of our ~~customers had closed their laboratories due to COVID-19. In addition, consumables~~HTP, commercially launched in August 2021, represented 43% and 44% of our product revenue for the three and six months ended ~~September~~June 30, 2022, respectively, compared with 15% and 9% of our product revenue for the three and six months ended June 30, 2021, ~~included revenue recognized from the sale of HTG Transcriptome Panel consumables.~~respectively. Revenue from the sale of ~~the HTG Transcriptome Panel represented 27% and 18% of~~ our ~~consumables revenue for~~HTP during the three and ~~nine~~six months ended ~~September~~June 30, 2021 ~~respectively.~~ related to the shipment of our first orders for HTP to Early Adopter Program collaborators in the second quarter of 2021.

Product-related services revenue, consisting of RUO sample processing using our HTG EdgeSeq instruments and consumables in our VERI/O laboratory and custom RUO assay design, ~~increased~~decreased by ~~53%~~40% to ~~$1.3~~$0.5 million for the three months ended ~~September~~June 30, ~~2021,~~2022, compared with ~~$0.9~~$0.8 million for the three months ended ~~September~~June 30, ~~2020, and~~2021. Product-related services revenue decreased ~~by approximately 1%~~29% to ~~$2.7~~$1.0 million for the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, compared ~~with $2.8~~to $1.4 million for the ~~nine~~six months ended ~~September~~June 30, 2020. Specifically, RUO sample processing revenue generated in our VERI/O laboratory increased by 111% to $1.3 million for the three months ended September 30, 2021, compared with $0.6 million for the three months ended September 30, 2020, and increased by 73% to $2.7 million for the nine months ended September 30, 2021, compared with $1.6 million for the same period in 2020. This increase in RUO sample processing services for the three and nine months ended September 30, 2021 was partially offset by the decrease in custom2021. RUO assay design services ~~in both periods.~~decreased to $0 for the six months ended June 30, 2022, compared to approximately $48,000 for the six months ended June 30, 2021. With the release of the ~~HTG Transcriptome Panel, which is designed to measure approximately 20,000 mRNA targets using our HTG EdgeSeq technology,~~HTP, revenue from RUO assay ~~development~~design services is expected to ~~be a smaller portion of our business moving forward,~~continue to remain low, as itRUO assay design services revenue is replaced by consumables purchases and sample processing laboratory services using the ~~HTG Transcriptome Panel.~~HTP. RUO sample processing revenue decreased primarily due to the timing of several biopharma programs pending decisions from data generated in previous studies using our technology. Revenue generated from sample processing services using the HTP represented 42% and 39% of product-related services revenue for the three and six months ended June 30, 2022, respectively, compared to 0% and 7% of our product-related services revenue for the three and six months ended June 30, 2021, respectively.

Cost of product and product-related services revenue

Cost of product and product-related services revenue includes ~~costs incurred to generate product~~product-related and ~~product-related services revenue.~~services-related costs. Product-related costs include the aggregate costs incurred in manufacturing, delivering, installing and servicing instruments and consumables. The components of our product-related costs of revenue include consumables and lab supplies, subcomponent and servicing costs, manufacturing costs incurred internally (which include direct labor costs), and equipment and infrastructure expenses associated with the manufacturing and distribution of our products. Due to the fixed nature of certain of these expenses, such as overhead, equipment and infrastructure, ~~those~~ associated with aour regulated industry and our expectations for further growth in customer demand, we expect our cost of product and product-related services revenue as a percentage to decrease over time as ~~we increase~~our product and product-related services revenue increases, further absorbing these fixed costs.

C~~ost~~Cost of product and product-related services revenue increased by 5%4% to $1.0 million for the three months ended ~~September~~June 30, ~~2021,~~2022, compared with ~~$0.9~~$1.0 million for the three months ended ~~September~~June 30, ~~2020.~~2021. Cost of product and product-related services revenue ~~decreased~~increased by 7%6% to ~~$2.7~~$1.9 million for the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, compared with ~~$2.9~~$1.8 million for the ~~nine~~six months ended ~~September~~June 30, ~~2020. This decrease~~2021. The increase in cost of product and product-related services revenue for the ~~nine~~three and six months ended ~~September~~June 30, ~~2021~~2022 compared with the same periods in ~~2020~~2021 primarily reflects ~~a reduction of~~an increase in compensation expense ~~in our cost~~resulting from the termination of ~~product and product-related services from~~the Employee Retention ~~Credits~~Credit (“ERC”) ~~secured~~benefits in the ~~first three quarters~~third quarter of ~~2021 in accordance with the Federal Consolidated Appropriations Act.~~2021.

Selling, general and administrative expenses

Selling, general and administrative expenses consist primarily of personnel costs for our sales and marketing, regulatory, legal, executive management and finance and accounting functions. The expenses also include third-party professional and consulting fees incurred by these functions, promotional expenses and facility and overhead costs for our administrative offices. Selling, general and administrative expenses ~~decreased~~increased by ~~11%~~10% to ~~$4.2~~$4.3 million for the three months ended ~~September~~June 30, ~~2021,~~2022 compared with ~~$4.8~~$3.9 million for the three months ended ~~September~~June 30, ~~2020.~~2021. Selling, general and administrative expenses ~~decreased~~increased by ~~12%~~16% to ~~$12.0~~$9.0 million for the ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, compared with ~~$13.7~~$7.8 million for the ~~nine~~six months ended ~~September~~June 30, ~~2020.~~2021. This ~~decrease~~increase in selling, general and administrative expense for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022, compared with the same periods in ~~2020~~2021 reflects an increase in compensation expense resulting from the termination of the ERC benefits in the third quarter of 2021 and an increase in legal costs related to measures to protect our intellectual property, partially offset by a decrease in stock-based and other compensation-related expense ~~items, as well as ERC benefits secured in the first three quarters of 2021.~~items.

Research and development expenses

Research and development expenses represent ~~amounts incurred to perform collaborative development services,~~ costs to develop new proprietary panels and technologies, including the technology related to our HTG Therapeutics business unit and costs to continue improving and expanding the utility of our HTG EdgeSeq technology. These expenses include payroll and related expenses, consulting expenses, laboratory supplies, facilities and equipment. Research and development costs are expensed as incurred. Research and development expenses increased by ~~22%~~44% to ~~$1.5~~$1.8 million for the three months ended ~~September~~June 30, ~~2021,~~2022, compared with $1.3 million for the three months ended ~~September~~June 30, ~~2020.~~2021. Research and development expenses increased by 42% to $3.8 million for the six months ended June 30, 2022, compared with $2.7 million for the six months ended June 30, 2021. This increase primarily reflects ~~hiring, payroll-related costs~~approximately $0.7 million and $1.4 million of technology, consulting and personnel investments made for the ~~initiation of feasibility studies associated with~~three and six months ended June 30, 2022, respectively, relating to HTG Therapeutics, compared to $0.2 million and $0.3 million for the three and six months ended June 30, 2021, respectively, as well as an increase in compensation expense resulting from the termination of the ERC benefits in the third quarter of 2021. ~~Research and development expenses decreased by 15% to $4.2 million for the nine months ended September 30, 2021, compared with $4.9 million for the nine months ended September 30, 2020.~~ This decrease is primarily due to a reduction in research and development headcount since the first quarter 2020 as a result of the completion of our existing collaborative development services programs in 2020 and the transitioning of our transcriptome concept project from our California research facility to our Tucson development laboratory for completion of the development of the HTG Transcriptome Panel in the second half of 2020. In addition, research and development expense for the three and nine months ended September 30, 2021 compared with the same period in 2020 reflects ERC credits recognized as an offset to compensation expense in the first three quarters of 2021.

Cash Flows for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 and ~~2020~~2021

The following table summarizes the primary sources and uses of cash for each of the periods presented:


	Six Months Ended June 30,						Change
	2022			2021			$			%
Net cash provided by (used in):
Operating activities	$	(11,789,104	)	$	(8,902,176	)	$	(2,886,928	)		32	%
Investing activities		3,978,198			(10,114,697	)		14,092,895			(139	%)
Financing activities		3,982,112			10,202,970			(6,220,858	)		(61	%)
Effect of exchange rate on cash		(14,578	)		(7,464	)		(7,114	)		95	%
Decrease in cash and cash equivalents	$	(3,843,372	)	$	(8,821,367	)	$	4,977,995			(56	%)

Nine Months Ended September 30,

Change

2021

2020

$

%

Net cash provided by (used in):

Operating activities

$
(13,118,546
)

$
(12,742,237
)

(376,309
)

3
%
Investing activities

(9,461,939
)

13,465,406

(22,927,345
)

(170
%)
Financing activities

10,425,167

7,262,021

3,163,146

44
%
Effect of exchange rates on cash

(12,848
)

9,283

(22,131
)

(238
%)
Increase (decrease) in cash, cash equivalents and restricted cash

$
(12,168,166
)

$
7,994,473

(20,162,639
)

(252
%)

Operating Activities

Net cash used in operating activities for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 was ~~$13.1~~$11.8 million compared with net cash used in operating activities of ~~$12.7~~$8.9 million for the ~~nine~~six months ended ~~September~~June 30, ~~2020.~~2021. Net cash used in operating activities for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 reflected (i) a net loss of ~~$12.0~~$12.4 million; (ii) net non-cash items consisting primarily of stock-based compensation expense of $0.5 million, depreciation and amortization expense of $0.4 million, amortization of loan discount and issuance costs of $0.2 million, and amortization of right-of-use assets of $0.2 million and (iii) a net cash outflow from changes in balances of operating assets and liabilities of $0.8 million.

Net cash used in operating activities for the six months ended June 30, 2021 was $8.9 million and reflected (i) a net loss of $7.5 million; (ii) net non-cash items consisting primarily of the gain on the forgiveness of our PPP loan of $1.7 million, stock-based compensation expense of ~~$1.0~~$0.7 million, depreciation and amortization expense ~~of $0.6 million, amortization of loan discount and issuance costs~~ of $0.4 million, amortization of right-of-use assets of ~~$0.4~~$0.3 million and loss on abandonment and disposal of assets of $0.2 million; and (iii) a net cash outflow from changes in balances of operating assets and liabilities of ~~$2.0 million.~~

Net cash used in operating activities for the nine months ended September 30, 2020 was $12.7 million and reflected (i) a net loss of $16.6 million; (ii) net non-cash items of $3.6 million, consisting primarily of stock-based compensation of $1.2 million, depreciation and amortization of $1.0 million, loss on extinguishment of MidCap Credit Facility of $0.5 million, and amortization of right-of-use assets of $0.5 million; and (iii) a net cash inflow from changes in balances of operating assets and liabilities of $0.2$1.4 million.

Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2021 was $9.5 million compared with net cash provided by investing activities of $13.5 million for the nine months ended September 30, 2020. Net cash used in investing activities for the nine months ended September 30, 2021 was comprised primarily of purchases of $17.9 million of available-for-sale securities, partially offset by $9.0 million of our available-for-sale securities maturing during the period.

Net cash provided by investing activities for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2022 was ~~$13.5~~$4.0 million compared with net cash used in investing activities of $10.1 million for the six months ended June 30, 2021. Net cash provided by investing activities for the six months ended June 30, 2022 was comprised primarily of $11.6 million of our available-for-sale securities maturing during the period combined with $7.6 million of our available-for-sale securities purchased during the period.

Net cash used in investing activities for the six months ended June 30, 2021 was $10.1 million and was comprised primarily of ~~maturities~~purchases of $16.2 million of available-for-sale securities, ~~of $25.5 million,~~ partially offset by ~~purchases~~$6.3 million of our available-for-sale securities ~~of $11.6 million.~~maturing during the period.

Financing Activities

Net cash provided by financing activities for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 was ~~$10.4~~$4.0 million compared with net cash provided by financing activities for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 of ~~$7.3~~$10.2 million. This activity for the ~~nine~~six months ended ~~September~~June 30, ~~2021~~2022 consisted primarily of ~~$10.7~~$7.2 million in net proceeds from ~~our ATM Offering and $0.6 million in proceeds from our stock purchase agreement (the “LP~~the March 2022 Purchase ~~Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”)~~Agreement (see Note 14), partially offset by ~~$0.4~~$2.5 million of payments ~~made~~ on ~~our outstanding NuvoGen obligation, and $0.5 million of payments made on our 2020 and 2021 Insurance Notes.~~

Net cash provided by financing activities for the nine months ended September 30, 2020 was $7.3 million. This activity for the nine months ended September 30, 2020 consisted primarily of $6.4 million in net proceeds from our ATM Offering, $1.7 million in proceeds from our PPP Loan, and $0.6 million in net proceeds from our Series A convertible preferred stock private placement, partially offset by $0.6 million of net payments to extinguish our QNAH Convertible Note and MidCap Credit Facility obligations with cash on hand and proceeds from our SVB Term Loan, ~~$0.5~~$0.3 million of payments made on our outstanding NuvoGen obligation, and $0.3 million of payments made on our 2021 Insurance Note.

Net cash provided by financing activities for the six months ended June 30, 2021 was $10.2 million. This activity for the six months ended June 30, 2021 consisted primarily of $10.7 million in net proceeds from our ATM Offering, partially offset by $0.3 million of payments made on our outstanding NuvoGen obligation, and $0.2 million of payments made on our 2020 and 2021 Insurance Notes.

Liquidity and Capital Resources

Since our inception, our operations have primarily been financed through the issuance of our common stock, redeemable convertible preferred stock, the incurrence of debt and cash received from product sales, services revenue and other income. As of ~~September~~June 30, ~~2021,~~2022, we had ~~$25.4~~$14.1 million in cash, cash equivalents and investments in short-term available-for-sale securities, and current liabilities of approximately ~~$8.1~~$10.2 million. As of ~~September~~June 30, ~~2021,~~2022, we also had approximately ~~$11.5~~$6.5 million of long-term liabilities outstanding, relating to our SVB Term Loan (see below), our NuvoGen ~~and 2021 Insurance Note obligations,~~obligation, and our ~~financing and~~ operating leases.

In November 2019, we entered into a Controlled Equity Offering Sales Agreement (the “Cantor Sales Agreement”) with Cantor as sales agent, pursuant to which we were able to offer and sell, from time to time, through Cantor, shares of our common stock by any method deemed to be an “at the market offering” as defined by rule 415(a)(4) under the Securities Act (the “ATM Offering”). We have sold an aggregate of 3,961,335 shares of our common stock in the ATM Offering between its inception and September 30, 2021 for net proceeds of $18.2 million pursuant to our shelf registration statement on Form S-3 (File No. 333-229045).

In February 2020, we issued 41,100 shares of our Series A convertible preferred stock (“Series A Preferred”) to accredited investors, in exchange for the investors surrendering to us for cancellation an aggregate of 274,000 shares of our common stock. In addition, we sold an aggregate of 10,170 additional shares of our Series A Preferred to the accredited investors for aggregate gross

proceeds of approximately $0.6 million, and transaction costs of approximately $37,000. Each share of Series A Preferred is convertible into 6.67 shares of the Company’s common stock, subject to proportional adjustment and beneficial ownership limitations. In June 2020, the investors elected to convert 27,500 shares of Series A Preferred to common stock, resulting in the issuance of 183,333 shares of the Company’s common stock. The remaining 23,770 Series A Preferred shares remain outstanding as of September 30, 2021. In the event of the Company’s liquidation, dissolution or winding up, holders of Series A Preferred will participate pari passu with any distribution of proceeds to holders of the Company’s common stock. Holders of Series A Preferred are entitled to receive dividends on shares of Series A Preferred equal (on an as converted to common stock basis) to and in the same form as dividends actually paid on the Company’s common stock. Shares of Series A Preferred generally have no voting rights, except as required by law.

In March 2020, we entered into the LP Purchase Agreement, pursuant to which, upon the terms and subject to the conditions and limitations set forth therein, we have the right to sell to Lincoln Park up to $20.0 million of shares of our common stock (“Purchase Shares”) from time to time over the 36-month term of the LP Purchase Agreement. The purchase price of the Purchase Shares will be based on recent closing prices of our common stock at the time of sale. We issued Lincoln Park an aggregate of 41,026 shares of our common stock as consideration for their purchase commitment pursuant to the LP Purchase Agreement. During the nine months ended September 30, 2021, we sold 298,850 shares of our common stock to Lincoln Park under the LP Purchase Agreement for aggregate proceeds of $1.6 million.

In April 2020, we received the proceeds from the PPP Loan in the amount of $1.7 million from SVB, as lender, pursuant to the Paycheck Protection Program of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). In May 2021, we received notification from SVB that the PPP Loan and related accrued interest, totaling $1,735,792, was forgiven in full by the U.S. Small Business Administration, and the PPP Loan note was canceled.

In June 2020, we entered into a Loan and Security Agreement (the “Loan Agreement”) for an asset-secured loan in the principal amount of $10.0 million with Silicon Valley Bank (“SVB”), as lender (the “SVB Term Loan”). The proceeds from the SVB Term Loan were fully funded on ~~the~~ June 25, 2020. The proceeds from the SVB Term Loan, together with cash on hand, were used to repay in full all outstanding amounts and fees due under our prior MidCap Credit Facility and ~~the QNAH Convertible Note.~~a subordinated convertible note that has since been repaid. Our SVB Term Loan bears interest at a floating rate equal to the greater of 2.50% above the Prime Rate (as defined in the Loan ~~and Security~~ Agreement) and 5.75% and originally required interest-only payments payable monthly in arrears through June 30, 2021. This interest-only period ~~has been~~was extended for an additional six months as a result of the Company’s achievement of the equity milestone defined in the Loan Agreement. ~~The~~Following the end of the extended interest-only period, ~~will be followed by~~we are obligated to pay equal monthly payments of principal and interest through the maturity date of December 1, 2023.

In ~~addition,~~March 2022, we ~~must comply~~entered into a Securities Purchase Agreement with a single investor pursuant to which we issued and sold to the investor 3,244,987 units at a price of $2.312 per unit (less $0.001 for each pre-funded warrant purchased in lieu of a share of common stock) for gross proceeds, before deducting the placement agent fees and other estimated fees and expenses, of approximately $7.5 million. Each unit consisted of one share of common stock (or one pre-funded warrant in lieu thereof), a common warrant to purchase one share of our common stock with a term of 24 months from the issuance date, and a common warrant to purchase one share of our common stock with a term of 66 months from the issuance date. Each of the common warrants is exercisable commencing on September 21, 2022 and has an exercise price of $2.062 per share. Each pre-funded warrant had an exercise price of $0.001 per share and had no expiration date. In May 2022, all of the 2,410,933 pre-funded warrants were exercised for proceeds of $2,411.

On July 14, 2022, the Company entered into an amendment (the “Term Loan Amendment”) to the SVB Term Loan, by and between the Company and SVB. Under the Term Loan Amendment, the Company and SVB agreed to remove the financial covenant ~~requiring that we maintain a certain amount of unrestricted cash~~ under the Loan Agreement ~~(see Note 8~~that had required the Company to ~~our condensed consolidated financial statements included elsewhere~~maintain unrestricted cash, including short term investments available-for-sale, of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months. In exchange for this ~~report)~~accommodation, the Company prepaid $2.5 million of outstanding principal under the Term Loan (the “Prepayment”). SVB waived the prepayment fee that otherwise would have applied to the Prepayment. The remaining outstanding principal amount due under the Term Loan will continue to be paid in equal monthly payments of principal and interest through the maturity date of December 1, 2023.

If sufficient additional capital is not available as and when needed, we may have to delay, scale back or discontinue one or more product development programs, curtail our commercial activities, significantly reduce expenses, sell assets (potentially at a discount to their fair value or carrying value), enter into relationships with third parties to develop or commercialize products or technologies that we otherwise would have sought to develop or commercialize independently, ~~cease operational altogether,~~ pursue a sale of the Company at a price that may result in a significant loss on investment for our stockholders, file for bankruptcy or seek other protection from creditors, or liquidate all assets. In addition, if we default under any of the terms of the Loan Agreement, SVB could accelerate the payment of the SVB Term Loan and ultimately foreclose on our assets.

Contractual Obligations, Commitments and Material Cash Requirements

~~Funding Requirements~~

We have had recurring operating losses and negative cash flows from operations since our inception and have an accumulated deficit of ~~$203.1~~$220.7 million as of ~~September~~June 30, ~~2021.~~2022. As of ~~September~~June 30, ~~2021,~~2022, we had cash, cash equivalents and investments in short-term available-for-sale securities of ~~approximately $25.4~~$14.1 million and current liabilities of ~~approximately $8.1~~$10.2 million. As of ~~September~~June 30, ~~2021,~~2022, we also had ~~$11.5~~$6.5 million in long-term liabilities primarily ~~attributable~~relating to ~~the~~our SVB Term Loan and our NuvoGen obligation.

We ~~cannot be certain that~~do not expect our existing resources will be sufficient to fund our planned operations and expenditures for at least the next 12 months from issuance of these ~~condensed~~ consolidated financial statements. ~~Potentially~~We currently expect that our existing resources will be sufficient to fund our planned operations and expenditures until January 2023. In addition, potentially changing circumstances, ~~especially~~including those related to COVID-19 and inflation, may also result in the depletion of our capital resources more rapidly than we currently anticipate. These circumstances raise substantial doubt about our ability to continue as a going concern.

Our primary ~~short-term~~capital needs, ~~for capital,~~including contractual obligations and commitments, which are subject to change, include:

•

Debt Obligations – As of June 30, 2022, our outstanding debt balance was $8.6 million. See Note 8, “Debt Obligations” within our condensed consolidated financial statements for further detail of our debt and the timing of expected future payments.

•

NuvoGen Obligation – As of June 30, 2022, our NuvoGen obligation balance was $4.2 million. See Note 10, “Other Agreements” within our condensed consolidated financial statements for further detail and the timing of expected future payments.

•

Operating Leases – As of June 30, 2022, our contractual commitment for operating leases was $1.2 million. See Note 11, “Leases” within our condensed consolidated financial statements for further detail of our lease obligations and the timing of expected future payments, including a four-year maturity schedule.

•

Planned costs to operating our business, including amounts required to fund working capital and capital expenditures;

•

Support of commercialization efforts related to our current and future products; and

•

Continued advancement of research and development efforts, including those related to our planned transcriptome panel.

•

~~planned costs to operating our business, including amounts required to fund working capital and capital expenditures;~~

•

~~repayment of debt obligations;~~

•

~~support of commercialization efforts related to our current and future products; and~~

•

~~continued advancement of research and development efforts, including those related to our planned transcriptome panel.~~

Until our revenue reaches a level sufficient to support self-sustaining cash flows, if ever, we ~~will need~~expect to ~~raise additional~~finance our cash needs through public or private equity offerings, debt financings, or other capital ~~to fund our continued operations, including our product development and commercialization activities related to our current and future products.~~sources which may include strategic collaborations, licensing arrangements or other arrangements with third parties. Future funding requirements will depend on a number of factors, including our ability to generate significant revenue, our ability to repay our debt obligations as they become due, the cost and timing of establishing additional sales, marketing and distribution capabilities, the ongoing cost of research and development activities, the cost and timing of regulatory clearances and approvals, the effect of competing technology and market developments, the nature and timing of companion diagnostic development collaborations we may establish and the extent to which we acquire or invest in businesses, products and technologies.

Additional capital may not be available at such times or in amounts needed by us. Even if sufficient capital is available to us, it might be available only on unfavorable terms. If we are unable to raise additional capital in the future when required and ~~insufficient~~in sufficient amounts or on terms acceptable to us, we may have to delay, scale back or discontinue one or more product development programs, curtail our commercialization activities, significantly reduce expenses, sell assets (potentially at a discount to their fair value or carrying value), enter into relationships with third parties to develop or commercialize products or technologies that we otherwise would have sought to develop or commercialize independently, cease operations altogether, pursue an acquisition of our company at a price that may result in a significant loss on investment to our stockholders, file for bankruptcy, seek other protection from creditors, or liquidate all of our assets. In addition, if we default under our SVB Term Loan agreement, our lender could foreclose on our assets.

Recent Accounting Pronouncements

See Note 2. Summary of Significant Accounting Policies – Recently Adopted and Recently Issued Accounting Pronouncements in the notes to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Critical Accounting Policies and Significant Judgments and Critical Accounting Estimates

~~Our management’s~~Management’s discussion and analysis of our financial condition and results of operations is based on our ~~condensed~~ consolidated financial statements, which have been prepared in accordance with ~~accounting principles generally accepted in the United States of America (“GAAP”).~~GAAP. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. ~~Although these~~Critical accounting policies and estimates are based on management’s best knowledge of current events and actions that may impact us in the future, the estimation process is, by its nature, uncertain given that estimates depend on events over which we may not have control. Though the impact of COVID-19 on our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates. If market and other conditions change from those that we ~~anticipate,~~consider most important to the portrayal of our ~~condensed consolidated~~ financial ~~statements may be materially affected. In addition, if~~condition and results of operations because they require our ~~assumptions change, we may~~most difficult, subjective or complex judgments, often as a result of the need to ~~revise our~~make estimates ~~or take other corrective actions, either~~about the effect of ~~which may also have a material effect on our condensed consolidated financial statements.~~

~~We believe~~matters that ~~our~~are inherently uncertain. Our critical accounting policies and estimates ~~have a higher degree of inherent uncertainty~~include those related to revenue recognition, stock-based compensation expense, inventory valuation, fair value measurements and ~~require our most significant judgments. In addition, had we used estimates different~~income taxes. Actual results could materially differ from ~~any of~~ these our condensed consolidated financial statements could have been materially different from those presented. Members of our senior management have discussed the development and selection of our critical accounting policies and estimates and ~~our disclosures regarding them, with~~such differences could affect the ~~Audit Committee~~results of ~~our Board of Directors. There were no changes~~operations in our critical accounting policies and estimates during the nine months ended September 30, 2021 from those set forth in “Critical Accounting Policies and Significant Judgments and Estimates” in our December 31, 2020 Annual Report on Form 10-K filed with the SEC on March 25, 2021.future periods.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported with the time periods specified

in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and ~~our~~ Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As of ~~September~~June 30, ~~2021,~~2022, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of ~~the end of the period covered by this quarterly report,~~June 30, 2022, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting.

An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer and ~~our~~ Chief Financial Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any ~~changes~~change in our internal control over financial reporting that occurred during ~~our latest fiscal~~the quarter ended June 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

We are not engaged in any material legal proceedings. However, in the normal course of business, we may from time to time be named as a party to legal claims, actions and complaints, including matters involving employment, intellectual property, vendors, customers or others.

Item 1A. Risk Factors.

RISK FACTOR SUMMARY

Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading “Risk Factors” and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the SEC, including our Annual Report on Form 10-K, filed with the SEC on March 29, 2022, before making investment decisions regarding our common stock.

•

We have incurred losses since our inception and expect to incur losses for the foreseeable future. We cannot be certain that we will achieve or sustain profitability.

•

We will need to raise additional capital to fund our operations in the future. If we are unsuccessful in attracting new capital, we may not be able to continue operations or may be forced to sell assets to do so. Alternatively, capital may not be available to us on favorable terms, or at all. If available, financing terms may lead to significant dilution of our stockholders’ equity.

•

Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share prices.

•

If we are unable to successfully commercialize our products, our business may be adversely affected.

•

COVID-19 has adversely affected our business and is expected to have an impact on our business for the foreseeable future.

•

Our financial results may vary significantly from quarter to quarter or may fall below the expectations of investors or securities analysts, each of which may adversely affectour stock price.

•

Payments under the instruments governing our indebtedness may reduce our working capital. In addition, a default under our SVB Term Loan could cause a material adverse effect on our financial position.

•

We may not be able to develop new products or enhance the capabilities of our systems to keep pace with rapidly changing technology and customer requirements, which could have a material adverse effect on our business and operating results.

•

Our HTG EdgeSeq product portfolio requires the use of NGS instrumentation and reagents and could be adversely affected by actions of third-party NGS product manufacturers over whom we have no control.

•

Our HTG Therapeutics business strategy may require significant investments in working capital and may not generate any revenue.

•

The life sciences research and diagnostic markets are highly competitive. We face competition from enhanced or alternative technologies and products, which could render our products and/or technologies obsolete. If we fail to compete effectively, our business and operating results will suffer.

•

Our current business depends on levels of research and development spending by academic and governmental research institutions and biopharmaceutical companies, a reduction in which could limit demand for our products and adversely affect our business and operating results.

•

As part of our current business model, we intend to seek and enter into strategic development collaborations and licensing arrangements with third parties to develop diagnostic tests, as well as therapeutic development partnerships and collaborations.

•

We are dependent on third-party suppliers for certain subcomponents of our products, including a single supplier for one subcomponent of our HTG EdgeSeq instruments.

•

Limitations in the use of our products could harm our reputation or decrease market acceptance of our products; undetected errors or defects in our products could harm our reputation, decrease market acceptance of our products or expose us to product liability claims.

•

If any members of our management team were to leave us or we are unable to recruit, train and retain key personnel, we may not achieve our goals.

•

Approval and/or clearance by the FDA and foreign regulatory authorities for any future diagnostic tests will take significant time and require significant research, development and clinical study expenditures and ultimately may not succeed.

•

If we are unable to protect our intellectual property effectively, our business will be harmed.

•

We may need to depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from selling some of our products.

•

~~We have incurred losses since our inception and expect to incur losses for the foreseeable future. We cannot be certain that we will achieve or sustain profitability.~~

•

~~If we are unable to successfully commercialize our products, our business may be adversely affected.~~

•

~~COVID-19 has adversely affected our business and is expected to have an impact on our business for the foreseeable future.~~

•

~~Our financial results may vary significantly from quarter to quarter or may fall below the expectations of investors or securities analysts, each of which may adversely affectour stock price.~~

•

~~Our HTG EdgeSeq product portfolio requires the use of NGS instrumentation and reagents and could be adversely affected by actions of third-party NGS product manufacturers over whom we have no control.~~

•

~~Our HTG Therapeutics business strategy may require significant investments in working capital and may not generate any revenue.~~

•

~~As part of our current business model, we intend to seek to enter into strategic development collaborations and licensing arrangements with third parties to develop diagnostic tests.~~

•

~~Our strategy of developing companion diagnostic products may require large investments in working capital and may not generate any revenues.~~

•

~~We are dependent on a single third-party supplier for a certain subcomponent of our systems and the loss of this supplier could harm our business.~~

•

~~If any members of our management team were to leave us or we are unable to recruit, train and retain key personnel, we may not achieve our goals.~~

•

Approval and/or clearance by the FDA and foreign regulatory authorities for any diagnostic tests will take significant time and require significant research, development and clinical study expenditures and ultimately may not succeed.

•

~~If we are unable to protect our intellectual property effectively, our business will be harmed.~~

•

~~We may need to depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from selling some of our products.~~

RISK FACTORS

An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this report, and in our other public filings, before deciding to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. You should consider all of the risk factors described when evaluating our business. We have marked with an asterisk (*) those risk factors that were not included as separate risk factors in, or reflect changes to, the similarly titled risk factors included in Part I, Item 1A, Risk Factors, in our Annual Report on Form 10-K, filed with the SEC on March ~~25, 2021.~~29, 2022.

Risks Related to our Business and Strategy

*We have incurred losses since our inception and expect to incur losses for the foreseeable future. We cannot be certain that we will achieve or sustain profitability.*

We have incurred losses since our inception and expect to incur losses in the future. We incurred net losses of ~~$4.5~~$5.9 million and ~~$12.0~~$12.4 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, respectively, compared with net losses of ~~$5.4~~$2.6 million and ~~$16.6~~$7.5 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively. As of ~~September~~June 30, ~~2021,~~2022, we had an accumulated deficit of ~~$203.1~~$220.7 million. We expect that our losses will continue for the foreseeable future as we will be required to invest significant additional funds to support product development, including development of new proprietary HTG EdgeSeq panels and products, the commercialization of our HTG EdgeSeq platform and proprietary consumables and advancement of our HTG Therapeutics business unit. We also expect that our selling, general and administrative expenses will continue to increase due to the additional costs associated with market development activities and expanding our staff to sell and support our products and services. Our ability to achieve or, if achieved, sustain profitability is based on numerous factors, many of which are beyond our control, including the market acceptance of our products and services, competitive product development and our market penetration and margins. We may never be able to generate sufficient revenue to achieve or, if achieved, sustain profitability.

We will need to raise additional capital to fund our operations in the future. If we are unsuccessful in attracting new capital, we may not be able to continue operations or may be forced to sell assets to do so. Alternatively, capital may not be available to us on favorable terms, or if at all. If available, financing terms may lead to significant dilution of our stockholders’ equity.*

We are not profitable and have had negative cash flow from operations since our inception. To fund our operations and develop and commercialize our products, we have relied primarily on equity and debt financings and revenue generated from the sale of our HTG EdgeSeq platform, proprietary consumables, related services and collaborative development service arrangements with biopharmaceutical company customers. We do not expect that our existing resources will be sufficient to fund our planned operations and expenditures for at least the next 12 months from the date of this report. We currently expect that our existing resources will be sufficient to fund our planned operations and expenditures until January 2023. In addition, potentially changing circumstances, including those related to COVID-19 and inflation, may also result in the depletion of our capital resources more rapidly than we currently anticipate. These circumstances raise substantial doubt about our ability to continue as a going concern. We will need to obtain additional funds to finance our operations. Additional capital may not be available at such times or amounts as needed by us. Historically we have financed our business in part by access to the capital markets. Even if capital is available, it might be available only on unfavorable terms. Any additional equity or convertible debt financing into which we enter could be dilutive to our existing stockholders. Any future debt financing into which we enter may impose covenants upon us that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, we may need to relinquish rights to our technologies or our products or grant licenses on terms that are not favorable to us. If access to sufficient capital is not available as and when needed, our business will be materially impaired, and we may be required to cease operations, curtail one or more product development or commercialization programs, or significantly reduce expenses, sell assets, seek a merger or joint venture partner, file for protection from creditors or liquidate all of our assets. Any of these factors could harm our operating results.

Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.*

The global economy, including credit and financial markets particularly in the emerging biotech sector, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. Similarly, the current Russia-Ukraine conflict has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive.

If we are unable to successfully commercialize our products, our business may be adversely affected.*

Our HTG Edge system was introduced for sale in the life sciences research market in the third quarter of 2013. Our HTG EdgeSeq chemistry was introduced for sale in the life sciences research market in the third quarter of 2014. Our dedicated HTG EdgeSeq platform was introduced for sale in the life sciences research market in the fourth quarter of 2015 and has been our primary product focus since 2016. Our VERI/O service laboratory was announced in June 2016. Our first diagnostic assay, based on our HTG EdgeSeq chemistry and automated on our HTG EdgeSeq platform, was introduced for sale in Europe in July 2016. We commercially launched our HTG Transcriptome Panel in August 2021. Although we believe that the HTG Transcriptome Panel will be a foundational product for RUO profiling, future companion diagnostics and potential proprietary diagnostic products and will allow us to further expand our product offerings outside of oncology and autoimmune and into additional markets such as transplant and diabetes, we have only recently initiated commercial sales of this panel and it may not have the commercial success that we anticipate or ~~hope~~strive for, or that it will allow us to expand our product offerings. We currently market our products through our own sales force in the United States and Europe and have distributors in parts of Europe. We intend to expand our sales and support teams in the United States and in Europe and to establish additional distributor and/or third-party contract sales team relationships in other parts of the world. However, we may not be able to market and sell our products effectively. Our sales of life science research products, profiling and diagnostic products, and potential future products will depend in large part on our ability to successfully increase the scope of our marketing efforts and establish and maintain a sales force commensurate with our then applicable markets. If we do not build and maintain an efficient and effective sales force and distributor relationships targeting these markets, our business and operating results will be adversely affected.

If our HTG EdgeSeq platform and proprietary profiling panels fail to achieve and sustain sufficient market acceptance, or we are not able to continue to expand our service or collaborative relationships with biopharmaceutical customers, either directly or through a collaboration partner, we will not generate expected revenue, and our prospects may be harmed.

We are currently focused on selling our HTG EdgeSeq platform and profiling panels within the life sciences research market and, where approved, in the diagnostic market. We plan to develop panels for many different disease states including companion diagnostics to determine the proper course of treatment for those diseases. We may experience reluctance, or refusal, on the part of physicians to order, and third-party payors to cover and provide adequate reimbursement for, our panels if the results of our research and clinical studies, and our sales and marketing activities relating to communication of these results, do not convey to physicians, third-party payors and patients that the HTG EdgeSeq platform and related profiling panels provide equivalent or better diagnostic information than other available technologies and methodologies. We believe our panels represent an emerging methodology in diagnosing disease states, and we may have to overcome resistance among physicians to adopting it for the marketing of our products to be successful. Even if we are able to obtain regulatory approval from the U.S. Food and Drug Administration (“FDA”) or other applicable regulatory authorities, the use of our panels may not become the standard diagnostic tool for those diseases on which we plan to focus our efforts.

In addition, a key component of our strategy is to develop diagnostic tools in conjunction with biopharmaceutical companies’ drug development programs, to help assess the proper course of treatment for specific diseases. Even if we are successful in developing those diagnostic tools and receive regulatory approval, we still may not be successful in marketing those diagnostic tests. Furthermore, the decision to advance an underlying drug candidate through clinical trials and ultimately to commercialization is at the discretion of biopharmaceutical companies with which we collaborate. Our biopharmaceutical partners may take certain actions that could negatively impact the utility and marketability of our diagnostic tests. For example, our biopharmaceutical partners could:

•

determine not to actively pursue the development or commercialization of an applicable drug candidate, including due to the failure to demonstrate sufficient efficacy, the occurrence of safety or tolerability issues, or any number of other reasons;

•

fail to obtain necessary regulatory approval of an applicable drug candidate;

•

obtain regulatory approval for a drug candidate in a manner that neither requires nor recommends the use of a companion diagnostic test prior to its use; or

•

choose alternative diagnostic tests to market with their products instead of ours.

•

~~fail to obtain necessary regulatory approval of an applicable drug candidate;~~

•

~~obtain regulatory approval for a drug candidate in a manner that neither requires nor recommends the use of a companion diagnostic test prior to its use; or~~

•

~~choose alternative diagnostic tests to market with their products instead of ours.~~

To the extent that we develop diagnostic assays for a biopharmaceutical company in collaboration with a collaboration partner, we may not have responsibility for some or all aspects of developing, marketing or commercializing any resulting diagnostic tests. In addition to this biopharmaceutical partner risk, a collaboration partner may take certain actions that could negatively impact the development, utility and marketability of the applicable diagnostic tests. For example, a collaboration partner could fail to satisfy or fall behind in its obligations to us or to the biopharmaceutical company for which we develop a companion diagnostic test, which may delay development, regulatory approvals, market development and/or commercialization of the applicable companion diagnostic test.

Our agreement with QML is non-exclusive and, in the future, either party may be unwilling to partner with the other, and we may be unable to implement a feasible partnering relationship for the development, manufacture, marketing and/or commercialization of companion diagnostic assays on acceptable terms, or at all. If we are unable to implement such a relationship, our efforts to develop, manufacture and commercialize companion diagnostic assays may be significantly delayed and limited in scale, or may not occur at all. Any of these events could limit our diagnostic test sales and revenue and have a material adverse effect on our business, operating results and financial condition.

We will need to raise additional capital to fund our operations in the future. If we are unsuccessful in attracting new capital, we may not be able to continue operations or may be forced to sell assets to do so. Alternatively, capital may not be available to us on favorable terms, or if at all. If available, financing terms may lead to significant dilution of our stockholders’ equity.

We are not profitable and have had negative cash flow from operations since our inception. To fund our operations and develop and commercialize our products, we have relied primarily on equity and debt financings and revenue generated from the sale of our HTG EdgeSeq platform, proprietary consumables, related services and collaborative development service arrangements with biopharmaceutical company customers. We currently anticipate that our cash and cash equivalents may be sufficient to enable us to fund our operations for at least the next 12 months. However, we will need to obtain additional funds to finance our operations in the future, and we could spend our available financial resources much faster than we currently expect. These circumstances raise substantial doubt about our ability to continue as a going concern. Additional capital may not be available at such times or amounts as needed by us. Historically we have financed our business in part by access to the capital markets. General market conditions resulting from the ongoing issues arising from COVID-19, as well as market conditions affecting companies in the life sciences industry in general, may make it difficult for us to seek financing from the capital markets on attractive terms, or at all. Even if capital is available, it might be available only on unfavorable terms. Any additional equity or convertible debt financing into which we enter could be dilutive to our existing stockholders. Any future debt financing into which we enter may impose covenants upon us that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, we may need to relinquish rights to our technologies or our products or grant licenses on terms that are not favorable to us. If access to sufficient capital is not available as and when needed, our business will be materially impaired, and we may be required to cease operations, curtail one or more product development or commercialization programs, or significantly reduce expenses, sell assets, seek a merger or joint venture partner, file for protection from creditors or liquidate all of our assets. Any of these factors could harm our operating results.

*COVID-19 has adversely affected our business and is expected to have an impact on our business for the foreseeable future.*

Our business, including our workforce, supply chain and customer base, has been adversely affected by COVID‑19.

COVID-19 has caused several states and countries to implement quarantines and/or significant restrictions on travel. In addition, affected regions, including several states within the United States, have previously implemented work restrictions that ~~prohibit~~limited many employees from going to work. Moreover, COVID-19 has resulted in business closures and a substantial reduction in economic activity in the United States and worldwide. The emergence of new variants of the SARS-CoV-2 virus raises the possibility that recurring cycles of restrictions will be imposed in the future, notwithstanding increasing vaccination ~~efforts.~~and immunity levels.

While significant uncertainty remains as to the future impact of the COVID-19 pandemic on our operations, and on the global economy as a whole, COVID-19 had a negative impact on our product and product-related services revenue ~~and collaborative development services revenue~~ in 2020~~. We~~ ~~experienced a significant slowing of revenue generation beginning~~ and 2021. While we have seen some recovery in ~~March 2020 as a result of COVID-19, and~~customers returning to work, we believe this period of reduced revenue will continue into ~~2021 due~~2022 as many customers have not returned to ~~disruptions to our customers’ businesses as a result of the pandemic.~~historical operating levels, are not yet allowing visitors on site at their facilities or have not resumed previously planned studies. The extent of this impact is likely to vary from customer to customer depending upon how they are or have been directly or indirectly impacted by local stay-at-home orders and other social distancing measures, priorities for the customers when the immediate impacts of the pandemic have passed, and the workforce and supplier impacts that each customer has experienced during the pandemic.

~~In March 2020, most of our workforce began working from home either all or substantially all of the time.~~ The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our development programs and regulatory timelines and negatively impact our commercial activities, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In addition, these widespread outbreaks of illness could adversely affect our workforce resulting in serious health issues and absenteeism.

It is also possible that further COVID-19 outbreaks will continue to impact our workforce, supply chains or distribution networks or otherwise impact our ability to conduct sample processing services ~~and custom assay design services and~~in our ~~ability~~laboratory or to ~~provide collaborative development services~~travel to customer facilities for ~~companion diagnostic development programs.~~commercial or support functions in the future. Governmental mandates may require forced shutdowns of our facilities for extended or indefinite periods. Pandemic outbreaks, including the COVID-19, could also substantially interfere with general commercial activity related to our supply chain and customer base, which could have a material adverse effect on our financial condition, results of operations, business or prospects. Restrictions resulting from COVID-19 may disrupt our supply chains or distribution networks or limit our ability to obtain sufficient materials for our consumables or instruments and may disrupt our ability to process customer samples or, to the extent we enter into collaborative services agreements with biopharmaceutical customers, perform collaborative development services. Further, to the extent our customers’ businesses are adversely affected by the pandemic, they might delay or reduce purchases from us or collaborative development projects with us, which could adversely affect our results of operations.

The ~~ultimate impact~~effects of ~~COVID-19~~ongoing or ~~a similar~~future health ~~epidemic is highly~~epidemics on our business remain uncertain and subject to change. WeWhile we do not ~~yet~~ know the full extent of potential delays or impacts on ~~our business, our customers’ businesses, healthcare systems or~~ the global economy, ~~as a whole. However,~~ these effects could have a material adverse impact on our operations, financial position and liquidity.

*36

Our business operations might be disrupted or adversely affected by catastrophic events.*

We manufacture our HTG EdgeSeq instrument and consumable products and perform our RUO profiling, custom RUO assay design services and collaborative development services in our Tucson, Arizona facilities. In addition, our Tucson facilities are the center for order processing, receipt of critical components of our HTG EdgeSeq instrument and shipping products to customers. We do not have redundant facilities. Damage or the inability to utilize our Tucson facilities and the equipment we use to perform research, development or services and manufacture our products could be costly, and we would require substantial lead-time to repair or replace this facility and equipment. The Tucson facilities may be harmed or rendered inoperable by natural or man-made disasters, including flooding, wind damage, power spikes and power outages, which may render it difficult or impossible for us to perform these critical functions for some period of time. The inability to manufacture consumables or instruments, process customer samples, perform development services or ship products to customers for even a short period of time may result in the loss of customers or harm our reputation, and we may be unable to regain those customers in the future. Although we possess insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. In addition, natural disasters or other catastrophic events in various parts of the world, including interruptions in the supply of natural resources, political and governmental changes, disruption in transportation networks or delivery services, severe weather conditions, wildfires and other fires, explosions, actions of animal rights activists, terrorist attacks, earthquakes, wars, conflicts (including the current Russia-Ukraine conflict), and public health issues could disrupt our operations or those of our collaborators, contractors and vendors or contribute to unfavorable economic or other conditions that could adversely impact us.

*Our financial results may vary significantly from quarter to quarter or may fall below the expectations of investors or securities analysts, each of which may adversely affect our stock price.*

Investors should consider our business and prospects considering the risks and difficulties we expect to encounter in the new, uncertain and rapidly evolving markets in which we compete. Because these markets are new and evolving, predicting their future growth and size is difficult. We expect that our visibility into future sales of our products, including volumes, prices and product mix between instruments, consumables and services, will continue to be limited and could result in unexpected fluctuations in our quarterly and annual operating results.

Numerous other factors, many of which are outside our control, may cause or contribute to significant fluctuations in our quarterly and annual operating results. For example, two customers accounted for ~~27%~~19% and ~~13%~~15% of our revenue for the ~~three~~six months ended ~~September~~June 30, ~~2021, and two~~2022. The three largest customers accounted for ~~52%~~23%, 22% and ~~11%~~15% of our accounts receivable balance as of ~~September~~June 30, ~~2021.~~2022. If orders from our top customers are discontinued and we are unable to establish new projects or continue to expand our customer base, our revenue in future periods may materially decrease. In addition, we experienced a significant slowing of product and product-related services revenue generation beginning in March 2020 as a result of COVID-19. This period of reduced revenue continued through the remainder of 2020, 2021 and is continuing into ~~2021~~2022 due to disruptions to our customers’ businesses as a result of the pandemic. The extent of this impact on our ongoing business is likely to vary from customer to customer depending upon how they are directly or indirectly impacted by local stay-at-home orders and other social distancing measures, priorities for the customers when the immediate impacts of the pandemic have passed, and the workforce and supplier impacts that each customer has experienced during the pandemic. Fluctuations in our operating results may make financial planning and forecasting difficult. In addition, these fluctuations may result in unanticipated decreases in our available cash, which could negatively affect our business and prospects. Factors that may contribute to fluctuations in our operating results include many of the risks described under the caption “Risk Factors – Risks Related to Our Business and Strategy” of this report. In addition, one or more of such factors may cause our revenue or operating expenses in one period to be disproportionately higher or lower relative to the others. Our products involve a significant capital commitment from our customers or may depend on customer studies that have variable or indefinite timelines and accordingly, involve a lengthy sales cycle. We may expend significant effort in attempting to make a particular sale, which may be deferred by the

customer or never occur. Accordingly, comparing our operating results on a period-to-period basis may not be meaningful, and investors should not rely on our past results as an indication of our future performance. If such fluctuations occur or if our operating results deviate from our expectations or the expectations of investors or securities analysts, our stock price may be adversely affected.

*37

Our sales cycle is lengthy and variable, which makes it difficult for us to forecast revenue and other operating results.*

Our sales process involves numerous interactions with multiple individuals within any given organization, and often includes in-depth analysis by potential customers of our products (where in some instances we will provide a demonstration unit for their use and evaluation), performance of proof-of-principle studies, preparation of extensive documentation and a lengthy review process. As a result of these factors, the capital investment required in purchasing our instrument and the budget cycles of our customers, the time from initial contact with a customer to our receipt of a purchase order can vary significantly and be up to 12 months or longer. Given the length and uncertainty of our sales cycle, we have in the past experienced, and likely will in the future experience, fluctuations in our product and product-related services revenue on a period-to-period basis. In addition, any failure to meet customer expectations could result in customers choosing to retain their existing systems or service providers or to purchase systems or services other than ours. ~~The~~To the extent we enter into collaborative services agreements with biopharmaceutical customers, the revenue that we expect to earn from our collaborative development services are also subject to an extended, variable timeline based on each project agreement, which will likely result in fluctuations in our collaborative development services revenue on a period-to-period basis as well. ~~Our collaborative development services~~

Pursuant to the terms of the NuvoGen obligation, we have paid NuvoGen $10.9 million, and are required to annually pay NuvoGen the greater of $400,000 or 6% of our yearly revenue ~~is also likely~~until the total aggregate cash compensation paid to NuvoGen under the agreement equals $15.0 million. Payments to NuvoGen will result in a reduction in our working capital as we continue to make payments on this obligation.

The SVB Term Loan requires us, and any debt arrangements we may enter into in the future may require us, to comply with various covenants that limit our ability to, among other things:

•

dispose of assets;

•

complete mergers or acquisitions;

•

incur indebtedness or modify existing debt agreements;

•

amend or modify certain material agreements;

•

engage in additional lines of business;

•

encumber assets;

•

pay dividends or make other distributions to holders of our capital stock;

•

make specified investments; and

•

engage in transactions with our affiliates.

These restrictions could inhibit our ability to pursue our business strategies. If we default under our obligations under the SVB Term Loan, the lender could proceed against the collateral granted to them to secure our indebtedness or declare all obligation under the SVB Term Loan to be ~~impacted~~due and payable. In certain circumstances, procedures by ~~COVID‑19.~~the lender could result in a loss by us of all of our equipment and inventory, which are included in the collateral granted to the lender. Our intellectual property is not included in the collateral granted to the lender but is subject to a negative pledge. In addition, upon any distribution of assets pursuant to any liquidation, insolvency, dissolution, reorganization or similar proceeding, the holders of secured indebtedness will be entitled to receive payment in full from the proceeds of the collateral securing our secured indebtedness before the holders of other indebtedness or our common stock will be entitled to receive any distribution with respect thereto.

Our success depends on our ability to develop new products and applications for our technology in existing and new markets, while improving the performance and cost-effectiveness of our systems. New technologies, techniques or products could emerge that might offer better combinations of price and performance than our current or future products and systems. Existing or future markets for our products, including gene expression analysis, liquid-based specimen analysis (e.g., plasma, blood and urine) and single-cell analysis, as well as potential markets for our diagnostic product candidates, are characterized by rapid technological change and innovation. It is critical to our success that we anticipate changes in technology and customer requirements and successfully introduce new, enhanced and competitive technologies to meet our customers’ and prospective customers’ needs on a timely and cost-effective basis. At the same time, however, we must carefully manage the introduction of new products. If customers believe that such products will offer enhanced features or be sold for a more attractive price, they may delay purchases until such products are available. We may also have excess or obsolete inventory of older products as we transition to new products and our experience in managing product transitions is very limited. If we do not successfully innovate and introduce new technology into our product lines or effectively manage the transitions to new product offerings, our revenue and results of operations will be adversely impacted.

Competitors may respond more quickly and effectively than we do to new or changing opportunities, technologies, standards or customer requirements. We anticipate that we will face increased competition in the future as existing companies and competitors develop new or improved products and as new companies enter the market with new technologies.

If we do not successfully manage the development and launch of new products, our financial results could be adversely affected.

We face risks associated with launching new products and with undertaking to comply with regulatory requirements for certain types of our ~~products (i.e., IVDs).~~products. If we encounter development or manufacturing challenges, adjust our product development priorities, or discover deficiencies during our product development cycle, the product launch date(s) may be delayed, or certain product development projects may be terminated. The expenses or losses associated with unsuccessful product development or launch activities or lack of market acceptance of our new products could adversely affect our business or financial condition.

*Our future success is dependent upon our ability to expand our customer base and introduce new applications.*

Our current customer base is primarily composed of biopharmaceutical companies, academic institutions and molecular labs that perform analyses using or directly or indirectly obtain services based on our HTG EdgeSeq platform and consumables for research use only, which means that the products or data from services may not be used for clinical diagnostic purposes. We have obtained CE markings in Europe for our HTG EdgeSeq consumables, including our HTG EdgeSeq DLBCL Cell of Origin Assay EU and our HTG EdgeSeq ~~Alk~~ALKPlus EU. These products may be used by customers for diagnostic purposes in Europe. With the EU transition to IVD Medical Device Regulation in May 2022, we would need to comply with these requirements in order to remain on the EU market other than research use only. Currently, we do not intend to and, where applicable, do not have appropriate licenses or permits to conduct diagnostic testing services. Our success will depend, in part, upon our ability to increase our market penetration among our customer bases and to expand our market by developing and marketing new companion diagnostic tests and RUO applications (whether product or service). We may not be able to successfully complete development of or commercialize any of our planned future tests and applications. To achieve these goals, we will need to conduct substantial research and development, conduct clinical

validation studies, expend significant funds, expand and scale-up our research, development, service and manufacturing processes and facilities, enter into service and collaborative development services arrangements with biopharmaceutical company customers, expand and train our sales force; and seek and obtain regulatory clearance or approvals of our new tests and applications, as required by applicable regulations. Additionally, we must demonstrate to laboratory directors, physicians and third-party payors that our current and any future diagnostic products are effective in obtaining clinically relevant information that can inform treatment decisions, and that our HTG EdgeSeq platform and related panels can enable an equivalent or superior approach than other available technology. Furthermore, we expect that a combination of increasing the installed base of our HTG EdgeSeq instruments and entering into additional service ~~and custom RUO assay design~~ agreements with biopharmaceutical customers will drive increased demand for our relatively high margin panels. If we are not able to successfully increase our installed base and biopharmaceutical customer relationships, then sales of our products and services, and our margins for these revenue items may not meet expectations. Attracting new customers and introducing new

products and services requires substantial time and expense. Any failure to expand our existing customer base, or launch new products, including diagnostic products or services, would adversely affect our ability to improve our operating results.

*The development of future products is dependent on new methods and/or technologies that we may not be successful in developing.*

We commercially launched our HTG Transcriptome Panel in August 2021. Although we believe that the HTG Transcriptome Panel will be a foundational product for RUO profiling, future companion diagnostics and potential proprietary diagnostic products, and will allow us to further expand our product offerings outside of oncology and autoimmune and into additional markets such as transplant and diabetes, we have only recently initiated commercial sales of this panel and it may not have the commercial success that we anticipate or hope for, or that it will allow us to expand our product offerings. In July 2021, we formed a new drug discovery business unit, HTG Therapeutics, which ~~is expected to use~~uses our HTG Transcriptome Panel and an epitranscriptome profiling technology to profile RNA modifications, and we expect that, by leveraging these profiling technologies earlier in the drug discovery process, HTG Therapeutics will generate lead compounds faster, and with potentially more favorable efficacy and toxicity profiles. However, there can be no assurance that HTG Therapeutics will be able to accomplish these goals or will otherwise be successful. In addition, we ~~are building~~have built a ~~full~~ machine learning-based chemical library design platform, which is expected to better predict the binding properties of a drug candidate to its target. If we are unsuccessful at developing this full machine learning-based chemical library design platform, or it, HTG Therapeutics or our HTG Transcriptome Panel do not provide the benefits that we anticipate, our future revenue opportunities will be limited.

A key element of our strategy is to establish our HTG EdgeSeq technology as the best sample and library preparation method for clinical applications of next-generation sequencers. We depend at least in part on the availability of NGS instrumentation and reagents, and the ability of our HTG EdgeSeq products to operate seamlessly with NGS instrumentation. Any significant interruption or delay in the ability of our HTG EdgeSeq products to operate on or with NGS instrumentation could reduce demand for our products and result in a loss of customers.

Our reputation, and our ability to continue to establish or develop our technology for clinical applications of next-generation sequencers, are dependent upon the availability of NGS instrumentation and the reliable performance of our products with NGS instrumentation. We are not able to control the providers of NGS instrumentation, which increases our vulnerability to interoperability problems with the products that they provide. For example, providers of NGS instruments may discontinue existing products, or introduce new NGS instrumentation products with little or no notice to us. This may cause some of our products not to be operable with one or more NGS instruments or may adversely affect regulatory approvals of our future IVD HTG EdgeSeq products, potentially for extended periods of time. Any interruption in the ability of our products to operate on NGS instruments could harm our reputation or decrease market acceptance of our products, and our business, financial condition and operating results may be materially and adversely affected. We also could experience additional expense in developing new products or changes to existing products to meet developments in NGS instrumentation, including fees charged by our development partners to access new technology, and our business, financial condition and operating results may be materially and adversely affected.

Current medical device regulation in the United States and other jurisdictions requires manufacturers of IVD molecular profiling tests that use NGS detection, referred to as NGS IVD tests, to include in regulatory submissions, technical information about the NGS products that are required for performance of, but are not supplied with, the NGS IVD test. These regulatory agencies also require that the NGS instrumentation have “locked” software for the detection of the NGS IVD test results. Thus, to obtain regulatory approval for NGS IVD tests, manufacturers like us, currently must have arrangements with NGS product manufacturers to gain access to technical information and NGS instrument software. We currently have agreements with two NGS product manufacturers that grant us rights to develop, manufacture and sell future HTG EdgeSeq NGS IVD tests in specified fields, subject to, among other things, the NGS product manufacturers’ rights to terminate such agreements and discontinue products or implement product design changes that could adversely affect our HTG EdgeSeq NGS IVD tests. There can be no assurance that our agreements with these NGS product manufacturers, or any future NGS product manufacturers that we contract with, will not be terminated earlier than we currently expect, that a NGS product manufacturer will perform its contractual duties to us, or that we will otherwise receive the benefits we anticipate receiving under those agreements. In addition, if regulatory agencies do not change their requirements for NGS IVD test approval or clearance and the NGS instrument manufacturers close their systems to third-party NGS IVD test development (in general or with specific NGS IVD test manufacturers) and we are not able to maintain or enforce our agreements with such manufacturers, we may not be able to meet our commercial goals and our business, financial condition and operating results may be materially and adversely affected.

*40

If we do not achieve, sustain or successfully manage our anticipated growth, our business and growth prospects will be harmed.

Our current personnel, systems and facilities may not be adequate to support our business plan and future growth. Our need to effectively manage our operations, growth and various projects requires that we, among other things:

•

continue to improve our operational, financial, management and regulatory compliance controls and reporting systems and procedures;

•

attract and retain sufficient numbers of talented employees;

•

manage our commercialization activities effectively and in a cost-effective manner;

•

manage our relationship with third parties related to the development and commercialization of our products; and

•

manage our development efforts effectively while carrying out our contractual obligations to contractors and other third parties.

•

~~continue to improve our operational, financial, management and regulatory compliance controls and reporting systems and procedures;~~

•

~~attract and retain sufficient numbers of talented employees;~~

•

~~manage our commercialization activities effectively and in a cost-effective manner;~~

•

~~manage our relationship with third parties related to the development and commercialization of our products; and~~

•

~~manage our development efforts effectively while carrying out our contractual obligations to contractors and other third parties.~~

Moreover, growth will place significant strains on our management and our operational and financial systems and processes. For example, expanded market penetration of our HTG EdgeSeq platform and related proprietary panels, and future development and approval of diagnostic products, are key elements of our growth strategy that will require us to hire and retain additional sales and marketing, regulatory, manufacturing and quality assurance personnel. If we do not successfully forecast the timing and cost of the development of new panels and diagnostic products, the regulatory clearance or approval for product marketing of any future diagnostic products or the demand and commercialization costs of such products, or manage our anticipated expenses accordingly, our operating results will be harmed.

*If regulatory limitations are placed on our products our business and growth will be harmed.

In many jurisdictions, including the United States, we are currently limited to marketing our HTG EdgeSeq platform and proprietary profiling panels for research use only, which means that we cannot make any diagnostic or clinical claims for those products in those jurisdictions.

We obtained the right to CE mark the HTG EdgeSeq DLBCL Cell of Origin Assay EU and the HTG EdgeSeq ALKPlus Assay EU for sale as IVDs in Europe, in July 2016 and March 2017, respectively. With the EU transition to IVD Medical Device Regulation in May 2022, we would need to comply with these requirements in order to remain on the EU market other than research use only. While our current ex-U.S. strategy is to focus our efforts on the RUO market, in the event we want to expand our ex-U.S. business opportunities outside of research use only there would likely be additional clinical validations and certifications that we would need to obtain and there can be no assurance that we would be able obtain to obtain any such validations or certifications on a timely basis, or at all. In addition, if clinical diagnostic laboratories or other customers outside the United States do not accept our tests, our ability to grow our business outside of the United States could be compromised.

*41

Our HTG Therapeutics business strategy may require significant investments in working capital and may not generate any revenue.*

In July 2021, we formed a new drug discovery business unit, HTG Therapeutics. This business unit ~~is expected to use~~uses our HTG Transcriptome Panel and an epitranscriptome profiling technology evolved from our original HTG EdgeSeq technology, HTG

EpiEdgeSeq, to profile RNA modifications. By leveraging these profiling technologies earlier in the drug discovery process, our objective is for HTG Therapeutics to generate lead compounds faster, and with potentially more favorable efficacy and toxicity profiles, with the ultimate goal of generating interest from pharmaceutical companies that results in research or licensing collaborations for, or acquisitions of, these compounds. However, while we have hired experienced employees and added drug development depth to our Board of Directors, as a company we have no prior experience with drug discovery and development and may not be successful in this endeavor. Moreover, drug discovery and development is expensive and will require investments in working capital by us that may be significant. Even if we are successful in partnering for one or more early-stage drug discovery programs with a pharmaceutical company, we will need to expend potentially significant capital resources on these programs prior to any such partnering, and potentially after, and there can be no assurance that we will generate meaningful ~~revenues~~revenue from these programs. We will need to raise additional funds in order to finance the implementation of our HTG Therapeutics business strategy, which could dilute our current investors or could impact our ability to continue our operations in the future.

*We expect to generate a portion of our revenue internationally and are subject to various risks relating to our international activities, which could adversely affect our operating results.*

For the three and ~~nine~~six months ended ~~September~~June 30, ~~2021,~~2022, approximately ~~24%~~42% and ~~30%~~32% of our revenue was generated from sales originated by customers located outside of the United States, respectively, compared with ~~19%~~30% and ~~31%~~34% for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively. We expect that a percentage of our future revenue will continue to come from international sources, and we expect to expand our overseas operations and develop opportunities in additional areas. Engaging in international business involves a number of difficulties and risks, including:

•

required compliance with existing and changing foreign regulatory requirements and laws;

•

required compliance with anti-bribery laws, such as the U.S. Foreign Corrupt Practices Act and U.K. Bribery Act, data privacy requirements, labor laws and anti-competition regulations;

•

export and import restrictions;

•

various reimbursement, pricing and insurance regimes;

•

laws and business practices favoring local companies;

•

longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;

•

political and economic instability, including due to the current Russia-Ukraine conflict;

•

potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements and other trade barriers, including transfer pricing, value added and other tax systems, double taxation and restrictions and/or taxation on repatriation of earnings;

•

tariffs, customs charges, bureaucratic requirements and other trade barriers;

•

difficulties and costs of staffing and managing foreign operations, including difficulties and costs associated with foreign employment laws;

•

increased financial accounting and reporting burdens and complexities; and

•

difficulties protecting, procuring, or enforcing intellectual property rights, including from reduced or varied protection for intellectual property rights in some countries.

•

~~required compliance with existing and changing foreign regulatory requirements and laws;~~

•

~~required compliance with anti-bribery laws, such as the U.S. Foreign Corrupt Practices Act and U.K. Bribery Act, data privacy requirements, labor laws and anti-competition regulations;~~

•

~~export and import restrictions;~~

•

~~various reimbursement, pricing and insurance regimes;~~

•

~~laws and business practices favoring local companies;~~

•

~~longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;~~

•

~~political and economic instability;~~

•

~~tariffs, customs charges, bureaucratic requirements and other trade barriers;~~

•

~~difficulties and costs of staffing and managing foreign operations, including difficulties and costs associated with foreign employment laws;~~

•

~~increased financial accounting and reporting burdens and complexities; and~~

•

~~difficulties protecting, procuring, or enforcing intellectual property rights, including from reduced or varied protection for intellectual property rights in some countries.~~

As we expand internationally our results of operations and cash flows will become increasingly subject to fluctuations due to changes in foreign currency exchange rates. Historically, most of our revenue has been denominated in U.S. dollars, although we have sold our products and services in local currency outside of the United States, principally the Euro. Our expenses are generally denominated in the currencies in which our operations are located, which is primarily in the United States. As our operations in countries outside of the United States grows, our results of operations and cash flows will increasingly be subject to fluctuations due to changes in foreign currency exchange rates, which could negatively impact our results of operations in the future. For example, if the value of the U.S. dollar increases relative to foreign currencies, in the absence of an offsetting change in local currency prices, our revenue could be adversely affected as we convert revenue from local currencies to U.S. dollars.

If we dedicate significant resources to our international operations and are unable to manage these risks effectively, our business, operating results and prospects will suffer. Moreover, we cannot be certain that the investment and additional resources required in establishing operations in other countries will produce desired levels of revenue or profitability.

In addition, any failure to comply with applicable legal and regulatory obligations could negatively impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of products and restrictions on certain business activities.

*If the utility of our HTG EdgeSeq platform, proprietary profiling panels, services and solutions in development is not supported by studies published in peer-reviewed medical publications, the rate of adoption of our current and future products and the rate of reimbursement of our future products by third-party payors may be negatively affected.

We anticipate that we will need to maintain a continuing presence in peer-reviewed publications to promote adoption of our products by biopharmaceutical companies, academic institutions and molecular labs and to promote favorable coverage and reimbursement decisions. We believe that peer-reviewed journal articles that provide evidence of the utility of our current and future products or the technology underlying the HTG EdgeSeq platform, consumables and services are important to our commercial success. It is critical to the success of our sales efforts that we educate a sufficient number of clinicians and administrators about our HTG EdgeSeq technology, including our HTG EpiEdgeSeq technology, our current panels and services and our future solutions, and demonstrate the research and clinical benefits of these solutions. Our customers may not adopt our current and future solutions, and third-party payors may not cover or adequately reimburse our future products, unless they determine, based on published peer-reviewed journal articles and the experience of other researchers and clinicians, that our products provide accurate, reliable, useful and cost-effective information. Peer-reviewed publications regarding our products and solutions may be limited by many factors, including delays in the completion of, poor design of, or lack of compelling data from studies that would be the subject of the article. If our current and future product and product-related service solutions or the technology underlying such products and services do not receive sufficient favorable exposure in peer-reviewed publications, the rate of research and clinical adoption and positive coverage and reimbursement decisions could be negatively affected.

We may provide our HTG EdgeSeq instrument and profiling panels free of charge or through other arrangements to customers or key opinion leaders through evaluation agreements or reagent rental programs, and these programs may not be successful in generating recurring revenue from sales of our systems and proprietary panels.

We sell our HTG EdgeSeq instrument and profiling panels under different arrangements to expand our installed base and facilitate the adoption of our platform.

In some instances, we provide equipment free of charge under evaluation agreements for a limited period of time to permit the user to evaluate the system for their purposes in anticipation of a decision to purchase the system. We retain title to the equipment under such arrangements unless the evaluator purchases the equipment, and in most cases, require evaluation customers to purchase a minimum quantity of consumables during the evaluation period.

When we place a system under a reagent rental agreement, we install equipment in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement. While some of these agreements did not historically contain a minimum purchase requirement, we have included a minimum purchase requirement in all current reagent rental agreements and will continue to do so in the future. We retain title to the equipment and such title is transferred to the customer at no additional charge at the end of the initial arrangement. The cost of the instrument under the agreement is expected to be recovered in the fees charged for consumables, to the extent sold, over the term of the agreement.

Other arrangements might include a research agreement whereby an academic collaborator agrees to provide biological samples in exchange for the use of an HTG EdgeSeq instrument at no cost in furtherance of the collaborator’s professional goals and/or the educational or research objectives of an applicable institution.

Any of the foregoing arrangements could result in lost revenue and profit and potentially harm our long-term goal of achieving profitable operations. In addition, we require customers who receive systems that we continue to own to carry insurance sufficient to protect us against any equipment losses, we cannot guarantee that they will maintain such coverage, which may expose us to a loss of the value of the equipment in the event of any loss or damage.

There are instances where we provide our systems to key opinion leaders free of charge, to gather data and publish the results of their research to assist our marketing efforts. We have no control over some of the work being performed by these key opinion leaders, or whether the results will be satisfactory. It is possible that the key opinion leader may generate data that is unsatisfactory and could potentially harm our marketing efforts. In addition, customers may from time to time create negative publicity about their experience with our systems, which could harm our reputation and negatively affect market perception and adoption of our platform.

Placing our HTG EdgeSeq instruments under evaluation agreements, under reagent rental agreements or with our key opinion leaders without receiving payment for the instruments could require substantial additional working capital to provide additional units for sale to our customers.

We face risks related to handling of hazardous materials and other regulations governing environmental safety.

Our operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations that both public officials and private individuals may seek to enforce. Our activities that are subject to these regulations include, among other things, our use of hazardous materials and the generation, transportation and storage of waste. We could discover that we or an acquired business is not in material compliance with these regulations. Existing laws and regulations may also be revised or reinterpreted, or new laws and regulations may become applicable to us, whether retroactively or prospectively, that may have a negative effect on our business and results of operations. It is also impossible to eliminate completely the risk of accidental environmental contamination or injury to individuals. In such an event, we could be liable for any damages that result, and any liability could exceed our resources or any applicable insurance coverage we may have, which events could adversely affect our business.

We face significant competition in the life sciences research and diagnostics markets. We currently compete with both established and early-stage life sciences research companies that design, manufacture and market instruments and consumables for gene expression analysis, liquid-based specimen analysis (e.g., plasma, blood and urine), single-cell analysis, PCR, digital PCR, other nucleic acid detection and additional applications. These companies use well-established laboratory techniques such as microarrays or qPCR as well as newer technologies such as next-generation sequencing. We believe our principal competitors in the life sciences research market are Abbott Molecular, Affymetrix, Inc., Agilent Technologies, Inc., ~~ArcherDx, Inc.,~~ BioRad Laboratories, Invitae (acquired by Archer Dx, Inc.), Fluidigm Corporation, Illumina, Inc., ~~Abbott Molecular,~~ Luminex Corporation, ~~Affymetrix, Inc.,~~ NanoString Technologies, Inc., Personal Genome Diagnostics (acquired by Labcorp), entities owned and controlled by QIAGEN N.V., Roche Diagnostics, a division of the Roche Group of companies, ~~Personal Genome Diagnostics~~ and Thermo Fisher Scientific, Inc. In addition, there are several other market entrants in the process of developing novel technologies for the life sciences market. One or more of our competitors could develop a product that is superior to a product we offer or intend to offer, or our technology and products may be rendered obsolete or uneconomical by advances in existing technologies.

Within the diagnostic market, there are competitors that manufacture systems for sales to hospitals and laboratories and other competitors that offer tests conducted through CLIA certified laboratories. We will also compete with commercial diagnostics companies. Most of our current competitors are either publicly traded, or are divisions of publicly traded companies, and enjoy a number of competitive advantages over us, including:

•

greater name and brand recognition, financial and human resources;

•

broader product lines;

•

larger sales forces and more established distributor networks;

•

substantial intellectual property portfolios;

•

larger and more established customer bases and relationships; and

•

better established, larger scale, and lower cost manufacturing capabilities.

•

~~greater name and brand recognition, financial and human resources;~~

•

~~broader product lines;~~

•

~~larger sales forces and more established distributor networks;~~

•

~~substantial intellectual property portfolios;~~

•

~~larger and more established customer bases and relationships; and~~

•

~~better established, larger scale, and lower cost manufacturing capabilities.~~

We believe that the principal competitive factors in all of our target markets include:

•

cost of capital equipment;

•

cost of consumables and supplies;

•

reputation among customers;

•

innovation in product offerings;

•

flexibility and ease-of-use;

•

accuracy and reproducibility of results; and

•

compatibility with existing laboratory processes, tools and methods.

•

~~cost of capital equipment;~~

•

~~cost of consumables and supplies;~~

•

~~reputation among customers;~~

•

~~innovation in product offerings;~~

•

~~flexibility and ease-of-use;~~

•

~~accuracy and reproducibility of results; and~~

•

~~compatibility with existing laboratory processes, tools and methods.~~

We believe that additional competitive factors specific to the diagnostics market include:

•

breadth of clinical decisions that can be influenced by information generated by tests;

•

volume, quality, and strength of clinical and analytical validation data;

•

availability of coverage and adequate reimbursement for testing services; and

•

economic benefit accrued to customers based on testing services enabled by products.

•

~~breadth of clinical decisions that can be influenced by information generated by tests;~~

•

~~volume, quality, and strength of clinical and analytical validation data;~~

•

~~availability of coverage and adequate reimbursement for testing services; and~~

•

~~economic benefit accrued to customers based on testing services enabled by products.~~

Our products may not compete favorably, and we may not be successful in the face of increasing competition from new products and technologies introduced by our existing competitors or new companies entering our markets. In addition, our competitors may have or may develop products or technologies that currently or in the future will enable them to produce competitive products with greater capabilities or at lower costs than ours. Any failure to compete effectively could materially and adversely affect our business, financial condition and operating results.

Our revenue is currently derived from sales of our HTG EdgeSeq instrument and related proprietary panels, the design of custom RUO assays and sample processing for research applications to biopharmaceutical companies, academic institutions and molecular labs, predominantly in the United States and ~~Europe, and collaborative development services.~~Europe. The demand for our products and services will depend in part upon the research and development budgets of these customers, which are impacted by factors beyond our control, such as:

•

changes in government programs that provide funding to research institutions and companies;

•

macroeconomic conditions and the political climate;

•

changes in the regulatory environment;

•

differences in budgetary cycles;

•

market-driven pressures to consolidate operations and reduce costs; and

•

market acceptance of relatively new technologies, such as ours.

•

~~changes in government programs that provide funding to research institutions and companies;~~

•

~~macroeconomic conditions and the political climate;~~

•

~~changes in the regulatory environment;~~

•

~~differences in budgetary cycles;~~

•

~~market-driven pressures to consolidate operations and reduce costs; and~~

•

~~market acceptance of relatively new technologies, such as ours.~~

We believe that any uncertainty regarding the availability of research funding may adversely affect our operating results and may adversely affect sales to customers or potential customers that rely on government funding. In addition, academic, governmental and other research institutions that fund research and development activities may be subject to stringent budgetary constraints that could result in spending reductions, reduced allocations or budget cutbacks, which could jeopardize the ability of these customers to purchase our products or services. Our operating results may fluctuate substantially due to reductions and delays in research and development expenditures by these customers. Any decrease in our customers’ budgets or expenditures, or in the size, scope or frequency of capital or operating expenditures, could materially and adversely affect our business, operating results and financial condition.

*45

As part of our current business model, we intend to seek to enter into strategic development collaborations and licensing arrangements with third parties.

We have relied, and expect to continue to rely, on strategic development collaborations and licensing agreements with third parties to develop or in-license technologies based on which products or services we may develop or offer. We have entered into agreements with third parties to facilitate or enable our development of assays, and ultimately diagnostic tests, to aid in the diagnosis of oncology diseases, such as breast cancer and melanoma, and other diseases. We intend to enter into additional similar agreements with life sciences companies, biopharmaceutical companies and other researchers for future diagnostic products. In addition, we intend to enter into early-stage drug discovery and development collaborations. However, we cannot guarantee that we will enter into any additional agreements or collaborations. For example, our life sciences research or biopharmaceutical customers are not obligated to collaborate with us or license technology to us, and they may choose to develop diagnostic products themselves or collaborate with our competitors. Establishing development collaborations and licensing arrangements is difficult and time-consuming. Discussions may not lead to development collaborations or licenses on favorable terms, or at all. Potential collaborators or licensors may elect not to work with us based upon their assessment of our financial, regulatory or intellectual property position. To the extent that we enter new collaborative development or licensing agreements, they may never result in the successful development or commercialization of

future tests or other products for a variety of reasons, including because our collaborators may not succeed in performing their obligations or may choose not to cooperate with us. We cannot control the amount and timing of our collaborators’ resources that will be devoted to performing their responsibilities under our agreements with them. Moreover, to the extent we agree to work exclusively with a party in a given area, our opportunities to collaborate with others would be limited. Even if we establish new relationships, they may never result in the successful development or commercialization of future tests or other products. Disputes with our collaborators could also impair our reputation or result in development delays, decreased revenue and litigation expenses.

Our research and development efforts will be hindered if we are not able to contract with third parties for access to archival patient samples.

Our future development of products for clinical indications will require access to archival patient samples for which data relevant to the clinical indication of interest is known. We rely on our ability to secure access to these archived patient samples, including FFPE tissue, plasma, serum, whole blood preserved in PAXgene, or various cytology preparations, together with the information pertaining to the clinical outcomes of the patients from which the samples were taken. Owners or custodians of relevant samples may be difficult to identify and/or identified samples may be of poor quality or limited in number or amount. Additionally, others compete with us for access to these samples for both research and commercial purposes. Even when an appropriate cohort of samples is identified, the process of negotiating access to these samples can be lengthy because it typically involves numerous parties and approval levels to resolve complex issues such as usage rights, institutional review board approval, privacy rights, publication rights, and intellectual property ownership. In addition, in some instances the cost to acquire samples can be prohibitively expensive. If we are not able to negotiate access to archived patient samples on a timely basis and on acceptable terms, or at all, or if our competitors or others secure access to these samples before us, our ability to research, develop and commercialize future products will be limited or delayed.

We are dependent on third-party suppliers for certain subcomponents of our products, including a single ~~third-party~~ supplier for ~~a certain~~one subcomponent of our ~~systems~~HTG EdgeSeq instruments.

We rely on third-party suppliers to supply certain subcomponents used in our HTG EdgeSeq instruments and ~~the loss of this supplier could harm our business.~~

~~We currently rely on~~consumables, including a single supplier, In Position Technologies, to produce a certain subcomponent used in our HTG EdgeSeq instruments. While we periodically forecast our needs for ~~this subcomponent,~~these subcomponents, our ~~contract~~contracts with ~~this supplier, which may be a standard purchase order, does~~these suppliers do not commit them to carry inventory or make available any particular quantities, and the ~~supplier~~suppliers may give other customers’ needs higher priority than ours and we may not be able to obtain adequate supplies in a timely manner or on commercially reasonable terms. If we were to lose ~~this supplier,~~any of these suppliers, we may not be able to identify or enter into agreements with alternative suppliers on a timely basis on acceptable terms, or at all. In addition, we have in the past experienced supply issues, as well as quality control problems such as shipment errors, with certain of our suppliers, and may experience problems in the future. If we should encounter delays or difficulties in securing the quality and quantity of ~~subcomponent~~subcomponents we require for our ~~instruments,~~products, our supply chain would be interrupted or our products may not perform as expected, which would adversely affect our sales. A loss or performance failure of ~~this supplier~~any of these suppliers could significantly delay the delivery or impact the performance of our ~~HTG EdgeSeq instruments,~~products, which in turn would materially affect our ability to generate revenue. If any of these events occur, our business and operating results could be materially harmed.

We may encounter manufacturing difficulties that could impede or delay production of our HTG EdgeSeq platform.

We began manufacturing our HTG EdgeSeq platform internally in 2016. We have limited experience with manufacturing the system and our internal manufacturing operations may encounter difficulties involving, among other things, scale-up of manufacturing processes, production efficiency and output, regulatory compliance, quality control and quality assurance, and shortages of qualified personnel. Any failure in our planned internal manufacturing operations could cause us to be unable to meet demand for these systems, delay the delivery of the system to customers, and harm our business relationships and reputation.

If we encounter difficulties in our planned internal manufacturing operations, we may need to engage a third-party supplier, provided we cannot be sure we will be able to do so in a timely manner, or at all, or on favorable terms.

Any of these factors could cause us to delay or suspend production of our HTG EdgeSeq platform, entail unplanned additional costs and materially harm our business, results of operations and financial condition.

We rely on distributors for sales of our products in several markets outside of the United States.

We have established exclusive and non-exclusive distribution agreements for our HTG EdgeSeq platform and related profiling panels within parts of Europe and the Middle East. We intend to continue to grow our business internationally, and to do so, in addition to expanding our own direct sales and support team, we plan to attract additional distributors and sales partners to maximize the commercial opportunity for our products. We cannot guarantee that we will be successful in attracting desirable distribution and sales partners or that we will be able to enter into such arrangements on favorable terms. Distributors and sales partners may not commit the necessary resources to market and sell our products to the level of our expectations or may favor marketing the products of our competitors. If current or future distributors or sales partners do not perform adequately, or we are unable to enter into effective arrangements with distributors or sales partners in particular geographic areas, we may not realize long-term international revenue growth.

*Clinical studies of any product candidate that we intend to market as an IVD kit may not be successful. ~~If we are unable to successfully complete non-clinical and clinical studies of our product candidates or experience significant delays in doing so, we will not be able to expand our IVD kit offerings.~~

Our clinical diagnostic business prospects in the United States and other applicable jurisdictions will depend on our ability to successfully complete clinical studies for product candidates that we intend to market as IVD kits. A failure of one or more clinical studies can occur at any stage of testing. The outcome of non-clinical studies may not be predictive of the success of clinical studies, and interim results, if any, of a clinical study do not necessarily predict final results. Moreover, non-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in non-clinical and clinical studies have nonetheless failed to obtain premarketing clearance or approval for their products. ~~Completion of clinical studies, announcement of results of the studies and our ability to obtain regulatory approvals could be delayed for a variety of reasons, including:~~

•

~~unsatisfactory results of any clinical study, including failure to meet study objectives~~;

•

~~the failure of our principal third-party investigators to perform our clinical studies on our anticipated schedules;~~

•

~~imposition of a clinical hold following an inspection of our clinical study operations or trial sites by the FDA or other regulatory authorities;~~

•

~~our inability to adhere to clinical study requirements directly or with third parties, such as contract research organizations (“CRO’s”);~~

•

~~different interpretations of our non-clinical and clinical data, which could initially lead to inconclusive results;~~

•

~~delays in obtaining suitable patient samples for use in a clinical study; and~~

•

~~delays on patient enrollment due to COVID-19~~.

Our development costs will increase if we have material delays in any clinical study or if we need to perform more or larger clinical studies than planned. If the delays are significant, or if any of our products do not prove to be equivalent to a predicate device or safe or effective, as applicable, or do not receive required regulatory approvals, our financial results and the commercial prospects for our product candidates will be harmed. Furthermore, our inability to complete our clinical studies in a timely manner could jeopardize our ability to obtain regulatory approval.

*Developing companion diagnostic products may require large investments in working capital and may not generate any revenue.

A component of our strategy is the development of companion diagnostic products designed to determine the appropriate patient population for administration of a particular therapeutic to more successfully treat a variety of illnesses. We may now choose to develop companion diagnostic products independently or with a collaboration partner. Successfully developing a companion diagnostic product depends both on regulatory approval for administration of the therapeutic, as well as regulatory approval of the associated diagnostic product. Even if we are successful in developing products that would be useful as companion diagnostic products, and potentially receive regulatory approval for such products, the biopharmaceutical companies that develop the corresponding therapeutics may ultimately be unsuccessful in obtaining regulatory approval for any such therapeutic, or, even if successful, select a competing technology to use in their regulatory submission instead of ours. The development, especially the

independent development, of companion diagnostic products requires a significant investment of working capital, which may not result in any future income. This could require us to raise additional funds which could dilute our current investors or could impact our ability to continue our operations in the future.

Our products are subject to the limitations set forth in the product labeling, which may not satisfy the needs of all customers. For example, in the past we have introduced new panels that initially were intended to be used with specific sample types. Because our customers desire that our panels be broadly applicable to many biological sample types, these initial limitations could harm our reputation or decrease market acceptance of our products. If that occurs, we may incur significant costs, the attention of our key personnel could be diverted, or other significant customer relations problems may arise, which could harm our business and operating results.

Similarly, our products may contain undetected errors or defects when first introduced or as new versions are released. Since our current customers use our products for research and, if cleared or approved for diagnostic applications, disruptions or other performance problems with our products may damage our customers’ businesses and could harm our reputation. If that occurs, we may incur significant costs, the attention of our key personnel could be diverted, or other significant customer relations problems may arise. We may also be subject to warranty and liability claims for damages related to errors or defects in our products. A material liability claim or other occurrence that harms our reputation or decreases market acceptance of our products could harm our business and operating results.

The sale and use of products or services based on our technologies, or activities related to our research and clinical studies, could lead to the filing of product liability claims if someone were to allege that one of our products contained a design or manufacturing defect which resulted in the failure to adequately perform the analysis for which it was designed. A product liability claim could result in substantial damages and be costly and time consuming to defend, either of which could materially harm our business or financial condition. We cannot assure investors that our product liability insurance could adequately protect our assets from the financial impact of defending a product liability claim. Any product liability claim brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing insurance coverage in the future.

*Payments under the instruments governing our indebtedness may reduce our working capital. In addition, a default under our SVB Term Loan could cause a material adverse effect on our financial position.

Pursuant to the terms of the NuvoGen obligation, we have paid NuvoGen $10.5 million, and are required to annually pay NuvoGen the greater of $400,000 or 6% of our yearly revenue until the total aggregate cash compensation paid to NuvoGen under the agreement equals $15.0 million. Payments to NuvoGen will result in a reduction in our working capital as we continue to make payments on this obligation.

~~The SVB Term Loan requires us, and any debt arrangements we may enter into in the future may require us, to comply with various covenants that limit our ability to, among other things:~~

•

~~dispose of assets;~~

•

~~complete mergers or acquisitions;~~

•

~~incur indebtedness or modify existing debt agreements;~~

•

~~amend or modify certain material agreements;~~

•

~~engage in additional lines of business;~~

•

~~encumber assets;~~

•

~~pay dividends or make other distributions to holders of our capital stock;~~

•

~~make specified investments; and~~

•

~~engage in transactions with our affiliates.~~

These restrictions could inhibit our ability to pursue our business strategies. If we default under our obligations under the SVB Term Loan, the lender could proceed against the collateral granted to them to secure our indebtedness or declare all obligation under the SVB Term Loan to be due and payable. In certain circumstances, procedures by the lender could result in a loss by us of all of our equipment and inventory, which are included in the collateral granted to the lender. Our intellectual property is not included in the collateral granted to the lender but is subject to a negative pledge. In addition, upon any distribution of assets pursuant to any liquidation, insolvency, dissolution, reorganization or similar proceeding, the holders of secured indebtedness will be entitled to receive payment in full from the proceeds of the collateral securing our secured indebtedness before the holders of other indebtedness or our common stock will be entitled to receive any distribution with respect thereto.

*Changes in laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.

New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the ~~legislation~~Biden administration and Congress have proposed various U.S. federal tax law changes, which if enacted in 2017, informally titled the Tax Cuts and Jobs Act (the “Tax Act”) enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspectscould have a material impact on our business, cash flow, financial condition or results of ~~the Tax Act could be repealed or modified in future legislation. For example, the CARES Act modified certain tax provisions of the Tax Act.~~operations. In addition, it is uncertain if and to what extent various states will conform to ~~any newly enacted~~ federal tax ~~legislation. Changes in corporate~~laws. Future tax ~~rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future~~ reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.

*Our ability to use net operating loss carryforwards and certain other tax attributes may be limited.

As of December 31, ~~2020,~~2021, we had federal net operating loss carryforwards (“NOLs”) to offset future taxable income of ~~$177.6~~$194.0 million, of which $121.8 million will begin to expire after ~~2021~~2023 if not utilized, while the remainder can be carried forward indefinitely. A lack of future taxable income would adversely affect our ability to utilize these NOLs. Under ~~the Tax Act, as modified by the CARES Act,~~current law, our federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely but the deductibility of these federal NOLs in tax years beginning after December 31, ~~2020~~2021 is limited to 80% of taxable income. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “IRC”), and corresponding provisions of state law, a corporation that undergoes an “ownership change” (generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period) is subject to limitations on its ability to utilize its pre-ownership change NOL carryforwards and certain other pre-ownership change tax attributes to offset post-ownership change income or taxes. We believe we may have already experienced one or more ownership changes and may in the future experience one or more additional ownership changes, and thus, our ability to utilize pre-ownership change NOL carryforwards and other pre-ownership change tax attributes to offset post-ownership change income or taxes may be limited. Such limitations may cause a portion of our NOL and credit carryforwards to expire before we are able to utilize them. In addition, at the state level, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those ~~assets~~.assets.

Acquisitions or joint ventures could disrupt our business, cause dilution to our stockholders and otherwise harm our business.

We may acquire other businesses, products or technologies as well as pursue strategic alliances, joint ventures, technology licenses or investments in complementary businesses. We have limited experience with respect to business, product or technology acquisitions or the formation of collaborations, strategic alliances and joint ventures or investing in complementary businesses. Any of these transactions could be material to our financial condition and operating results and expose us to many risks, including:

•

disruption in our relationships with customers, distributors or suppliers as a result of such a transaction;

•

unanticipated liabilities related to acquired companies;

•

difficulties integrating acquired personnel, technologies and operations into our existing business;

•

diversion of management time and focus from operating our business to acquisition integration challenges;

•

increases in our expenses and reductions in our cash available for operations and other uses; and

•

possible write-offs or impairment charges relating to acquired businesses.

•

~~disruption in our relationships with customers, distributors or suppliers as a result of such a transaction;~~

•

~~unanticipated liabilities related to acquired companies;~~

•

~~difficulties integrating acquired personnel, technologies and operations into our existing business;~~

•

~~diversion of management time and focus from operating our business to acquisition integration challenges;~~

•

~~increases in our expenses and reductions in our cash available for operations and other uses; and~~

•

~~possible write-offs or impairment charges relating to acquired businesses.~~

Foreign acquisitions involve unique risks in addition to those mentioned above, including those related to integration of operations across different cultures and languages, currency risks and the particular economic, political and regulatory risks associated with specific countries. Also, the anticipated benefit of any acquisition may not materialize. Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results.

If any members of our management team were to leave us or we are unable to recruit, train and retain key personnel, we may not achieve our goals.

Our future success depends on our ability to recruit, train, retain and motivate key personnel, including our senior management, research and development, manufacturing, service and sales and marketing personnel. If we were to lose one or more of our key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategies. Competition for qualified personnel is intense, and we may not be able to attract talent. Our growth depends, in part, on attracting, retaining and motivating highly trained sales personnel with the necessary scientific background and ability to understand our systems at a technical level to effectively identify and sell to potential new customers, including new biopharmaceutical company customers. In particular, the commercialization of our HTG EdgeSeq platform and related panels requires us to continue to establish and maintain sales and support teams to optimize the markets for research tools and, where approved, diagnostic assays, and to fully optimize a broad array of diagnostic market opportunities as we receive approval for any future diagnostic products. We do not maintain fixed term employment contracts or key man life insurance relating to any of our employees. Because of the complex and technical nature of our products and the dynamic market in which we compete, any failure to retain our management team or to attract, train, retain and motivate other qualified personnel could materially harm our operating results and growth prospects.

Our operating results may be harmed if we are required to collect sales, services or other related taxes for our products and services in jurisdictions where we have not historically done so.

We do not believe that we are required to collect sales, use, services or other similar taxes from our customers in certain jurisdictions. However, one or more countries or states may seek to impose sales, use, services, or other tax collection obligations on us, including for past sales. A successful assertion by one or more jurisdictions that we should collect sales or other taxes on the sale of our products and services could result in substantial tax liabilities for past sales and decrease our ability to compete for future sales. Each country and each state has different rules and regulations governing sales and use taxes and these rules and regulations are subject to varying interpretations that may change over time. We review these rules and regulations periodically and, when we believe sales and use taxes apply in a particular jurisdiction, voluntarily engage tax authorities in order to determine how to comply with their rules and regulations. However, we cannot guarantee that we will not be subject to sales and use taxes or related penalties for past sales in jurisdictions where we presently believe sales and use taxes are not due.

Providers of goods or services are typically held responsible by taxing authorities for the collection and payment of any applicable sales and similar taxes. If one or more taxing authorities determines that taxes should have, but have not, been paid with respect to our products and services, we may be liable for past taxes in addition to being required to collect sales or similar taxes in respect of our products and services going forward. Liability for past taxes may also include substantial interest and penalty charges. Our customer contracts provide that our customers must pay all applicable sales and similar taxes. Nevertheless, customers may be reluctant to pay back taxes and may refuse responsibility for interest or penalties associated with those taxes or we may determine that it would not be feasible to seek reimbursement. If we are required to collect and pay back taxes and the associated interest and penalties and if our customers do not reimburse us for all or a portion of these amounts, we will have incurred unplanned expenses that may be substantial. Moreover, imposition of such taxes on our products and services going forward will effectively increase the cost of such products and services to our customers.

Many states are also pursuing legislative expansion of the scope of goods and services that are subject to sales and similar taxes as well as the circumstances in which a vendor of goods and services must collect such taxes. Following the U.S. Supreme Court decision in South Dakota v. Wayfair, Inc., states are now free to levy taxes on sales of goods and services based on an “economic nexus,” regardless of whether the seller has a physical presence in the state. Furthermore, legislative proposals have been introduced in Congress that would provide states with additional authority to impose such taxes. Accordingly, it is possible that either federal or state legislative changes may require us to collect additional sales and similar taxes from our customers in the future.

Our insurance policies are expensive and protect us only from some business risks, which may leave us exposed to significant uninsured liabilities.

We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, foreign liability, employee benefits liability, property, automobile, umbrella, workers’ compensation, crime (including cybercrime), fiduciary, products liability, pollution, errors and omissions and directors’ and officers’ insurance. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.

Performance issues, service interruptions or price increases by our shipping carriers could adversely affect our business and harm our reputation and ability to provide our services on a timely basis.

Expedited, reliable shipping is essential to our operations. We rely heavily on providers of transport services for reliable and secure point-to-point transport of our HTG EdgeSeq instrument and consumables to our customers and, as applicable, customers’ samples to our laboratory, and for enhanced tracking of these shipments. Should a carrier encounter delivery performance issues such as loss, damage or destruction of any instrumentation, consumables or samples, it would be costly to replace such instrumentation or consumables in a timely manner and may be difficult to replace customers’ samples lost or damaged in shipping, and such occurrences may damage our reputation and lead to decreased demand for our products and increased cost and expense to our business. In addition, any significant increase in shipping rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe weather, natural disasters or other service interruptions affecting delivery services we use would adversely affect our ability to process orders for our products or receive recipient samples on a timely basis.

Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or diagnostic products to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

*The withdrawal of the United Kingdom from the European Union, commonly referred to as “Brexit,” may adversely impact our ability to obtain regulatory approvals of our product candidates in the United Kingdom and the European Union, result in restrictions or imposition of taxes and duties for importing our product candidates into the United Kingdom or the European Union, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the United Kingdom and the European Union.

Following the result of a referendum in 2016, the United Kingdom left the European Union on January 31, 2020, commonly referred to as “Brexit.” Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the European Union, the United Kingdom was subject to a transition period that ended December 31, 2020, or the Transition Period, during which EU rules continued to apply. ~~A trade and cooperation agreement, or the Trade and Cooperation Agreement, that outlines the future trading relationship between the United Kingdom and the European Union was agreed in December 2020.~~

Since a significant proportion of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from EU directives and regulations, Brexit has had, and may continue to have, a material impact on the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom or the European Union. For example, Great Britain is no longer covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA and, and a separate marketing authorization will be required to marker our product candidates in Great Britain. ~~It is currently unclear whether the Medicines & Healthcare products Regulatory~~50

~~Agency, or MHRA, in the U.K. is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive.~~

While the Trade and Cooperation Agreement provides for the tariff-free trade of medicinal products between the UK and the EU there may be additional non-tariff costs to such trade which did not exist prior to the end of the Transition Period. Further, should the UK diverge from the EU from a regulatory perspective in relation to medicinal products, tariffs could be put into place in the future. We could therefore, both now and in the future, face significant additional expenses (when compared to the position prior to the end of the Transition Period) to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the UK It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the United Kingdom.

*Cyber security risks and the failure to maintain the confidentiality, integrity and availability of our data, computer hardware, software, internet applications and related tools and functions could result in damage to our reputation and/or subject us to costs, fines, penalties, lawsuits, business interruption or otherwise adversely affect our business.

Our business requires collecting, processing, manipulating, analyzing, disclosing and storing large amounts of proprietary, confidential and sensitive data, including personal information about our employees and others, information we collect from samples we process, intellectual property, trade secrets, and proprietary business information owned or controlled by ourselves or other third parties. In addition, we rely on enterprise software systems and third-party service providers and sub-processors to operate and manage our business. The confidentiality, availability, integrity and protection of our data is critical to our business and relevant stakeholders have a high expectation that we will adequately protect confidential and sensitive data, including personal data. We also maintain personally identifiable information. Our business therefore depends on the continuous, effective, reliable and secure operation of our data, computer hardware, software, networks, internet servers and related infrastructure including those of our collaborators, service providers and contractors. To the extent that our hardware and software malfunction or access to our data is interrupted or otherwise compromised, our business could suffer. If we, our service providers, partners or other relevant third parties have experienced or in the future experience any security incident(s) that result in any data loss, deletion or destruction, unauthorized access to, loss of, unauthorized acquisition or disclosure of, or inadvertent exposure of sensitive information, or compromise related to the security, confidentiality, integrity or availability of our (or their) information technology, software, services, communications or data, it may result in a material adverse impact, including without limitation, regulatory investigations or enforcement actions, litigation, indemnity obligations, negative publicity and financial loss. Further, failures or significant downtime of our information technology or telecommunication systems or those used by our third-party service providers could cause significant interruptions in our operations, including preventing us from conducting tests or research and development activities and preventing us from managing the administrative aspects of our ~~business.~~business

The regulatory environment governing information, security and privacy is increasingly demanding and continues to evolve. Maintaining compliance with applicable security and privacy regulations may increase our operating costs. Although we have implemented physical, technical and administrative safeguards designed to protect our data, information technology systems and communications software, we are still vulnerable to natural or man-made hazards, such as natural disasters, fire, storm, flood, power loss, wind damage, terrorism, war, telecommunications failures, physical or software break-ins, inadvertent acts, malicious intrusion, malware, data leakage, viruses and similar events. Moreover, we are vulnerable to cyberattacks, malicious internet-based activity and online and offline fraud, which are prevalent and continue to increase. In addition to traditional computer “hackers,” threat actors, software bugs, malicious code (such as viruses and worms), employee theft or misuse, denial-of-service attacks (such as credential stuffing), and ransomware attacks, sophisticated nation-state and nation-state supported actors now engage in attacks (including advanced persistent threat intrusions). We may also be the subject of phishing attacks, viruses, malware installation, server malfunction, software or hardware failures, loss of data and other computer assets, adware or other similar issues. Ransomware attacks, including those from organized criminal threat actors, nation-states and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions, delays, or outages in our operations, loss of data (including sensitive customer information), loss of income, significant extra expenses to restore data or systems, reputational loss and the diversion of funds. To alleviate the financial, operational and reputational impact of a ransomware attack, it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including, for example, if applicable laws or regulations prohibit such payments). Similarly, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our systems and networks or the systems and networks of third parties that support us and our services. Additionally, due to the COVID-19 pandemic and our remote workforce, there is an increased risk to our information technology assets and data. These events may result in damage to or the impairment of key business processes, or the loss or corruption of confidential information, including intellectual property, proprietary business information and personal data. Such disruptions and breaches of security could have a material adverse effect on our business, financial condition and results of operations.

We could be required to expend significant resources, fundamentally change our business activities and practices or modify our services, software, operations or information technology in an effort to protect against security breaches and to mitigate, detect and remediate actual and potential vulnerabilities and security incidents. There can be no assurances that our security measures or those of our service providers, partners, and other third parties will be effective in protecting against all security breaches and the material adverse impacts that may arise from such breaches.

Despite the security controls we have in place, cyber events are very difficult to avoid. We have experienced specific instances of cyber events, including attempted compromises, in the past, and there could be unauthorized access, acquisition, disclosure and use of non-public information (including personal data) in the future. The techniques used to attack information technology systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world. As a result, we or relevant third parties on which we rely may not be able to address these techniques proactively or implement adequate preventative measures. If our data or information technology systems (or those of third parties upon which we rely) are compromised, we could be subject to reputational damage, fines, penalties, damages, litigation and enforcement actions, and we could lose trade secrets, the occurrence of which could harm our business. In addition, such a compromise may require notification to governmental agencies, supervisory

bodies, credit reporting agencies, the media or individuals pursuant to contract or various federal, state and foreign data protection, privacy and security laws, regulations and guidelines, if applicable. Such disclosures are costly, and the disclosures or the failure to comply with such requirements, could lead to material adverse impacts, including without limitation, negative publicity, a loss of customer confidence in our services or security measures or breach of contract claims. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages if we fail to comply with applicable data protection laws, privacy policies or data protection obligations related to information security or security breaches. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or adequately mitigate liabilities or damages with respect to claims, costs, expenses, litigation, fines, penalties, business loss, data loss, regulatory actions or material adverse impacts arising out of our privacy and security practices, processing or security incidents we may experience, or that such coverage will continue to be available on commercially reasonable terms or at all. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements) could have an adverse effect on our business. In addition, we cannot be sure that our existing insurance coverage and coverage for errors and omissions will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim.

*We are subject to stringent and changing privacy and data security laws, contractual obligations, self-regulatory schemes, government regulation, and standards related to data privacy and security. The actual or perceived failure by us, our customers, partners or vendors to comply with U.S. and foreign privacy and data protection laws, regulations and standards, external and internal privacy and security policies and representations, and other privacy and data-security related obligations may adversely affect our reputation, legal liability, business, operations and financial performance.

We are subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, retention, processing and security of personal data, such as information that we collect about employees and patients in the United States and abroad. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, affect our or our collaborators’, service providers’ and contractors’ ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. We are also subject to the terms of our external and internal privacy and security policies, representations, certifications, standards, publications, frameworks, and contractual obligations related to our collection, processing, use and disclosure of personal data and/or other confidential information. Although we endeavor to comply with our published policies and other obligations, and take steps to ensure that our external and internal privacy and security policies and representations are not inaccurate, incomplete, deceptive, unfair, or misrepresentative of our actual practices, we may at times fail to do so or may be perceived to have failed to do so. Compliance with these and any other applicable privacy and data security laws, regulations and obligations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms, potentially at significant expense, to ensure compliance with the new data protection rules. Any failure or perceived failure by us or our collaborators, service providers and contractors to comply with federal, state or foreign laws or regulation, our internal policies and procedures, representations or our contracts governing processing, of personal data could result in negative publicity, disruptions or interruptions in our operations, fines, penalties (including changes to our data practices), lawsuits, liability, an inability to process personal data, diversion of management time and effort and proceedings against us by governmental entities or others, all of which could adversely affect our business, financial condition, results of operations and growth prospects. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.

In the United States, California adopted the California Consumer Privacy Act (“CCPA”), which became effective in January 2020. The CCPA establishes a privacy framework for covered businesses, including an expansive definition of personal information and data privacy rights for California residents. The CCPA includes a framework with potentially severe statutory damages and

private rights of action. The CCPA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data. As we expand our operations, the CCPA may increase our compliance costs and potential liability. The CCPA will be expanded substantially on January 1, 2023, when the California Privacy Rights Act of 2020 (“CPRA”) becomes fully operative. The CPRA will significantly modify the CCPA, including by expanding consumers’ rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. We may be subject to additional U.S. privacy regulations in the future, including the Virginia Consumer Data Protection Act, or VCDPA, and the Colorado Privacy Act, both of which become effective in 2023. New legislation proposed or enacted in a number of states may impose, or have the potential to impose, additional obligations on companies that collect, store, use, retain, disclose, transfer and otherwise process confidential, sensitive and personal information, and will continue to shape the data privacy environment nationally. To the extent multiple state-level laws are introduced with inconsistent or conflicting standards and there is no federal law to preempt such laws, compliance with such laws could be difficult and costly to achieve.

Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. Many countries in these regions have established or are in the process of establishing privacy and data security legal frameworks with which we, our collaborators, service providers and contractors must comply. For example, the EU has adopted the General Data Protection Regulation (EU) 2016/679 (“GDPR”), which went into effect in May 2018 and introduces strict requirements for processing the personal data of individuals in the EU. The GDPR has and will continue to increase compliance burdens on us, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and process information about them. The processing of sensitive personal data, such as health information, may impose heightened compliance burdens under the GDPR and is a topic of active interest among foreign regulators. In addition, the GDPR provides for more robust regulatory enforcement and fines of up to €20 million or 4% of the annual global revenue of the noncompliant company, whichever is greater. As we expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. Further, the UK’s decision to leave the EU, often referred to as Brexit, has created uncertainty with regard to the regulation of data protection in the UK, including with respect to whether laws or regulations will apply to us consistent with the GDPR in the future and how data transfers to and from the UK will be regulated.

European data protection laws, including the GDPR, generally restrict the transfer of personal data from Europe, including the European Economic Area, United Kingdom and Switzerland, to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. One of the primary safeguards allowing U.S. companies to import personal data from Europe has been certification to the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks administered by the U.S. Department of Commerce. However, the Court of Justice of the European Union recently invalidated the EU-U.S. Privacy Shield. The same decision also raised questions about whether one of the primary alternatives to the EU-U.S. Privacy Shield, namely, the European Commission’s Standard Contractual Clauses, can lawfully be used for personal data transfers from Europe to the United States or most other countries. The European Commission recently proposed updates to the SCCs, and additional regulatory guidance has been released that seeks to impose additional obligations on companies seeking to rely on the SCCs. However, at present, there are few, if any, viable alternatives to the EU-U.S. Privacy Shield and the Standard Contractual Clauses. Similarly, the Swiss Federal Data Protection and Information Commissioner recently opined that the Swiss-U.S. Privacy Shield is inadequate for transfers from Europe to the United States and the United Kingdom, whose data protection laws are similar to those of the European Union, may similarly invalidate use of the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield, respectively, as mechanisms for lawful personal data transfers from those countries to the United States. As such, if we are unable to rely valid data transfer solution for personal data transfers for Europe, we will face increased exposure to substantial fines under European data protection laws as well as injunctions against processing personal data from Europe. Inability to import personal data from the European Economic Area, United Kingdom or Switzerland may also restrict our activities in Europe; limit our ability to collaborate with service providers, contractors and other companies subject to European data protection laws; and require us to increase our data processing capabilities in Europe at significant expense. Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business.

Risks Related to Government Regulation and Diagnostic Product Reimbursement

Before we begin to label and market our products for use as clinical diagnostics in the United States, including as companion diagnostics, unless an exemption applies, we will be required to obtain either 510(k) clearance or PMA from the FDA. In addition, we may be required to seek FDA clearance or approval for any changes or modifications to our products that could significantly affect their safety or effectiveness or would constitute a change in intended use. The PMA and 510(k) clearance processes can be expensive, time-consuming and uncertain. In addition to the time required to conduct clinical studies, if necessary, it generally takes from four to twelve months from submission of an application to obtain 510(k) clearance, and nine to 18 months for a PMA; however, it may take longer, and 510(k) clearance or PMA approval may never be obtained. Even if the FDA accepts a 510(k) or PMA submission for filing, the FDA may request additional information or clinical studies during its review. Our ability to obtain additional regulatory clearances or approvals for new products and indications may be significantly delayed or may never be obtained. The requirements of the more rigorous PMA process could delay product introductions and increase the costs associated with FDA compliance. As with all IVD products, the FDA reserves the right to redefine the regulatory path at the time of submission or during the review process and could require a more burdensome approach. Even if we were to obtain regulatory approval or clearance, it may not be for the uses we believe are important or commercially attractive, in which case we would not be permitted to market our product for those uses.

A 510(k) clearance or PMA submission for any future medical device product would likely place substantial restrictions on how the device is marketed or sold, and we will be required to continue to comply with extensive regulatory requirements, including, but not limited to Quality Systems Regulations (“QSRs”), registering manufacturing facilities, listing the products with the FDA, and complying with labeling, marketing, complaint handling, adverse event and medical device reporting requirements and corrections and removals. We cannot assure you that we will successfully maintain the clearances or approvals we may receive in the future. In addition, any clearances or approvals we obtain may be revoked if any issues arise that bring into question our products’ safety or effectiveness. Any failure to maintain compliance with FDA regulatory requirements could harm our business, financial condition and results of operations.

Sales of our diagnostic products outside the United States will be subject to foreign regulatory requirements governing clinical studies, vigilance reporting, marketing approval, manufacturing, product licensing, pricing and reimbursement. These regulatory requirements vary greatly from country to country. As a result, the time required to obtain approvals outside the United States may differ from that required to obtain FDA approval and we may not be able to obtain foreign regulatory approvals on a timely basis or at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA and foreign regulatory authorities could require additional testing. In addition, the FDA regulates exports of medical devices. Failure to comply with these regulatory requirements or obtain required approvals could impair our ability to commercialize our diagnostic products outside of the United States.

Our research use only products for the life sciences market could become subject to regulation as medical devices by the FDA or other regulatory agencies in the future, which could increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our life sciences business and results of operations.

In the United States, our products are currently labeled and sold for research use only, and not for the diagnosis or treatment of disease, and are sold to a variety of parties, including biopharmaceutical companies, academic institutions and molecular labs. Because such products are not intended for use in clinical practice in diagnostics, and the products cannot include clinical or diagnostic claims, they are exempt from many regulatory requirements otherwise applicable to medical devices. In particular, while the FDA regulations require that RUO products be labeled, “For Research Use Only. Not for use in diagnostic procedures,” the regulations do not otherwise subject such products to the FDA’s pre- and post-market controls for medical devices.

A significant change in the laws governing RUO products or how they are enforced may require us to change our business model in order to maintain compliance. For instance, in November 2013 the FDA issued a guidance document entitled “Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only” (the “RUO Guidance”) which highlights the FDA’s interpretation that distribution of RUO products with any labeling, advertising or promotion that suggests that clinical laboratories can validate the test through their own procedures and subsequently offer it for clinical diagnostic use as a laboratory developed test is in conflict with RUO status. The RUO Guidance further articulates the FDA’s position that any assistance offered in performing clinical validation or verification, or similar specialized technical support, to clinical laboratories, conflicts with RUO status. If we engage in any activities that the FDA deems to be in conflict with the RUO status held by the products that we sell, we may be subject to immediate, severe and broad FDA enforcement action that would adversely affect our ability to continue operations. Accordingly, if the FDA finds that we are distributing our RUO products in a manner that is inconsistent with its regulations or guidance, we may be forced to stop distribution of our RUO tests until we are in compliance, which would reduce our revenue, increase our costs and adversely affect our business, prospects, results of operations and financial condition. In addition, the FDA’s proposed implementation for a new framework for the regulation of LDTs may negatively impact the LDT market and thereby reduce demand for RUO products.

If the FDA requires marketing authorization of our RUO products in the future, there can be no assurance that the FDA will ultimately grant any clearance or approval requested by us in a timely manner, or at all.

We expect to rely on third parties to conduct any future studies of our diagnostic products that may be required by the FDA or other regulatory authorities, and those third parties may not perform satisfactorily.

We do not have the ability to independently conduct the clinical studies or other studies that may be required to obtain FDA and other regulatory clearance or approval for our diagnostic products, including the HTG EdgeSeq instrument and related proprietary panels. Accordingly, we expect to rely on third parties, such as medical institutions, CRO’s and clinical investigators, and providers of NGS instrumentation, to conduct such studies and/or to provide information necessary for our submissions to regulatory authorities. Our reliance on these third parties for clinical development activities or information will reduce our control over these activities. These third parties may not complete activities on schedule or conduct studies in accordance with regulatory requirements or our study design. Similarly, providers of NGS instrumentation may not place the same importance on our regulatory submissions as we do. Our reliance on third parties that we do not control will not relieve us of any applicable requirement to prepare, and ensure compliance with, the various procedures required under good clinical practices, or the submission of all information required in connection with requested regulatory approvals. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our studies may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for our diagnostic products.

Even if we are able to obtain regulatory approval or clearance for our diagnostic products, we will continue to be subject to ongoing and extensive regulatory requirements, and our failure to comply with these requirements could substantially harm our business.

If we receive regulatory approval or clearance for our diagnostic products, we will be subject to ongoing FDA obligations and continued regulatory oversight and review, such as compliance with QSRs, inspections by the FDA, continued adverse event and malfunction reporting, corrections and removals reporting, registration and listing, and promotional restrictions, and we may also be subject to additional FDA post-marketing obligations. If we are not able to maintain regulatory compliance, we may not be permitted to market our diagnostic products and/or may be subject to fines, injunctions, and civil penalties; recall or seizure of products; operating restrictions; and criminal prosecution. In addition, we may be subject to similar regulatory compliance actions of foreign jurisdictions.

*If Medicare and other third-party payors in the United States and foreign countries do not approve coverage and adequate reimbursement for our future clinical diagnostic tests enabled by our technology, the commercial success of our diagnostic products would be compromised.

We plan to develop, obtain regulatory approval for and sell clinical diagnostics products for a number of different indications. Successful commercialization of our clinical diagnostic products depends, in large part, on the availability of coverage and adequate reimbursement for testing services using our diagnostic products from third-party payors, including government insurance plans, managed care organizations and private insurance plans. There is significant uncertainty surrounding third-party coverage and reimbursement for the use of tests that incorporate new technology, such as the HTG EdgeSeq platform and related applications and assays. Reimbursement rates have the potential to fluctuate depending on the region in which the testing is provided, the type of facility or treatment center at which the testing is done, and the third-party payor responsible for payment. If our customers are unable to obtain positive coverage decisions from third-party payors approving reimbursement for our tests at adequate levels, the commercial success of our products would be compromised, and our revenue would be significantly limited. Even if we do obtain favorable reimbursement for our tests, third-party payors may withdraw their coverage policies, review and adjust the rate of reimbursement, require co-payments from patients or stop paying for our tests, which would reduce revenue for testing services based on our technology and demand for our diagnostic products.

The American Medical Association Current Procedural Terminology (“CPT”) Editorial Panel created CPT codes that could be used by our customers to report testing for certain large-scale multianalyte genomic sequencing procedures (“GSPs”), including our diagnostic products, if approved. Effective January 1, 2015, these codes allow for uniform reporting of broad genomic testing panels using technology similar to ours. While these codes standardize reporting for these tests, coverage and payment rates for GSPs remain uncertain and we cannot guarantee that coverage and reimbursement for these tests will be provided in the amounts we expect, or at all. We cannot assure that CMS and other third-party payors will establish reimbursement rates sufficient to cover the costs incurred by our customers in using our clinical diagnostic products, if approved.

Even if we are able to establish coverage and reimbursement codes for our clinical diagnostic products in development, we will continue to be subject to significant pricing pressure, which could harm our business, results of operations, financial condition and prospects.

Third-party payors, including managed care organizations as well as government payors such as Medicare and Medicaid, have increased their efforts to control the cost, utilization and delivery of healthcare services, which may include decreased coverage or reduced reimbursement. From time to time, Congress has considered and implemented changes to the Medicare fee schedules in conjunction with budgetary legislation, and pricing and payment terms, including the possible requirement of a patient co-payment for Medicare beneficiaries for laboratory tests covered by Medicare, and are subject to change at any time. Reductions in the reimbursement rate of third-party payors have occurred and may occur in the future. Reductions in the prices at which testing services based on our technology are reimbursed in the future could result in pricing pressures and have a negative impact on our revenue. In many countries outside of the United States, various coverage, pricing and reimbursement approvals are required. We expect that it will take several years to establish broad coverage and reimbursement for testing services based on our products with payors in countries outside of the United States, and our efforts may not be successful.

We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws and other federal and state healthcare laws applicable to our business and marketing practices. If we are unable to comply, or have not complied, with such laws, we could face substantial penalties.

Our operations may be, and may continue to be, directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal and state anti-kickback statutes, false claims statutes, civil monetary penalties laws, patient data privacy and security laws, physician transparency laws and marketing compliance laws. These laws may impact, among other things, our proposed sales and marketing and education programs.

The laws that may affect our ability to operate include, but are not limited to:

•

The Federal Anti-kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in-kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs; a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation, rather, if one purpose of the remuneration is to induce referrals, the Federal Anti-Kickback Statute is violated.

•

The federal physician self-referral prohibition, commonly known as the Stark Law, which prohibits, among other things, physicians who have a financial relationship, including an investment, ownership or compensation relationship with an entity, from referring Medicare and Medicaid patients to that entity for designated health services, which include clinical laboratory services, unless an exception applies. Similarly, entities may not bill Medicare, Medicaid or any other party for services furnished pursuant to a prohibited referral. Unlike the Federal Anti-Kickback Statute, the Stark Law is a strict liability statute, meaning that all of the requirements of a Stark Law exception must be met in order to be compliant with the law.

•

Federal civil and criminal false claims laws, including the federal civil False Claims Act, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other governmental third-party payors that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money to the Federal Government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the Federal Government, which may apply to entities that provide coding and billing advice to customers; the Federal Government may assert that a claim including items or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.

•

The Federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which created additional federal civil and criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; similar to the Federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute or specific intent to violate it to have committed a violation.

•

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (“HITECH”), and their respective implementing regulations, which impose requirements on covered entities, which include certain healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their contractors that perform services for them that involve the use, maintenance, or disclosure of individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information.

•

The Federal Physician Payments Sunshine Act, which require certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to physicians, defined to include physicians, dentists, optometrists, podiatrists and chiropractors, other healthcare practitioners (such as physicians assistants and nurse practitioners), and teaching hospitals, as well as applicable manufacturers and group purchasing organizations to report annually to CMS certain ownership and investment interests held by physicians and their immediate family members.

•

State law equivalents of each of the above federal laws, such as anti-kickback, self-referral, and false claims laws which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state laws that require device companies to comply with the industry’s voluntary compliance guidelines and the applicable compliance guidance promulgated by the Federal Government that otherwise restricts payments that may be made to healthcare providers; state laws that require device manufacturers to file reports with states regarding marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities (compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships, which could potentially have a negative effect on our business and/or increase enforcement scrutiny of our activities); and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, with differing effects.

•

The Federal Physician Payments Sunshine Act, which require certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to physicians, defined to include physicians, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals, as well as applicable manufacturers and group purchasing organizations to report annually to CMS certain ownership and investment interests held by physicians and their immediate family members, which will be expanded beginning in 2022, to require applicable manufacturers to report such information regarding its payments and other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants and certified nurse midwives during the previous year.

•

Promotional activities for FDA-regulated products have been the subject of significant enforcement actions brought under healthcare reimbursement laws, fraud and abuse laws, and consumer protection statutes, among other theories. Advertising and promotion of medical devices are also regulated by the Federal Trade Commission and by state regulatory and enforcement authorities. In addition, under the Federal Lanham Act and similar state laws, competitors and others can initiate litigation relating to advertising claims.

In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.

Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our relationships with physicians and other health care providers, and our evaluation, reagent rental and collaborative development agreements with customers, and sales and marketing efforts could be subject to challenge under one or more of such laws.

If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, imprisonment, disgorgement, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.

We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, principal investigators, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless or negligent failures to, among other things: (i) comply with the regulations of the FDA, CMS, the Department of Health and Human Services Office of Inspector General (“OIG”) and other similar foreign regulatory bodies; (ii) provide true, complete and accurate information to the FDA and other similar regulatory bodies; (iii) comply with manufacturing standards we have established; (iv) comply with healthcare fraud and abuse laws and regulations in the United States and similar foreign fraudulent misconduct laws; or (v) report financial information or data accurately, or disclose unauthorized activities to us. These laws may impact, among other things, our activities with collaborators and key opinion leaders, as well as our sales, marketing and education programs. In particular, the promotion, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We currently have a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and our code of conduct and the other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations. Any of these actions or investigations could result in substantial costs to us, including legal fees, and divert the attention of management from operating our business.

*Healthcare policy changes, including recently enacted legislation reforming the United States healthcare system, may have a material adverse effect on our financial condition and results of operations.*

On April 1, 2014, the Protecting Access to Medicare Act of 2014 (“PAMA”) was signed into law, which, among other things, significantly altered the current payment methodology under the Medicare Clinical Laboratory Fee Schedule (“CLFS”). Effective January 1, 2018, the CLFS is based on weighted median private payor rates as required by PAMA. Under the law, starting January 1, 2016 and every three years thereafter (or annually in the case of advanced diagnostic lab tests), applicable clinical laboratories must report laboratory test payment data for each Medicare-covered clinical diagnostic lab test that it furnishes. The most recent data collection period was from January 1 through June 30, 2019, followed by a six-month validation period from July 1, 2019 through December 31, 2019. Thereafter, applicable laboratories will report their data. The reported data must include the payment rate (reflecting all discounts, rebates, coupons and other price concessions) and the volume of each test that was paid by each private payor (including health insurance issuers, group health plans, Medicare Advantage plans and Medicaid managed care organizations). ~~In January 2020, CMS announced that~~Reporting of payment data ~~reporting~~under PAMA for clinical diagnostic laboratory tests ishas been delayed ~~by one year.~~ ~~Moreover, the CARES Act, enacted in March 2020, further delays the reporting period by an additional year.~~ ~~Therefore, data that was originally required to be reported~~on numerous occasions. Based on current law, between January 1, ~~2020~~2023 and March 31, ~~2020 must now~~2023, applicable laboratories will be ~~reported between January 1, 2022 and March 31, 2022. Covered laboratories must~~required to report on data ~~from the original data collection period of~~collected during January 1, 2019 ~~through~~and June 30, 2019. ~~Data reporting for these tests~~This data will ~~then resume on a three-year cycle beginning in 2025.~~be utilized to determine 2024 to 2026 CLFS rates. The payment rate applies to laboratory tests furnished by a hospital laboratory if the test is separately paid under the hospital outpatient prospective payment system. In addition, CMS updated the statutory phase-in provisions such that the rates for clinical diagnostic laboratory tests in 2020 could not be reduced by more than 10% of the rates for 2019. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), the statutory phase-in of the payment reductions has been extended through 2024, with a 0% reduction cap for 2021-2022, and a 15% reduction cap for 2023 through 2025. It is still too early to predict the full impact on reimbursement for our products in development. ~~In addition, CMS updated the statutory phase-in provisions such that, for 2020, the rates for clinical diagnostic laboratory tests may not be reduced by more than 10% of the rates for 2019.~~ ~~Pursuant to the CARES Act, the statutory phase-in of payment reductions has been extended through 2024, with a 0% reduction cap for 2021, and~~ ~~a 15% reduction cap for each of 2022, 2023, and 2024.~~

Also, under PAMA, CMS is required to adopt temporary billing codes to identify new tests and new advanced diagnostic laboratory tests that have been cleared or approved by the FDA. For an existing test that is cleared or approved by the FDA and for which Medicare payment is made as of April 1, 2014, CMS is required to assign a unique billing code if one has not already been assigned by the agency. In addition to assigning the code, CMS was required to publicly report payment for the tests. We cannot determine at this time the full impact of the law, including its implementing regulations, on our business, financial condition and results of operations.

The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”), made changes that significantly impacted the biopharmaceutical and medical device industries and clinical laboratories. For example, the ACA imposes a multifactor productivity adjustment to the reimbursement rate paid under Medicare for certain clinical diagnostic laboratory tests, which may reduce payment rates. These or any future proposed or mandated reductions in payments may apply to some or all of the clinical laboratory tests that our diagnostics customers use our technology to deliver to Medicare beneficiaries and may reduce demand for our diagnostic products.

Other significant measures contained in the ACA include, for example, coordination and promotion of research on comparative clinical effectiveness of different technologies and procedures, initiatives to revise Medicare payment methodologies, such as bundling of payments across the continuum of care by providers and physicians, and initiatives to promote quality indicators in payment methodologies. The ACA also includes significant new fraud and abuse measures, including required disclosures of financial arrangements with physician customers, lower thresholds for violations and increasing potential penalties for such violations. However, the future of the ACA is uncertain. There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, then-President Trump signed several Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Congress considered legislation to repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (the “Tax Act”), includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA ~~marketplace, which began on February 15, 2021 and remained open through August 15, 2021.~~marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.

In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, then-President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation’s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013, and, following the passage of other legislative amendments, ~~including the Bipartisan Budget Act of 2018,~~ will stay in effect through 2030 unless additional Congressional action is taken. However, COVID-19 relief legislation, including the CARES Act, has suspended the 2% Medicare sequester from May 1, 2020 through ~~December~~March 31, ~~2021.~~2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Further, Congress and the Biden administration are considering additional health reform measures. On January 2, 2013, then-President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

Various healthcare reform proposals have also emerged from federal and state governments. Changes in healthcare law or policy, such as the creation of broad test utilization limits for diagnostic products in general or requirements that Medicare patients pay for portions of clinical laboratory tests or services received, could substantially impact the sales of our tests, increase costs and divert management’s attention from our business. In addition, sales of our tests outside of the United States will subject us to foreign regulatory requirements, which may also change over time.

We cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the United States in which we may do business, or the effect any future legislation or regulation will have on us. The full impact of the ACA, as well as other laws and reform measures that may be proposed and adopted in the future, remains uncertain, but may continue the downward pressure on medical device pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs, which could have a material adverse effect on our business operations.

Risks Related to Intellectual Property

*If we are unable to protect our intellectual property effectively, our business will be harmed.

We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Our U.S. and foreign patent and patent application portfolio relates to our nuclease-protection-based technologies as well as to lung cancer and melanoma and DLBCL biomarker panels discovered using our nuclease-protection-based technology. We have exclusive or non-exclusive licenses to multiple U.S. and foreign patents and patent applications covering technologies that we may elect to utilize in developing diagnostic tests for use on our HTG EdgeSeq platform. Those licensed patents and patent applications cover technologies related to the diagnosis of breast cancer and melanoma.

If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.

We cannot assure investors that any of our currently pending or future patent applications will result in issued patents, and we cannot predict how long it will take for such patents to be issued. Further, we cannot assure investors that other parties will not challenge any patents issued to us or that courts or regulatory agencies will hold our patents to be valid or enforceable. We cannot guarantee investors that we will be successful in defending challenges made against our patents. Any successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents.

The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies’ patents has emerged to date in the United States. Furthermore, in the biotechnology field, courts frequently render opinions that may adversely affect the patentability of certain inventions or discoveries, including opinions that may adversely affect the patentability of methods for analyzing or comparing nucleic acids molecules, such as RNA or DNA.

The patent positions of companies engaged in development and commercialization of molecular diagnostic tests are particularly uncertain. Various courts, including the U.S. Supreme Court, have recently rendered decisions that impact the scope of patentability of certain inventions or discoveries relating to molecular diagnostics. Specifically, these decisions stand for the proposition that patent claims that recite laws of nature (for example, the relationships between gene expression levels and the likelihood of risk of recurrence of cancer) are not themselves patentable unless those patent claims have sufficient additional features that provide practical assurance that the processes are genuine inventive applications of those laws rather than patent drafting efforts designed to monopolize the law of nature itself. What constitutes a “sufficient” additional feature is uncertain. Accordingly, this evolving case law in the United States may adversely impact our ability to obtain new patents and may facilitate third-party challenges to our existing owned and licensed patents.

The laws of some non-U.S. countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.

Changes in either the patent laws or in interpretations of patent laws in the United States or other countries may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. For example:

•

We might not have been the first to make the inventions covered by each of our patents and pending patent applications.

•

We might not have been the first to file patent applications for these inventions.

•

Others may independently develop similar or alternative products and technologies or duplicate any of our products and technologies.

•

It is possible that none of our pending patent applications will result in issued patents, and even if they issue as patents, they may not provide a basis for commercially viable products, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties.

•

We may not develop additional proprietary products and technologies that are patentable.

•

The patents of others may have an adverse effect on our business.

•

We apply for patents covering our products and technologies and uses thereof, as we deem appropriate. However, we may fail to apply for patents on important products and technologies in a timely fashion or at all.

•

~~We might not have been the first to make the inventions covered by each of our patents and pending patent applications.~~

•

~~We might not have been the first to file patent applications for these inventions.~~

•

~~Others may independently develop similar or alternative products and technologies or duplicate any of our products and technologies.~~

•

~~We may not develop additional proprietary products and technologies that are patentable.~~

•

~~The patents of others may have an adverse effect on our business.~~

•

In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third-party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets.

In addition, competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If our intellectual property is not adequately protected so as to protect our market against competitors’ products and methods, our competitive position could be adversely affected, as could our business.

We have not yet registered certain of our trademarks, including “HTG Edge,” “HTG EdgeSeq,” “VERI/O,” “qNPA,” “HTG Transcriptome Panel” and “HTG EpiEdgeSeq” in all of our potential markets. If we apply to register these trademarks, our applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.

To the extent our intellectual property, including licensed intellectual property, offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate protection against our competitors’ products, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time consuming and expensive.

*We may be involved in lawsuits to protect or enforce our patent or other proprietary rights, to determine the scope, coverage and validity of others’ patent or other proprietary rights, or to defend against third-party claims of intellectual property infringement, any of which could be time-intensive and costly and may adversely impact our business or stock price.*

We may from time to time receive notices of claims of infringement and misappropriation or misuse of other parties’ proprietary rights, including with respect to third-party trade secrets, infringement by us of third-party patents and trademarks or other rights, or challenges to the validity or enforceability of our patents, trademarks or other rights. Some of these claims may lead to litigation. We cannot assure investors that such actions will not be asserted or prosecuted against us or that we will prevail in any or all such actions.

Litigation may be necessary for us to enforce our patent and other proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. ~~The~~For example, we are involved in a patent litigation matter with BioSpyder Technologies, Inc. in which we are asserting that BioSpyder has infringed the claims of one of our U.S. patents related to our HTG EdgeSeq technology. BioSpyder has asserted a counterclaim, alleging that the same U.S. patent is invalid. We are vigorously defending against this counterclaim and expect to prevail. However, the outcome of this and any other litigation or other proceeding is inherently uncertain and might not be favorable to us. In addition, any litigation that may be necessary in the future could result in substantial costs, even if we were to prevail, and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.

As we move into new markets and applications for our products, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. Our competitors and others may now and in the future have significantly larger and more mature patent portfolios than we currently have. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product revenue and against whom our own patents may provide little or no deterrence or protection. Therefore, our commercial success may depend in part on our non-infringement of the patents or proprietary rights of third parties. Numerous significant intellectual property issues have been litigated, and will likely continue to be litigated, between existing and new participants in our existing and targeted markets and competitors may assert that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets. We have not conducted comprehensive freedom-to-operate searches to determine whether the commercialization of our products or other business activities would infringe patents issued to third parties. Third parties may assert that we are employing their proprietary technology without authorization. In addition, our competitors and others may have patents or may in the future obtain patents and claim that use of our products infringes these patents. We could incur substantial costs and divert the attention of our management and technical personnel in defending against any of these claims. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products, and could result in the award of substantial damages against us. In the event of a successful claim of infringement against us, we may be required to pay damages and obtain one or more licenses from third parties or be prohibited from selling certain products. We may not be able to obtain these licenses at a reasonable cost, if at all. We could therefore incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our margins. In addition, we could encounter delays in product introductions while we attempt to develop alternative methods or products to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses on favorable terms could prevent us from commercializing products, and the prohibition of sale of any of our products could materially affect our ability to grow and gain market acceptance for our products.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.

In addition, our agreements with some of our suppliers, distributors, customers and other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims against us, including the claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify any of these third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results, or financial condition.

We may need to depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from selling some of our products.

We have entered into several license agreements with third parties for certain licensed technologies that are, or may become relevant to the products we market, or plan to market. In addition, we may in the future elect to license third-party intellectual property to further our business objectives and/or as needed for freedom to operate for our products. We do not and will not own the patents, patent applications or other intellectual property rights that are a subject of these licenses. Our rights to use these technologies and employ the inventions claimed in the licensed patents, patent applications and other intellectual property rights are or will be subject to the continuation of and compliance with the terms of those licenses.

We might not be able to obtain licenses to technology or other intellectual property rights that we require. Even if such licenses are obtainable, they may not be available at a reasonable cost or multiple licenses may be needed for the same product (e.g., stacked royalties). We could therefore incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our margins. Further, we could encounter delays in product introductions, or interruptions in product sales, as we develop alternative methods or products.

In some cases, we do not or may not control the prosecution, maintenance, or filing of the patents or patent applications to which we hold licenses, or the enforcement of these patents against third parties. As a result, we cannot be certain that drafting or prosecution of the licensed patents and patent applications by the licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights.

Certain of the U.S. patent rights we own, have licensed or may license relate to technology that was developed with U.S. government grants, in which case the U.S. government has certain rights in those inventions, including, among others, march-in license rights. In addition, federal regulations impose certain domestic manufacturing requirements with respect to any products within the scope of those U.S. patent claims.

We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our employees’ former employers.

Many of our employees were previously employed at other medical diagnostic companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. A loss of key research personnel work product could hamper or prevent our ability to commercialize certain potential products, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.

Our products contain third-party open-source software components, and failure to comply with the terms of the underlying open-source software licenses could restrict our ability to sell our products.

Our products contain software tools licensed by third-party authors under “open-source” licenses. Use and distribution of open-source software may entail greater risks than use of third-party commercial software, as open-source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code. Some open-source licenses contain requirements that we make available source code for modifications or derivative works we create based upon the type of open-source software we use. If we combine our proprietary software with open-source software in a certain manner, we could, under certain open-source licenses, be required to release the source code of our proprietary software to the public. This would allow our competitors to create similar products with less development effort and time and ultimately could result in a loss of product sales.

Although we monitor our use of open-source software to avoid subjecting our products to conditions we do not intend, the terms of many open-source licenses have not been interpreted by U.S. courts, and there is a risk that these licenses could be construed in a way that could impose unanticipated conditions or restrictions on our ability to commercialize our products. Moreover, we cannot assure investors that our processes for controlling our use of open-source software in our products will be effective. If we are held to have breached the terms of an open-source software license, we could be required to seek licenses from third parties to continue offering our products on terms that are not economically feasible, to re-engineer our products, to discontinue the sale of our products if re-engineering could not be accomplished on a timely basis, or to make generally available, in source code form, our proprietary code, any of which could adversely affect our business, operating results, and financial condition.

We use third-party software that may be difficult to replace or cause errors or failures of our products that could lead to lost customers or harm to our reputation.

We use software licensed from third parties in our products. In the future, this software may not be available to us on commercially reasonable terms, or at all. Any loss of the right to use any of this software could result in delays in the production of our products until equivalent technology is either developed by us, or, if available, is identified, obtained and integrated, which could harm our business. In addition, any errors or defects in third-party software, or other third-party software failures could result in errors, defects or cause our products to fail, which could harm our business and be costly to correct. Many of these providers attempt to impose limitations on their liability for such errors, defects or failures, and if enforceable, we may have additional liability to our customers or third-party providers that could harm our reputation and increase our operating costs.

We will need to maintain our relationships with third-party software providers and to obtain software from such providers that do not contain any errors or defects. Any failure to do so could adversely impact our ability to deliver reliable products to our customers and could harm our results of operations.

Risks Related to Being a Public Company

Complying with the laws and regulations affecting public companies increases our costs and the demands on management and could harm our operating results.

As a public company, we will continue to incur significant legal, accounting and other expenses. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and Nasdaq, impose numerous requirements on public companies, including corporate governance requirements. Our management and other personnel will need to continue to devote a substantial amount of time to compliance with these laws and regulations. These requirements have resulted and will continue to result in significant legal, accounting, and financial compliance costs and have made and will continue to make some activities more time consuming and costly.

As a “non-accelerated filer” we have availed ourselves of the exemption from the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404. When our independent registered public accounting firm is required to undertake an assessment of our internal control over financial reporting, the cost of our compliance with Section 404 will correspondingly increase. Our compliance with applicable provisions of Section 404 will require that we incur substantial accounting expense and expend significant management time on compliance-related issues as we implement additional corporate governance practices and comply with reporting requirements. Moreover, if we are not able to comply with the requirements of Section 404 applicable to us in a timely manner, or if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.

Furthermore, investor perceptions of our company may suffer if deficiencies are found, and this could cause a decline in the market price of our stock. Irrespective of compliance with Section 404, any failure of our internal control over financial reporting could have a material adverse effect on our stated operating results and harm our reputation. If we are unable to implement these requirements effectively or efficiently, it could harm our operations, financial reporting, or financial results and could result in an adverse opinion on our internal controls from our independent registered public accounting firm.

*We are a “smaller reporting company” and a “non-accelerated filer” and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to smaller reporting companies or non-accelerated filers could make our common stock less attractive to investors.*

We are a “smaller reporting company” and a “non-accelerated filer” as defined in the Exchange Act, and for as long as we continue to be a “smaller reporting company” or a “non-accelerated filer,” we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to “smaller reporting companies” or “non-accelerated filers,” including, but not limited to, not being required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404 (for so long as we are a “non-accelerated filer”) and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements (for so long as we are a “smaller reporting company”). We ~~expect to be both~~are a “smaller reporting company” and a “non-accelerated filer” and, based on our public float as of June 30, 2022, will continue to be a "smaller reporting company" and "non-accelerated filer" in ~~2022.~~2023. We cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. If some investors find our common stock less attractive as a result of any choices to reduce future disclosure, there may be a less active trading market for our common stock and our stock price may be more volatile.

Risks Related to Our Common Stock

We expect that our stock price will fluctuate significantly.

The trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include:

•

actual or anticipated quarterly variation in our results of operations or the results of our competitors;

•

announcements by us or our competitors of new products, significant contracts, commercial relationships or capital commitments;

•

failure to obtain or delays in obtaining product approvals or clearances from the FDA or foreign regulators;

•

adverse regulatory or coverage and reimbursement announcements;

•

issuance of new or changed securities analysts’ reports or recommendations for our stock;

•

developments or disputes concerning our intellectual property or other proprietary rights;

•

commencement of, or our involvement in, litigation;

•

market conditions in the life sciences and molecular diagnostics markets;

•

manufacturing disruptions;

•

any future sales of our common stock or other securities;

•

any change to the composition of our Board of Directors, executive officers or key personnel;

•

our failure to meet applicable Nasdaq listing standards and the possible delisting of our common stock from Nasdaq;

•

announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;

•

general economic conditions and slow or negative growth of our markets

•

other events or factors, including those resulting from such events, or the prospect of such events, including war, terrorism and other international conflicts, such as the recent Russian invasion of Ukraine as well as continued and any new sanctions against Russia by, among others, the United States and the European Union, which restrict a wide range of trade and financial dealings with Russia and Russia parties, public health issues including health epidemics or pandemics, such as COVID-19, and natural disasters such as fire, hurricanes, earthquakes, tornados or other adverse weather and climate conditions, whether occurring in the United States or elsewhere, any of which could disrupt our operations, disrupt the operations of our suppliers or result in political or economic instability; and

•

the other factors described in this report under the caption “Risk Factors – Risks Related to Our Common Stock.”

•

~~actual or anticipated quarterly variation in our results of operations or the results of our competitors;~~

•

~~announcements by us or our competitors of new products, significant contracts, commercial relationships or capital commitments;~~

•

~~failure to obtain or delays in obtaining product approvals or clearances from the FDA or foreign regulators;~~

•

~~adverse regulatory or coverage and reimbursement announcements;~~

•

~~issuance of new or changed securities analysts’ reports or recommendations for our stock;~~

•

~~developments or disputes concerning our intellectual property or other proprietary rights;~~

•

~~commencement of, or our involvement in, litigation;~~

•

~~market conditions in the life sciences and molecular diagnostics markets;~~

•

~~manufacturing disruptions;~~

•

~~any future sales of our common stock or other securities;~~

•

~~any change to the composition of our Board of Directors, executive officers or key personnel;~~

•

~~our failure to meet applicable Nasdaq listing standards and the possible delisting of our common stock from Nasdaq;~~

•

~~announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;~~

•

~~disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, COVID-19;~~

•

~~general economic conditions and slow or negative growth of our markets; and~~

•

~~the other factors described in this report under the caption “Risk Factors – Risks Related to Our Common Stock.”~~

The stock market in general, and market prices for the securities of health technology companies like ours in particular, have from ~~time to time~~time-to-time experienced volatility that often has been unrelated to the operating performance of the underlying companies. COVID-19, for example, has resulted in significant volatility in the stock market over the last several months. These broad market and industry fluctuations may adversely affect the market price of our common stock, regardless of our operating performance. In several recent situations where the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit against us, the defense and disposition of the lawsuit could be costly and divert the time and attention of our management and harm our operating results.

In addition, to date our common stock has generally been sporadically and thinly traded. As a consequence, the trading of relatively small quantities of our shares may disproportionately influence the price of our common stock in either direction. The price for our common stock could decline precipitously if even a moderate amount of our common stock is sold on the market without commensurate demand.

*Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

We expect that significant additional capital will be needed in the future to continue our planned operations. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by these and subsequent sales. New investors could also gain rights superior to our existing stockholders.

Pursuant to our 2020 Equity Incentive Plan (“2020 Plan”) ~~our Board of Directors is~~, we are authorized to grant stock options and other equity-based awards to our employees, directors and consultants. Pursuant to our 2021 Inducement Plan (“Inducement Plan”), we are authorized to grant up to 300,000 shares to new employees as inducements material to such new employees entering into employment with us. The number of shares which may be granted under the Inducement Plan may be increased in the future by our board of directors without stockholder approval. In addition, our amended and restated 2014 Employee Stock Purchase Plan (“ESPP”) authorizes us to offer, sell and issue shares to our employees. Increases in the number of shares available for future grant or purchase may result in additional dilution, which could cause our stock price to decline.

If we are unable to continue to satisfy the applicable continued listing requirements of Nasdaq, our common stock could be delisted.

Our common stock is currently listed on The Nasdaq Capital Market under the symbol “HTGM.” In order to maintain this listing, we must continue to satisfy minimum financial and other continued listing requirements and standards. There can be no assurance that we will be able to continue to comply with the applicable listing standards.

If we were not able to comply with applicable listing standards, our shares of common stock would be subject to delisting. The delisting of our common stock from trading on Nasdaq may have a material adverse effect on the market for, and liquidity and price of, our common stock and impair our ability to raise capital. Delisting from Nasdaq could also have other negative results, including, without limitation, the potential loss of confidence by customers and employees, the loss of institutional investor interest and fewer business development opportunities. In the event that our common stock is delisted from Nasdaq and is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further.

We do not intend to pay dividends on our common stock in the foreseeable future.

We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, our ability to pay cash dividends is currently prohibited by the terms of our debt facility, and any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.

Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third-party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.

Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These provisions include:

•

authorizing the issuance of “blank check” preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;

•

limiting the removal of directors by the stockholders;

•

creating a staggered board of directors;

•

prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;

•

eliminating the ability of stockholders to call a special meeting of stockholders; and

•

establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.

•

~~authorizing the issuance of “blank check” preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;~~

•

~~limiting the removal of directors by the stockholders;~~

•

~~creating a staggered board of directors;~~

•

~~prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;~~

•

~~eliminating the ability of stockholders to call a special meeting of stockholders; and~~

•

~~establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.~~

These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our Board of Directors. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.

Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.

Our amended and restated certificate of incorporation and our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; (3) any action asserting a claim against us or any of our directors or officers or other employees arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate or our amended and restated bylaws; and/or (4) any action asserting a claim against us or any of our directors or officers or other employees governed by the internal affairs doctrine. The foregoing provisions do not apply to actions brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.

These exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find the exclusive forum provision in our governing documents to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.

General Risk Factors

Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.

Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock.

If we fail to maintain proper and effective internal controls, our ability to produce accurate consolidated financial statements on a timely basis could be impaired.*

We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of The Nasdaq Stock Market (“Nasdaq”). The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). We have performed system and process evaluation and testing of our internal ~~controls~~control over financial reporting to allow management to report annually on the effectiveness of our internal ~~controls~~control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. This has required and will require that we incur substantial professional fees and internal costs to augment our accounting and finance functions and that we expend significant management efforts as we continue to make this assessment and ensure maintenance of proper internal controls on an ongoing basis.

If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we fail to establish and maintain proper and effective internal control over financial reporting, we may not be able to produce timely and accurate consolidated financial statements, and our ability to accurately report our financial results could be adversely affected. If that were to happen, the market price of our stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.

In addition, for so long as we remain a non-accelerated filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act. An independent assessment of the effectiveness of our internal controls could detect problems that our management’s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.

If securities or industry analysts do not publish research reports about our business, or if they issue an adverse opinion about our business, our stock price and trading volume could decline.

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us issues an adverse opinion about our company, our stock

price would likely decline. If one or more of these analysts ceases coverage of us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

~~None.~~

Item 5. Other Information.

None.

~~None.~~

Item 6. Exhibits.

EXHIBIT INDEX


Exhibit Number		Description

2.1		Asset Purchase Agreement dated January 9, 2001, as amended by and between the Registrant, ~~NuvoGen, L.L.C.,~~Neogen, LLC, Stephen Felder and Richard Kris (incorporated by reference to Exhibit 2.1 to the Registrant’s registration Statement on Form S-1, as amended (File No. 333-201313), originally filed with the SEC on December 30, 2014).

3.1		Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on May 12, 2015).

3.2		Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on November 19, 2020).

3.3		Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 0001-37369), filed with the SEC on February 26, 2020.

~~3.4~~		Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on May 12, 2015).

4.1		Reference is made to Exhibits 3.1 , 3.2, and3.3.~~and~~ ~~3.4~~.

4.2		Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K, originally filed with the SEC on March 25, 2021).

4.3		Series E Preferred Stock Warrant issued by the Registrant to Silicon Valley Bank, dated August 22, 2014 (incorporated by reference to Exhibit 4.4 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-201313), originally filed with the SEC on December 30, 2014).

4.4		Series E Preferred Stock Warrant issued by the Registrant to Oxford Finance LLC, dated August 22, 2014 (incorporated by reference to Exhibit 4.5 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-201313), originally filed with the SEC on December 30, 2014).

4.5		Form of Warrant issued by Registrant to bridge financing investors (incorporated by reference to Exhibit 4.6 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-201313), originally filed with the SEC on December 30, 2014).

~~4.6~~		Form of Warrant issued by Registrant to bridge financing investors (incorporated by reference to Exhibit 4.7 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-201313), originally filed with the SEC on December 30, 2014).

~~4.7~~		Common Stock Warrant issued by the Registrant to Oxford Finance LLC, dated March 28, 2016 (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on June 30, 2016).

~~4.8~~4.6		Warrant issued to MidCap Funding XXVIII Trust, dated March 26, 2018 (incorporated by reference to Exhibit 4.10 to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on May 10, 2018).

~~4.9~~4.7		Form of Pre-Funded Warrant to Purchase Shares of Common Stock, dated September 24, 2019 (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on September 23, 2019).

~~4.10~~		Warrant to Purchase Common Stock, issued to Silicon Valley Bank on June 24, 2020 (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on June 25, 2020).

~~10.1~~4.8		~~Third Amendment, dated September 27, 2021, to Standard Commercial-Industrial Multi Tenant Triple Net Lease, dated July 11, 2008, between the Company and Pegasus Properties L.P.~~Form of Common Stock Warrant (24-month term) issued on March 21, 2022 (incorporated by reference to Exhibit ~~10.1~~4.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37369), filed with the SEC on ~~September 29, 2021)~~March 21, 2022).

~~Exhibit~~ ~~Number~~		~~Description~~

~~10.2~~4.9		~~Fourth Amendment, dated September 27, 2021, to Standard Commercial-Industrial Multi Tenant Triple Net Lease, dated May 11, 2011, between the Company and Pegasus Properties L.P.~~Form of Common Stock Warrant (66-month term) issued on March 21, 2022 (incorporated by reference to Exhibit ~~10.2~~4.3 to the Registrant’s Current Report on Form 8-K ~~filed with the SEC on September 29, 2021).~~

~~10.3~~		~~HTG Molecular Diagnostics, Inc. 2021 Inducement Plan, as amended (incorporated by reference to Exhibit 99.1 to the Registrant’s Registration Statement on Form S-8~~ (File No. ~~333-258977)~~001-37369), filed with the SEC on ~~August 20, 2021)~~March 21, 2022).

4.10
~~10.4~~		~~Form~~Registration Rights Agreement, dated as of ~~Stock Option Grant Notice, Option Agreement~~March 17, 2022 between the Registrant and ~~Notice of Exercise under~~ the ~~HTG Molecular Diagnostics, Inc. 2021 Inducement Plan~~purchaser party thereto (incorporated by reference to Exhibit ~~99.2~~4.4 to the Registrant’s ~~Registration Statement~~Current Report on Form ~~S-8~~8-K (File No. ~~333-258977)~~001-37369), filed with the SEC on ~~August 20, 2021)~~March 21, 2022).

10.1
~~10.5~~		~~Form of Restricted Stock Unit Grant Notice~~First Amendment to Loan and ~~Restricted Stock Unit Award~~Security Agreement, ~~under~~dated July 14, 2022, by and between Silicon Valley Bank and the HTG Molecular Diagnostics, Inc. 2021 Inducement Plan (incorporated by reference to Exhibit 99.3 to the Registrant’s Registration Statement on Form S-8 (File No. 333-258977), filed with the SEC on August 20, 2021).

~~10.6~~		~~HTG Molecular Diagnostics, Inc. Amended and Restated 2014 Employee Stock Purchase Plan~~Company (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37369), filed with the ~~Commission~~SEC on ~~August 19, 2021)~~July 8, 2022).

31.1		Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.

31.2		Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.


32.1		Certification of the Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of the Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	HTG Molecular Diagnostics, Inc.

Date: ~~November 10, 2021~~August 11, 2022	By:	/s/ John L. Lubniewski
		John L. Lubniewski
		President and Chief Executive Officer (Principal Executive Officer)

Date: ~~November 10, 2021~~August 11, 2022	By:	/s/ Laura L. Godlewski
		Laura L. Godlewski
		Senior Vice President of Finance and ~~Principal~~Administration ~~Accounting Officer~~ (Principal Accounting Officer)

	Three and Nine Months Ended September 30, 2021
	Series A Convertible Preferred Stock				Common Stock					Additional Paid-In			Accumulated Other Comprehensive			Accumulated			Total Stockholders'
	Shares		Amount		Shares			Amount		Capital			Income (Loss)			Deficit			Equity

Balance at January 1, 2021		23,770	$	24		5,199,997		$	5,200	$	205,661,999		$	5,298		$	(191,187,861	)	$	14,484,660
Stock-based compensation expense		—		—		—			—		337,823			—			—			337,823
Release of restricted stock awards		—		—		1,390			1		—			—			—			1
Net share settlement of restricted stock awards		—		—		(250	)		—		(1,197	)		—			—			(1,197	)
Employee stock purchase plan expense		—		—		—			—		13,115			—			—			13,115
Issuance of common stock from ATM offering, net of commissions of approximately $0.2 million		—		—		1,058,045			1,058		6,854,140			—			—			6,855,198
Exercise of stock options		—		—		75			—		326			—			—			326
Net loss		—		—		—			—		—			—			(4,848,307	)		(4,848,307	)
Foreign currency translation adjustment		—		—		—			—		—			(1,557	)		—			(1,557	)
Balance at March 31, 2021		23,770	$	24		6,259,257		$	6,259	$	212,866,206		$	3,741		$	(196,036,168	)	$	16,840,062
Stock-based compensation expense		—		—		—			—		339,369			—			—			339,369
Release of restricted stock awards		—		—		992			1		—			—			—			1
Net share settlement of restricted stock awards		—		—		(127	)		—		(695	)		—			—			(695	)
Employee stock purchase plan expense		—		—		—			—		13,116			—			—			13,116
Stock issued under stock purchase plans		—		—		13,637			13		53,424			—			—			53,437
Issuance of common stock from ATM offering, net of commissions of approximately $0.1 million		—		—		992,834			993		3,809,628			—			—			3,810,621
Exercise of pre-funded warrants				—		144,881			145		(145	)		—			—			—
Net loss		—		—		—			—		—			—			(2,614,952	)		(2,614,952	)
Foreign currency translation adjustment		—		—		—			—		—			(145	)		—			(145	)
Balance at June 30, 2021		23,770	$	24		7,411,474		$	7,411	$	217,080,903		$	3,596		$	(198,651,120	)	$	18,440,814
Stock-based compensation expense		—		—		—			—		323,172			—			—			323,172
Release of restricted stock awards		—		—		1,158			2		—			—			—			2
Net share settlement of restricted stock awards		—		—		(117	)		—		(679	)		—			—			(679	)
Employee stock purchase plan expense		—		—		—			—		15,719			—			—			15,719
Issuance of common stock in connection with LP Purchase Agreement		—		—		101,218			101		599,878			—			—			599,979
Net loss		—		—		—			—		—			—			(4,490,622	)		(4,490,622	)
Foreign currency translation adjustment		—		—		—			—		—			(1,013	)		—			(1,013	)
Balance at September 30, 2021		23,770	$	24		7,513,733		$	7,514	$	218,018,993		$	2,583		$	(203,141,742	)	$	14,887,372

Issuance of common stock from ATM offering, net of commissions costs of $79,000	—		—	263,482		263		2,556,749		—			—			2,557,012
Net loss	—		—	—		—		—		—			(5,411,788	)		(5,411,788	)
Unrealized loss on short-term investments	—		—	—		—		—		(17,501	)		—			(17,501	)
Foreign currency translation adjustment	—		—	—		—		—		1,225			—			1,225
Balance at September 30, 2020	23,770	$	24	4,738,597	$	4,739	$	203,087,744	$	6,727		$	(186,897,880	)	$	16,201,354

	September 30, 2021
	Level 1		Level 2		Level 3		Total
Asset included in:
Cash and cash equivalents
Money market securities	$	10,055,376	$	—	$	—	$	10,055,376
Investments available-for-sale at fair value
Corporate debt securities		—		15,187,672		—		15,187,672
Total	$	10,055,376	$	15,187,672	$	—	$	25,243,048

	December 31, 2020
	Level 1		Level 2		Level 3		Total
Asset included in:
Cash and cash equivalents
Money market securities	$	17,497,282	$	—	$	—	$	17,497,282
Corporate debt securities		—		4,499,270		��		4,499,270
Investments available-for-sale at fair value
Corporate debt securities		—		6,298,075		—		6,298,075
Total	$	17,497,282	$	10,797,345	$	—	$	28,294,627

	Under
	1 Year		1 to 2 Years		Total
Corporate debt securities		15,187,672		—		15,187,672
Total available-for-sale securities	$	15,187,672	$	—	$	15,187,672

	Product Revenue			Custom RUO Assay Design		Sample Processing			Total Contract Liability
Balance at January 1, 2021	$	103,580		$	-	$	93,884		$	197,464
Deferral of revenue		261,100			—		525,899			786,999
Recognition of deferred revenue		(198,438	)		—		(535,501	)		(733,939	)
Balance at September 30, 2021	$	166,242		$	—	$	84,282		$	250,524

2021	$	151,225
2022		479,432
2023		400,000
2024		400,000
2025		400,000
2026 and beyond		2,702,661
Total NuvoGen obligation payments		4,533,318
Plus interest accretion		70,170
Total NuvoGen obligation, net	$	4,603,488

2021	$	111,441
2022		481,549
2023		484,719
2024		484,631
2025		40,382
Total		1,602,722
Less present value discount		(148,425	)
Total operating lease liabilities	$	1,454,297
Less operating lease liabilities - current		(398,313	)
Operating lease liabilities - non-current	$	1,055,984

2021	$	5,772
2022		20,715
2023		18,396
2024		16,080
Total		60,963
Less present value discount		(8,328	)
Financing lease liabilities, net	$	52,635

	Number of Shares			Weighted- Average Grant Date Fair Value Per Share
Balance at December 31, 2020		12,214		$	28.61
Released		(3,540	)		29.96
Forfeited		(2,373	)		51.00
Balance at September 30, 2021		6,301		$	19.40
Vested and unissued at September 30, 2021		989		$	26.14

	Three Months Ended September 30,						Change						Nine Months Ended September 30,						Change
	2021			2020			$			%			2021			2020			$			%
Revenue:
Product and product-related services	$	2,520,410		$	1,701,068		$	819,342			48	%	$	6,029,760		$	5,417,731		$	612,029			11	%
Collaborative development services		—			76,030			(76,030	)		(100	%)		—			548,135			(548,135	)		(100	%)
Total revenue		2,520,410			1,777,098			743,312			42	%		6,029,760			5,965,866			63,894			1	%
Operating expenses:
Cost of product and product-related services revenue		983,761			940,892			42,869			5	%		2,740,004			2,931,026			(191,022	)		(7	%)
Selling, general and administrative		4,232,313			4,752,321			(520,008	)		(11	%)		11,995,747			13,683,069			(1,687,322	)		(12	%)
Research and development		1,534,818			1,255,416			279,402			22	%		4,188,219			4,914,467			(726,248	)		(15	%)
Total operating expenses		6,750,892			6,948,629			(197,737	)		(3	%)		18,923,970			21,528,562			(2,604,592	)		(12	%)
Operating loss		(4,230,482	)		(5,171,531	)		941,049			(18	%)		(12,894,210	)		(15,562,696	)		2,668,486			(17	%)
Gain on forgiveness of PPP Loan		—			—			—			0	%		1,735,792			—			1,735,792			100	%
Loss on extinguishment of MidCap Credit Facility		—			—			—			0	%		—			(522,394	)		522,394			(100	%)
Other income (expense)		(258,206	)		(238,676	)		(19,530	)		8	%		(774,820	)		(482,599	)		(292,221	)		61	%
Net loss before income taxes	$	(4,488,688	)	$	(5,410,207	)	$	921,519			(17	%)	$	(11,933,238	)	$	(16,567,689	)	$	4,634,451			(28	%)